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The incredible clinical and commercial successes of recombinant protein 
therapeutics cemented the use of mammalian cells as the premier production hosts for these 
products.  However, we can further exploit these cells to harness their potential for 
addressing current and future medical needs through metabolic and advanced engineering 
of these cells.  To do so, we need a deeper understanding of the intricate gene regulation 
network that governs these cells and the ability to attain precise control of gene expression 
levels.  In addition, some of these applications, such as gene therapy and immunotherapy, 
could benefit greatly by refraining from using viral-derived genetic elements.  Therefore, 
this work seeks to establish additional transcriptional control elements to improve our 
ability to regulate expression with generalizable approaches and methods, facilitating the 
adaptation of these techniques for any mammalian cell type of interest. 
Here, we successfully demonstrated three key genetic elements can be utilized to 
tune gene expression in a rational manner.  First, we conducted a genome-wide screen to 
survey genomic integration sites that support high transcriptional activity.  We showed that 
CRISPR/Cas9-mediated de novo integration into one of these transcriptional hot-spots at 
the GRIK1 locus resulted in a 2.4-fold increase in heterologous gene expression over 
random integration.  Subsequently, we set the groundwork necessary to evaluate a cell line 
 ix
development strategy that aims to increase the frequency of successful de novo targeted 
integrations.  Second, we utilized two approaches for rational promoter engineering.  We 
established a transcriptomics-guided workflow for de novo synthetic promoter design 
based on the Design-Build-Test paradigm.  By using this workflow, we generated two 
synthetic designs that were comparable to a strong viral promoter and a strong endogenous 
promoter.  We also employed an alternative approach by creating hybrid promoters, which 
resulted in a hybrid promoter variant that was also comparable to the same viral and 
endogenous promoters.  Third, we exploited the general mammalian terminator structure 
and created a synthetic terminator that was comparable to a strong viral terminator.  We 
evaluated 12 endogenous and 30 synthetic terminators for heterologous gene expression 
and revealed interactions between several key components of the terminator.  Critically, 
we showed that transgene expression was 1.9x higher with endogenous and synthetic 
elements when compared with strong viral-derived elements.  Ultimately, we showed that 
transgene expression can be finely adjusted by the approaches and methods described in 
this dissertation, and that viral-derived elements can be readily substituted by our synthetic 
designs. 
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Chapter 1: Introduction1 
The increase in quality, quantity, and complexity of recombinant products heavily 
drives the need to predictably engineer model and complex mammalian cells for their 
bioproduction.  However, until recently, limited tools offered the ability to precisely 
manipulate their genomes, thus impeding the full potential of rational cell line development 
processes.  Furthermore, the issues of cell productivity, cell stability, cost of goods and 
services, and speed of development have put new demands on the field1, 2.  Synthetic 
biology tools, which have long been applied to microbial cell systems, can improve the 
speed of R&D and reduce cost of goods.  Recent advances in site-specific genome editing 
techniques3, 4, genetic regulatory elements5, and metabolic and pathway engineering6 of 
mammalian cell systems can ultimately facilitate faster and more flexible cell line 
development.  In particular, targeted genome editing can combine the advances in synthetic 
and systems biology with current cellular hosts to further push productivity and expand the 
product repertoire.  Moreover, many of these advances collectively enable the precise and 
gradated expression levels required for other metabolite production and immune cell 
engineering applications. 
1.1. CELLULAR ENGINEERING OF MAMMALIAN PRODUCTION HOSTS 
Our capacity to culture and engineer mammalian cell systems for protein 
production has rapidly expanded in past decades and has raised the importance of 
mammalian bioprocess engineering efforts.  These advancements have led to increases in 
                                                 
1 Part of the content in this chapter adapted from two previously authored publications. JKC equally contributed to the 
writing of the 2012 manuscript and wrote the 2014 manuscript, and incorporated additional information that resulted in 
this chapter. 
Lanza, A., Cheng, J., & Alper, H. (2012). Emerging synthetic biology tools for engineering mammalian cell systems 
and expediting cell line development. Curr Opin Chem Eng, 1(4), 403–410.  Copyright © 2012 Elsevier Ltd. 
Cheng, J. K., & Alper, H. S. (2014). The genome editing toolbox: a spectrum of approaches for targeted modification. 
Curr Opin Biotechnol, 30(0), 87–94.  Copyright © 2014 Elsevier Ltd. 
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the quality, quantity and complexity of recombinant products.  This improvement is most 
apparent in the ever-increasing titers of monoclonal antibodies that have gone from 50 
mg/L to upwards of 5 g/L in just over two decades7.  Mammalian cells remain the 
predominant host for producing antibodies and other protein therapeutics based on 
advantageous post-translational modifications, reduced immunogenicity, and the 
establishment of an infrastructure of mammalian cell cultivation and bioprocess 
engineering at pharmaceutical companies.  Yet, issues of cell productivity, cell stability, 
cost of goods and services, and speed of development have put new demands on the field.   
In general, the cost of bringing a drug to the market is quite high2 as a result of 
significant R&D, clinical testing, and failure rates.  While tools of metabolic engineering 
and synthetic biology cannot solve clinical testing and failure rates, they can improve the 
speed of R&D as well as reduce cost of goods.  To this end, new synthetic approaches are 
becoming available to improve the speed, accuracy, and yield of cell culture systems.  
These advances will continue to solidify the need for the cell-based bioprocess engineering 
that lies at the heart of most protein-based pharmaceutical companies.  Recent 
advancements in site-specific genome editing techniques, genetic regulatory elements, and 
metabolic and pathway engineering of mammalian cell systems improve mammalian host 
cell engineering (Figure 1-1).  These advancements, coupled with a better understanding 
of cell systems captured through -omics approaches8, 9, facilitate faster and more flexible 
cell line development, ultimately reducing cost and time. 
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Figure 1-1: Genome editing and genetic elements enable metabolic and pathway 
engineering in mammalian cell line development. 
 
Targeted genome editing tools permit manipulation of mammalian cells with increased 
specificity over homologous recombination and illegitimate integration, and facilitate the 
introduction of synthetic parts such as enhancers, promoters, miRNAs, and other 
regulatory elements into mammalian cells.  The combination of these tools expands 
metabolic engineering in these cells to improve production and hasten cell line 
development. 
Metabolic engineering serves as the discipline that combines genome editing 
techniques and genetic control elements to manufacture products of interest.  While 
metabolic engineering has long been applied to microbial organisms10, 11, limitations in the 
ability to make precise genetic manipulations delayed complete metabolic engineering of 
mammalian cell systems.  Utilizing many of the tools described below, researchers are now 
beginning to rationally engineer the metabolism and pathways of mammalian cells for 
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enhanced product formation, higher cell densities, and decreased byproduct formation, as 
depicted in Figure 1-1.  This is a critical advancement that could expand the types of 
compounds produced in mammalian cells, as well as improve titers and productivity.  
Apoptosis, for example, is a normal cellular phenomena but is detrimental in a cell culture 
process 12.  Recently, researchers have used ZFNs to generate CHO cell lines lacking pro-
apoptotic genes and these cell lines have shown resistance to apoptotic inducers12.  This 
study utilized both genomic information and a site-specific genome editing technique to 
modify the intrinsic apoptosis pathway.  Alternatively, up-regulation of miRNA was shown 
to inhibit anti-apoptotic genes13 and microarray profiling efforts in HEK293 cells identified 
several miRNAs as up-regulated when cells undergo apoptosis14.  These efforts will lead 
to more robust host cells. 
Similarly, reduced formation of lactate, a metabolic byproduct, is known to 
improve cell growth and product formation15, 16.  An apoptosis-resistant, lower lactate 
producing CHO cell line was recently developed by over-expressing an anti-apoptotic gene 
and suppressing a lactate-converting enzyme17.  Over-expression of other anti-apoptotic 
genes resulted in shifted nutrient consumption profiles and decreased lactate and ammonia 
accumulation18.  Improvements in efficiency and cellular metabolism have also been 
achieved by generating glutamine synthetase null strains using ZFNs19. 
Recently, CHO-derived cell lines were engineered to constitutively express a 
mammalian global sensor (mTOR)20 that is responsible for controlling several metabolic 
activities. The ectopic expression of mTOR in CHO-K1 cells resulted in several profound 
effects including higher specific productivity20.  Ultimately, IgG production was increased 
nearly four-fold over non-engineered parental cells, and these benefits were translated in 
bioreactors20. 
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The first study using metabolic engineering to produce a non-protein product, 
heparan sulfate (HS), in CHO cells both demonstrated the feasibility and highlighted the 
limitations of such an approach in mammalian systems6.  Although the activity of the 
engineered HS is significantly less than current pharmaceutical grade heparin, this work 
illustrates the potential to metabolically engineer mammalian cells for complex products.  
Furthermore, disaccharide analysis of the engineered HS suggests that tuning enzyme 
expression (possibly through the genetic elements previously described) could lead to 
pharmaceutical grade HS.  Mammalian cell systems also aid vaccine development by 
producing glycoproteins and virus-like particles. Recently, two studies demonstrated that 
recombinant hemagglutinin produced from HEK cells confer protection against pathogenic 
influenza viruses21, 22.  Further improvements have been achieved by engineering cellular 
glycosylation and protein secretion, and these findings have previously been summarized23, 
24.   
1.2. TRANSITIONING TOWARDS SITE-SPECIFIC TRANSGENE INTEGRATION IN 
MAMMALIAN HOSTS 
Achieving mg/L quantities of an antibody can easily be achieved by introducing a 
transgene into a host cell.  However, the production of gram quantities (upwards to tens of 
grams per liter) requires a combination of cell line engineering, expression optimization, 
and advanced culturing control.  As we continue to push the envelope for titer and to 
expand our scope of products, we require increasingly precise methods to modify the 
genome.  Yet, until recently, the genetic tools available to make targeted edits exhibited 
rather coarse resolution even for model organisms. 
Enabling targeted editing of eukaryotic and mammalian genomes diversifies the 
biopharmaceutical repertoire and offers design of selection systems beyond current 
schemes (e.g. dihydrofolate reductase-deficient CHO cell lines or antibiotic resistance).  As 
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described above, metabolic engineering of mammalian cells to produce the first 
bioengineered heparin is imminent6.  Furthermore, combining pathway understanding with 
well-characterized synthetic genetic parts will enable additional complex products to be 
produced.  These efforts will be greatly expedited by targeted genomic edits.  Moreover, 
these technologies open up the possibility to engineer hosts cell lines without selection 
markers (or in some cases, for marker-less genome editing), thus bypassing antibiotic 
selection schemes that can be suboptimal depending on the selecting agent used25. 
With the increasing synthetic toolkit for genetic editing, cell line development is 
about to experience a renewal at the intersection of systems biology and synthetic biology.  
Recent advancements in a spectrum of targeted genome editing tools (Figure 1-2) ranging 
from coarse, loci-level resolution to precise, base-pair specific modifications can be readily 
adapted to each application.  High-throughput analytical methods and cheap genome 
sequencing enable a more precise linkage between genotype and phenotype.  These 
approaches could theoretically allow researchers to make concerted and rational decisions 
about the genotype of a cell line.  This capacity to move beyond random libraries and 
integrations (or at the very least, understand why and how a cell line performs as it does in 
an effort to recapture high productivity for another molecule), require a sophisticated suite 
of genome editing tools.  Moreover, the complexity across different cell types and cell lines 
makes such a vision challenging. 
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Figure 1-2: Targeted genome editing spans coarse, regional locus-level recognition to 
nucleotide-level specificity. 
 
Targeted genome editing tools permit manipulation of a variety of host cells relevant to 
the biopharmaceutical industry.  The combination of the tools described here improves 
prospects for engineering in these cells.  Transposases recognize ITR sequences flanking 
the DNA cargo and mediate movement of the cargo elsewhere in the genome (e.g. TA-
rich regions).  Recognition sites for recombinases such as loxP/FRT are specified as 
DNA sequences.  Group II introns require additional proteins (e.g. reverse transcriptase) 
to fully carry out their targeted integration into the genome.  The target DNA sequence is 
sufficient for inducing specific cleavage by nucleases; however, the guide RNA (gRNA) 
is required to direct Cas9 nuclease to the target site including the PAM.  Abbreviations 
and symbols: denote the targeted cleavage site triggered by the nuclease. ZFN, zinc-
finger nuclease. TALEN, transcription activator-like effector nuclease. PAM, protospacer 
adjacent motif. ITR, inverted terminal repeats. RNP, ribonucleoprotein. 
A variety of techniques (Figure 1-2) have been developed to edit genomes 
including adapting components from other species (e.g. transposases, recombinases, group 
II introns, and RNA-directed nucleases) and creating synthetic approaches comprised of 
discrete building blocks (e.g. zinc-finger and transcription activator-like effector 
nucleases).  This spectrum of targeted genome editing tools has a myriad of capabilities 
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and applications, but each approach has distinct drawbacks and limitations (see Table 1 
from Curr. Opin. Biotechnol. 2014 publication26). 
1.2.1. Exploiting established genetic elements 
Genetic engineering is required to transform mammalian host cells into super-
producers of proteins.  Specifically, efficient mammalian cell engineering requires precise, 
reliable genome editing techniques to enable the expression of heterologous genes and 
deletion of unwanted genes.  In contrast to the ease of genome editing in microbial systems, 
mammalian cell engineering still relies heavily on semi-random integration8, 27 and low 
probability homologous recombination events28-30 coupled with laborious screening8, 31-33.  
However, classes of enzymes naturally exist which can recognize specific DNA sequences 
and modify those genomic loci.  These enzymes are being engineered as synthetic tools to 
recognize new sequences and perform precise genomic modifications, such as double 
strand breaks (DSBs) that facilitate gene deletions, insertions and replacements. 
Transposable elements, such as transposons and group II introns, and recombinases 
were among the first genome editing tools applied to mammalian cell lines.  Transposons, 
group II introns, and recombinase-mediated cassette exchanges link desired genetic cargo 
as part of the mobile element with recognition sites flanking this cargo (Figure 1-2).  
Transposon-aided insertion is mediated by sequence recognition rules (e.g. TA-rich region) 
that vary depending on the transposable element.  Self-splicing group II introns target DNA 
with the same or similar sequences to the donor sequence containing the intron and 
incorporate the intron sequence through reverse transcription.  Lastly, recombinases 
recognize specific DNA sequences (e.g. loxP and FRT) between which exchanges or 
rearrangements occur. 
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In the context of pharmaceutical applications, transposable elements (for an active 
list in vertebrates, see review by Ivics34) such as Sleeping Beauty (SB) and PiggyBAC (PB) 
can serve as a safe alternative to viral vectors for gene delivery34-39.  Such systems require 
expression of the transposase and can deliver genetic cargo to pre-set loci due to particular 
sequence preferences and genomic integration patterns of the transposases34.  As an 
example, functional wild-type heme oxygenase-1 was delivered to the livers of mice 
inflicted with sickle cell disease using a SB transposase plasmid36 and this SB system 
recently showed a positive outlook for a human clinical study37.  Moreover, using SB to 
generate fluorescent reporter clones in human embryonic stem cells (hESCs) preserved the 
undifferentiated state and differentiation pattern, facilitating the study of a complex cell 
type38, thus indicating a low level of genetic and epigenetic disruption by this system.  
Since different transposons have varying cargo size limitations, local transposition 
tendencies, and integration site preferences, PB was used instead of SB in a mice genetic 
screen for oncogene discovery39. 
Similar to transposases, recombinases such as Cre and FLP require flanking 
recognition sites at the target genomic locus, but can enable insertions, deletions, 
replacements, and rearrangements.  Pre-integrated sites (potentially at transcriptional hot-
spots in the genome) can enable re-targeting40.  Such re-targeting in human cells is 
achievable at high rates (over 10%) as demonstrated by swapping of fluorescent markers41.  
Even in hESCs and mouse fibroblasts (NIH 3T3), Cre and FLP recombinases were used in 
conjunction with high recombination activity42.  When coupled with inducible or tissue-
specific promoters, controlled, targeted expression in model organisms with limited tools 
is possible43.  Recently, the Cre/loxP system was used to construct human artificial 
chromosomes that are stably maintained, serving as another potential alternative to viral 
vectors44.  Despite promise and versatility of this genome editing tool41-43, recombination 
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efficiencies depend on the cell type and genomic locus, potentially resulting in a labor-
intensive endeavor (especially when screening for desired clone). 
Recombinase and transposon based genome editing shows great promise in non-
mammalian hosts.  For example, by combining the Cre recombinase with the mobile group 
II intron (Targetron) systems, the Genome Editing via Targetrons and Recombinases 
(GETR) platform mediated large genome edits in bacteria with high efficiencies45.  In this 
platform, careful design of recombination sites and selection of introns can mitigate 
potentially deleterious events such as scarring and unplanned homologous recombination 
between introns45.  Previously, highly specific gene disruption was achieved in E. coli, a 
common biopharmaceutical production host, with frequencies up to 22%46.  Group II intron 
activity was also demonstrated in eukaryotes, and the resulting site-specific integration or 
double-strand break (DSB) induced homology directed repair (HDR) was dictated by Mg2+ 
concentration46. 
Artificial chromosomes present an alternative technology that does not require 
integration into the host genome.  This technology is used in some bacterial and fungal 
applications and can support large quantities of recombinant DNA.  Recently, artificial 
chromosome expression (ACE) technology was used to generate monoclonal antibody 
expressing CHO cells exhibiting high productivity31.  The recent discovery of small, 
circular microDNAs in mammalian tissues represents another genetic avenue that could be 
engineered to complement and extend existing transgene expression technologies47.  
Improved transient expression was demonstrated in modified HEK293 cells expressing 
Epstein-Barr virus nuclear antigen 148.  A similar approach in CHO cells using the Epi-
CHO transient gene expression (TGE) system showed up to a 64% increase in monoclonal 
antibody titer when compared to previously reported systems49, 50.  These tools collectively 
provide significant flexibility and precision in genome editing.  These represent significant 
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improvements over standard practices such as homologous recombination or illegitimate 
integration, resulting in faster cell line development and higher titers for better bioprocesses 
and potentially easier downstream product separation.  Thus, many of these approaches 
could be further adapted and optimized to achieve genome editing in mammalian hosts. 
1.2.2. Customizable genomic editing via targeted nucleases 
The ability to precisely cleave DNA (through restriction enzymes) was a critical 
turning point that led to the establishment of recombinant DNA technology and the growth 
of the biopharmaceutical industry.  Recently, there has been great effort in establishing 
these techniques in vivo.  By inducing a double-stranded break (DSB) at the cleavage site, 
the cell’s repair pathways are triggered and the break is generally resolved with non-
homologous end joining (NHEJ) or HDR.  NHEJ results in nucleotide insertions or 
deletions (indels), which is ideal for interrupting gene function at the specific locus and 
introducing heterologous gene expression.  
Zinc-finger nucleases (ZFNs) can be obtained by fusing a zinc finger DNA-binding 
domain to a DNA-cleavage domain (typically derived from FokI Type IIS endonuclease).  
In this manner, custom editing targets can be specified at the sequence level.  ZFNs do not 
require generic targeting sequences and are modular in assembly, allowing great flexibility 
in their targeting29.  ZFNs facilitate both genomic integrations and gene knockouts29.  
Custom ZFNs can be ordered through companies such as Sangamo BioSciences and have 
been demonstrated in a variety of cell types and applications51, including the rapid and 
efficient deletion of genes52, 53.  Recently, zinc-finger recombinases (ZFR) were developed 
by fusing zinc finger domains and serine recombinases, and utilized in human cells to 
deliver reporter genes at specific loci27.  Although this method requires pre-insertion of 
ZFR recognition sites, DNA damage responses are circumvented and thus higher levels of 
 12
specificity are achieved27.  Recently, this technology enabled improved cell line 
development for monoclonal antibody production in Chinese hamster ovary cells19.  
Despite different methods used to construct ZFNs54, 55, off-target cleavage was detectable 
in many applications54, 56, 57.  In particular, ZFNs targeting human CCR5 often showed 
cleavage activity at the highly homologous CCR2 locus54, similar to CRISPR/Cas958.  
Moreover, ZFNs can be costly and time-consuming to produce, with mutation efficiencies 
only up to 18.8% in certain applications55. 
Like ZFNs, transcription activator-like effector nucleases (TALENs) contain a 
DNA-binding domain and cleavage domain.  Transcription activator-like effector 
nucleases (TALENs) are also modular in nature and can be built to recognize any DNA 
sequence59, 60.  Efficient endogenous deletions61 and gene insertions62 were recently 
demonstrated in human cells using TALEN architecture.  Comparable efficiencies to ZFNs 
were seen when five distinct genomic loci were targeted in both hESCs and induced 
pluripotent stem cells (iPSCs)62.  However, a CCR5-specific TALEN showed less off-
targeting activity at the CCR2 locus compared to its ZFN counterpart, suggesting better 
specificity63.  Comparable efficiency was observed between CRISPR/Cas9 and TALENs 
when modifying human pluripotent stem cells64.  Furthermore, TALEN-mediated HDR in 
β-thalassemia iPSCs successfully corrected disease-causing mutations without transgene 
integration and while maintaining pluripotency65.  In another study, hESCs and iPSCs were 
edited by TALENs at four genes to produce representative human disease-related models66.  
Even heritable mutations eliminating IgM function can be established using TALENs67.  
Miller, et al. and Cermak, et al. described strategies for TALEN designs68, 69, though 
production capacity was rather limited.  To address this limitation, recently, the FLASH 
method for automated medium- to high-throughput TALEN production can generate 
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>7,200 arrays per year70.  As a result, this technology is becoming more accessible for 
genome editing71. 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and 
CRISPR associated (Cas) genes natively function together as a prokaryotic immune 
system.  In recent years, this system has been adapted as a potent targeted genome editing 
tool with broad host system capabilities58, 64, 72-82.  The recognition sequence for Cas 
nuclease cleavage is a short protospacer adjacent motif (PAM) sequence (Figure 1-2), 
enabling targeted DSBs across many cell types72-76.  The most common Cas9 nuclease is 
derived from S. pyogenes (SpCas9), yet orthologs show orthogonal function, enabling 
simultaneous and independent targeted gene regulation in bacteria and human cells75.  
While heralded as a new, powerful approach for genome editing, significant off-targeting 
(up to 50%) was observed in human cells72.  This off-targeting primarily triggers NHEJ, 
often with deleterious consequences at unintended genomic loci, and modifications to Cas9 
converting it from a nuclease to a nickase (or using paired Cas9 nickases) can reduce this 
promiscuous activity74, 77, 83, 84. 
Aside from targeted gene disruption, the targeted recognition properties of these 
nucleases enable novel applications as synthetic markers and actuators58, 64, 72-82.  As an 
alternative to fluorescence in-situ hybridization, chromatin conformation and dynamics in 
live human cells can be studied using a fluorescently tagged, nuclease-deactivated Cas978.  
Even heavily repeated regions, such as telomeres, can be imaged with this repurposed 
Cas978. With comparable performance to RNA-interference, genome-scale knockdown 
screening is possible with CRISPR/Cas9 in E.coli79 and in human cells85, evaluating 
>18,000 genes with >64,000 unique guide RNA sequences80.  Activating and repressive 
domains can be fused to catalytically inactive Cas9 to enhance or decrease endogenous 
gene expression in eukaryotes76, 81, while similar strategies can be combined with TAL 
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effector arrays86 and zinc finger proteins87.  Even targets with small loci, such as 
microRNA, can be disrupted88. Furthermore, targeted editing of histone modifications can 
be achieved by combining histone demethlyase activity with TAL effector arrays89 or 
nuclease-deficient Cas990, thus modulating gene expression at an epigenomic level.  These 
quick adaptations of the nuclease systems certainly do not entirely encompass their 
potential as they have yet to be fully characterized.  Moreover, these approaches 
demonstrate a newfound way to modify more than just genome sequences in cell lines of 
interest. 
While there are still challenges to these recent editing techniques, methods are 
established to better probe and address their limitations, particularly for off-targeting with 
nuclease directed editing56, 57, 72, 77, 82-84, 91, 92.  With this improved understanding of the Cas9 
nuclease activity, researchers developed high fidelity variants the common S. pyogenes-
derived Cas9 in recent years93, 94 and a small-molecule inducible variant95 to combat the 
propensity for off-target activity.  Such mutagenic concerns preclude their use in the clinic 
currently, but their potential use for personalized medicine and gene therapy is certainly 
becoming more realistic. By combining several of these techniques, such as stable 
expression of a transgene via an episomal vector96, certain diseases can be treated with 
nuclease-induced HDR of mutant/diseased alleles. Alternatively, the delivery of the Cas9 
became a focus of attention to address their potential applications in conjunction with 
adeno-associated virus, leading to novel methods to introduce this nuclease activity97-99.  
Recent efforts also demonstrated editing of the mouse and human immunoglobulin 
genes100.  Thus, in addition to their application in engineering host cell lines for high 
productivity and amenable development, these editing tools are poised to transform 
therapies as their technologies mature. 
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1.3. CIS- AND TRANS-ACTING GENETIC ELEMENTS  
Genome editing alone is not sufficient to provide the gene expression regulation 
required of these mammalian hosts.  To address this issue, genetic elements can be used to 
synthetically regulate gene expression and facilitate protein production and metabolic 
engineering efforts.  Some of these tools include genetic elements such as enhancers, 
promoters, internal ribosome entry sites (IRES), ubiquitous chromatin opening elements 
(UCOEs), scaffold/matrix attachment regions (S/MARs), and micro RNAs (miRNAs), 
which can be combined with both recombinant and native genes to enhance genetic 
engineering efforts in these cells.  The utility of related genetic elements has been 
demonstrated in microbes101-105; however, adaptation and adoption across mammalian 
genomes is in its early stages106. 
Enhancers are cis-acting genetic elements that help regulate transcriptional activity.  
Recently, a short enhancer sequence was paired with a minimal promoter, yielding tunable 
expression and levels exceeding that of the strongest known native mammalian 
promoters107.  Such enhancer elements can be systematically dissected using high-
throughput techniques recently developed and applied to mammalian regulatory 
elements106, 108.  In a similar manner, these techniques can be adapted for the systematic 
analysis of other elements, such as promoters and silencers and can also enable the 
development of novel regulatory elements.  These efforts can be expanded through 
bioinformatics mining of recently published sequences such as the CHO genome109.   
Promoters with well-characterized transcription levels are critical genetic parts that 
enable heterologous gene expression and construction of advanced genetic circuits.  While 
tools are widely available for tuning gene expression in microorganisms110-112, the 
counterparts in mammalian cell systems are just emerging.  Two types of promoter 
elements are useful for recombinant cell lines: constitutive (constant expression) and 
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inducible (modulated expression by a small molecule or other trigger).  By modifying the 
TATA and CAAT box elements, synthetic constitutive promoters capable of 40-fold range 
expression levels were recently developed and implemented in several cell types113, 114.   
These promoters allow for better, higher-resolution optimization of gene expression in the 
context of metabolic pathways and heterologous transgene expression.  Furthermore, 
sequence shuffling was used to generate fully constitutive synthetic promoters in 
mammalian cells115.  In some applications, inducibility is desired to enable temporal 
bioprocessing control.  To this end, several inducible promoters have been well-established 
in mammalian cell systems116 and have spurred the development of synthetic circuits 
capable of modulating multiple genes.  As examples, the cumate gene switch was adapted 
from microbes and successfully implemented in mammalian systems117.  Tetracycline-
responsive promoters were recently expanded to include aptamer-based control, mediating 
transgene expression in a small molecule concentration-dependent manner118, 119.   
Furthermore, a biotin-inducible expression system demonstrated direct correlation between 
biotin concentration and reporter gene expression in both CHO and HEK cells, and gene 
expression can be triggered even at large scales120.  In each of these instances, gene 
expression control (whether constitutive or inducible) is critical for optimizing cellular 
hosts for protein production.  
An IRES permits mRNA translation initiation and increases the flexibility afforded 
by synthetic and native promoters by allowing for expression of multiple genes using a 
single promoter and controlling the ratio of protein expression.  These elements are 
particularly critical since the light chain (LC) and heavy chain (HC) of antibodies are 
expressed as separate genes.  This approach was recently demonstrated using IRES-
mediated tricistronic vectors, resulting in more positive clones and higher clonal 
productivity by controlling the expression ratio of LC to HC121. The use of an IRES 
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demonstrates the additional layer of complexity needed for optimizing cellular hosts for 
antibody production.  
Finally, there are additional elements that help expand the toolkit for engineering 
mammalian cells, including post-transcriptional regulatory elements122, 123, UCOEs124-126, 
and S/MAR127 elements. UCOEs can help regulate transgene expression by modifying 
chromatin state and overcoming transgene silencing124.  The impact of these elements is 
evinced by increased protein titers125 and improved transgene stability126 in cell culture. 
S/MARs similarly modify chromatin state and were recently used to prolong transgene 
expression127 and initiate gene amplification in animal cells128.  In addition, miRNAs can 
play a significant role in engineering gene networks and protein production by binding 
complementary mRNA sequence resulting in reduced translation.  For example, by 
profiling highly conserved miRNA expression in IgG-producing CHO cells, several 
differentially expressed miRNAs were identified to potentially regulate gene expression, 
cellular growth and proliferation, and the overall cell cycle129.  Productivity of CHO cells 
was increased by exogenously increasing cellular miR-7 levels130.  As a high level of 
miRNA sequences are conserved between the Chinese hamster and other mammals131, this 
work can likely be extended to other cellular systems.  Many of these elements may need 
to be combined for high and stable expression levels required to further optimize and 
improve protein production, while they are also additional orthogonal elements to 
complement the common cis-acting genetic elements. 
1.4. THE PATH FORWARD 
Despite many recent advances in improved synthetic biology techniques, more 
improvements are needed before cellular engineering of mammalian cells occurs at a level 
on par with microbial industrial hosts.  The growing need for cell culture systems and cell 
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lines that facilitate rapid screening of pharmaceutical candidates in pre-clinical phases is 
strongly driven by the desire to reduce both the cost and time required for developing a 
pharmaceutical.  Pivotal studies implementing the tools described above illustrate progress 
in the field to quickly produce molecules of increasing complexity.  Moreover, these 
genetic tools create precise and predictable changes within a cell and aid in efforts of 
Quality by Design (QbD) throughout the cell line development process.  Chromosomal 
context and epigenetic mechanisms should also be considered, as they greatly influence 
genomic architecture132.  Some of the tools described cause modifications to epigenetic 
structure, such as S/MARs, IRESs and UCOEs. 
In particular, the explosion of targeted genome editing techniques now available 
can certainly benefit the biopharmaceutical industry from candidate discovery through 
licensed commercialization.  The ability to perform genetic screens in model organisms 
and even representative human cell lines should improve the chances of developing a 
successful therapeutic.  Identifying and targeting loci with high transcriptional activity for 
transgene expression in production hosts can improve product yields, ultimately reducing 
manufacturing costs.  Another laborious and time-consuming step in developing 
mammalian cell lines is isolating highly productive clones through selection, and adapting 
the work by Jiang, et al.133 could expedite this process.  
By adapting advances in synthetic biology from microorganisms to complex 
mammalian cell systems and developing additional pioneering tools, it is possible to 
produce a wider range of specialty compounds beyond recombinant proteins.  Advanced 
genome editing tools, in conjunction with novel, synthetic genetic elements, can be used 
to predictably design mammalian cell systems for industrial biotechnology.  However, 
some of the genetic elements described above, particularly synthetic promoters, could 
exhibit distinctly different behavior depending on the cell type under investigation113, 126.  
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Even combining these elements may not successfully mitigate this challenge126.  Yet, these 
combinations can bestow beneficial effects upon other important considerations in 
mammalian cell engineering, such as transgene silencing125.  As a result, more effort is 
required in the field to further expand and adapt these synthetic parts for broad utility and 
application.  Collectively, these prospective advances help mitigate the great complexity 
and lack of tools currently impeding cell line development processes.  High productivity, 
high stability, and the ability to adapt cells for continuous culturing will continue to drive 
goals and targets for future cell lines.  Advances in the area of synthetic biology outlined 
here will ultimately minimize the cost burden associated with pharmaceutical development 
of both novel therapies and biosimilars of the future. 
Therefore, the work presented in this dissertation represents a significant step 
forward in developing and characterizing the tools to precisely regulate gene expression in 
mammalian cells.  These discrete and predictable levels of gene expression are critical in 
complex applications beyond simple gene overexpression for production, such as 
metabolic engineering immune cell engineering applications with intricate gene expression 
networks.  As such, mammalian cells will continue to be a valuable cell factory and model 
organism for addressing medical needs in the future. 
In particular, this dissertation addresses how we can precisely regulate gene 
expression through directing transgene integration into prescribed loci, exploring a strategy 
to improve integration into target loci, and modulating mRNA abundance.  To combat the 
issue of random integration of transgenes, Chapter 2 describes an approach to pre-catalogue 
preferential integration loci for high transcriptional activity.  With these established loci, 
Chapter 3 explores a strategy to improve successful integration events into the target loci.  
Chapters 4 and 5 evaluate orthogonal approaches to promoter engineering for driving 
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transcription in mammalian hosts, while Chapter 6 exploits the conserved 3’ UTR structure 
to create a set of endogenous and synthetic terminators for tuning expression. 
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Chapter 2: Placing the message – establishing transgene integration 
loci2 
2.1. CHAPTER SUMMARY 
Mammalian cell line development requires streamlined methodologies that will 
reduce both the cost and time to identify candidate cell lines.  Improvements in site-specific 
genomic editing techniques can result in flexible, predictable, and robust cell line 
engineering.  However, an outstanding question in the field is the specific site of 
integration.  Here, we seek to identify productive loci within the human genome that will 
result in stable, high expression of heterologous DNA.  Using an unbiased, random 
integration approach and a green fluorescent reporter construct, we identified ten single-
integrant, recombinant human cell lines that exhibit stable, high-level expression.  From 
these cell lines, eight unique corresponding integration loci were identified.  These loci are 
concentrated in non-protein coding regions or intronic regions of protein coding genes.  
Expression mapping of the surrounding genes revealed minimal disruption of endogenous 
gene expression.  Finally, we demonstrated that targeted de novo integration at one of the 
identified loci, the 12th exon-intron region of the GRIK1 gene on chromosome 21, resulted 
in superior expression and stability compared to the standard, illegitimate integration 
approach at levels approaching 4-fold.  The information identified here along with recent 
advances in site-specific genomic editing techniques can lead to expedited cell line 
development.   
                                                 
2 The content in this chapter can be found in a previously authored publication. JKC and AML equally 
contributed to the experiments and analyses, and collectively wrote the manuscript comprising this chapter. 
Reprinted with permission from Cheng, J. K., Lewis, A. M., Kim, D. S., Dyess, T., & Alper, H. S. (2016). 
Identifying and retargeting transcriptional hot spots in the human genome. Biotechnol J, 11(8), 1100–1109. 
DOI: 10.1002/biot.201600015.  Copyright © 2016 WILEY-VCH Verlag GmbH %26 Co. KGaA, 
Weinheim. 
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2.2. INTRODUCTION 
Cellular hosts can produce a wide range of useful products including therapeutics, 
antibiotics, biofuels, specialty chemicals and other small molecules6, 11, 134.  In particular, 
mammalian cell lines such as CHO, HeLa, HEK293 and HT1080 are important industrial 
hosts commonly used to produce protein therapeutics, such as insulin, antibodies, 
cytokines, enzyme replacement therapies, and growth factors1.  Specifically, three globally, 
commercially available therapeutics are produced in the human-derived cell line 
HT1080135, with additional in the pipeline.  However, these cell lines remain harder to 
engineer than bacterial and fungal counterparts.  Precision genome engineering tools 
together with a synthetic biology paradigm have fueled a renaissance for strain 
engineering102, 136, yet, these tools inherently require knowledge of the genomic 
architecture.  As a result, most current strain development programs that rely on stable cell 
line development (CLD) often include time-consuming, labor-intensive, repetitive and 
expensive screening of thousands of potential cell lines7, 137-139.  Consequently, site-specific 
integration of transgenes into pre-characterized loci would speed the CLD process and 
yield significant cost and time-savings. 
Over the past decade, the genome editing toolbox for mammalian cells has rapidly 
expanded26.  Technologies including Cre and FLP recombinase41, 140, ΦC31 integrase141, 
142, zinc-finger nucleases27, 143, transcription activator-like effector nucleases59, 68, and more 
recently, clustered regularly interspaced short palindromic repeats (CRISPR) systems144 
have enabled new ways to integrate transgenes.  However, two commonalities arise for 
each of these methods: (1) the need to create double-strand breaks in DNA to mediate non-
homologous end joining and homology-directed DNA repair and (2) the need to pre-
determine high expression loci.  Moreover, commercialization and continued improvement 
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of these methods demonstrates their importance for varied applications including CLD145, 
146. 
While efficiency of integration (both re-integration and de novo targeting) has 
increased, it is still unclear what genomic loci are best for high expression.  Specifically, 
not all genomic loci are equal with respect to their capacity to facilitate and stably maintain 
high levels of transgene expression.  The importance of integration sites has been well 
established7, 137, 139, 147, 148, however, limited information is available about desirable sites 
with only a few characterized in particular cell types with interesting characteristics149, 150.  
Variations in expression across the genome has been demonstrated in other model 
organisms including E. coli151, S. cerevisiae152 and zebrafish153 with upwards of 8-fold 
difference in expression levels for yeast152.  In the absence of similar studies for 
mammalian cells, pre-determined criteria, such as ‘Good Safe Harbours’154 have been 
applied a priori to identify potentially useful integration sites155.  Outside of such 
experimental genomic searches, global expression sets have limited utility since non-
coding regions can serve as good sites for high-level transgene expression.  Many 
commercial technologies for site-specific integration continually exploit a small number of 
integration loci.  However, little consideration has been given to the nature of these sites 
and only a small number of exonic sequences are used156, 157, thus ignoring a large portion 
of the protein coding and all non-coding regions. 
The phenomenon of genomic hot spots is ubiquitous as cell biology processes 
including meiotic recombination158, epigenetic modifications159, 160, viral integration161-164, 
chromatin structure165, 166, and transcriptional capacity165 exhibit a loci-dependent bias with 
a non-random distribution across the genome167.  Additionally, retroviral integration occurs 
at a non-random frequency across the genome and exhibits an integration bias with defined 
motifs and preference for CpG islands, regions of high gene density, and regions near 
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transcription start sites and transcription factor binding sites163, 168-171.  These sites are 
important since they indicate natural propensities for viral integration as well as provide a 
mechanism for viral-assisted gene therapy.   
At first approximation, integration into euchromatin, lightly packed gene-rich 
regions, is most likely to favor expression whereas integration into heterochromatin is 
unlikely to confer transcription capacity, as these regions are often silenced by histone 
deacetylation, histone methylation and promoter methylation137.  Recombinant protein 
production in the HEK293 and CHO Flp-In host cell lines highlights the importance of 
targeting an integration site within euchromatin and the benefit of site-specific 
integration172, 173.  In addition, multiple integration copies can be specifically targeted into 
the same locus using Cre recombinase and mutant loxP sites for gene amplification174.  
However, these case studies required the development of these specific host cell lines with 
FRT or loxP targeting sites in the desired, pre-described locus.  Furthermore, the 
integration of a transgene may affect chromatin structure and thus change the 
transcriptional capacity for a given locus.  Thus, a cataloging of regions within the genome 
that can enable and maintain stable, high-level transcription of a transgene (so called 
‘transcriptional hot spots’) will serve as a great coupling to emerging genome editing 
technologies.  To this end, we seek to identify transcriptionally active areas using a 
genome-wide screen in the HT1080 mammalian host, demonstrate improved expression 
and stability of these sites compared to illegitimate integration, map the surrounding 
expression landscape, and demonstrate the capacity for precision re-targeting to this loci.  
In doing so, the work in this chapter addresses an unmet need at the forefront of human 
genome research, cell line development, and biologics research by providing a catalogue 
of genomic hot spots supportive of high-level, stable transgene expression.  
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2.3. RESULTS AND DISCUSSION 
2.3.1. Establishing single-cell clones with stable and high expression capacity 
Initially, we conducted an unbiased survey of the human genome to identify 
genomic loci that afforded stable, high-level heterologous gene expression.  To do so, a 
random integration strategy was used in conjunction with a transgenic reporter construct 
(Figure 2-1) to explore the entire genome.  These constructs contained both antibiotic 
selection markers and fluorescent reporter genes (GFP) expressed with the CMV promoter.  
The human sarcoma cell line, HT1080, was transfected with a linearized pIRES-hrGFP 
reporter construct (Figure 2-1A) and subjected to a sequential selection first by Zeocin™ 
selection (previously demonstrated as superior in establishing recombinant human cell 
populations25 followed by GFP expression.  Expression of the GFP reporter gene was 
measured using flow cytometry.  Bulk populations exhibited a broad range in expression, 
as evident by high coefficients of variance, with higher enrichment of mean GFP 
expression coinciding with more stringent antibiotic selection (Supplemental Figure S1a 
of the publication175).  We pursued this work in the human cell line HT1080, as opposed 
to another common industrial host such as CHO, since the CHO genome was unavailable 
at the time of these experiments176, 177 and the human genome was well-annotated, 
facilitating loci identification. 
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Figure 2-1:  Dual-selection transgene constructs for high expression clones. 
 
 
 
HT1080 cells were transfected with two heterologous constructs, each containing a single 
promoter and IRES to allow for simultaneous expression of two genes that enable dual 
expression.  (A) the pIRES-hrGFP construct contains the Zeocin resistance gene in the 
first cistron and a human optimized GFP gene in the second cistron.  (B) the pHL-GFP 
contruct contains a GFP gene in the first cistron and the puromycin resistance gene in the 
second position.  (C) the pAML-Zeo construct was used for retargeting of the 12th exon 
of the GRIK1 gene on chromosome 21. (D) the hrGFP and SEAP expression cassettes 
used for de novo integrations. 
Recombinant populations established using 100 and 250 ug/mL Zeocin™ were 
further enriched using FACS sorting to select the top 10-15% of GFP expression.  The 
expression profiles of the resulting sorted populations (demonstrating enrichment) are 
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shown in Supplemental Figure S1b of the publication175.  Using a similar approach, 
hygromycin-resistant single cell clones were established by Shire Human Genetic 
Therapies using the pHL-GFP reporter construct (Figure 2-1B) and cells were enriched 
using FACS.  In both cases, dilution cloning was performed to isolate single cell clones 
and establish homogenous populations.  In an effort to identify stable clone lines, the 
expansion of single cell clones, which took place over a period of 6-8 weeks, was 
performed without any antibiotic selection.  Following expansion of both populations, 
stable GFP expression and transgene copy number was evaluated.  This combined effort 
(both the Zeocin™ and hygromycin-based clones) resulted in a total of ten clones with 
single site integration (single transgene copy), high geometric mean GFP fluorescence 
(Figure 2-2A), stable expression, and high GFP RNA expression according to RT-PCR 
(Figure 2-2B).  Each of these clones had a stable expression profile and mRNA levels that 
are very high relative to average expression of human genes (in particular, compare native 
gene expression with transgene in Figure 2-3).  Even so, we do observe a difference in 
rank order for clone expression using these two quantitation methods of flow cytometry 
(geometric mean GFP) and RT-PCR (relative gene expression level).  We noted that 
absolute fluorescence values did not always correlate with mRNA expression which 
indicates other influences in the cell.  Flow cytometry was performed using live cells, and 
could be influenced by cell morphology, culture viability, and day-to-day instrument 
variability.  Real-time PCR is a highly sensitive in vitro assay that measures transcript level 
(a level that does not always correlate precisely with protein abundance).  Nevertheless, 
we do see a similar range of expression (10 log-fold) between the highest and lowest 
expressing clones across these two methods. 
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Figure 2-2:  Isolated single cell clones exhibit high protein and mRNA expression. 
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Figure 2-2, continued: 
 
Ten single cell clonal populations were isolated from the recombinant populations and 
protein (A) and mRNA expression (B) were measured.  A. GFP expression profiles for 
clonal populations (A-J, labeled based on approximately descending geometric mean 
fluorescence) were measured using flow cytometry and are shown in blue compared to 
untransfected HT1080 (black).  B. Relative mRNA expression (SD) of the clonal 
populations (A-J) was measured by RT-PCR for the first cistron, hrGFP.  mRNA 
expression levels are normalized arbitrarily to clone F for comparison purposes. 
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Figure 2-3:  mRNA expression maps for protein-coding sequences surrounding 
integration loci.  
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Figure 2-3, continued: 
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Figure 2-3, continued: 
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Figure 2-3, continued: 
 
Fold change in mRNA expression (SD) was measured in surrounding protein-coding 
genes relative to the house-keeping gene RPS11 (an endogenous gene of high expression) 
for the wild-type cell line and the cell line with integrated transgene.  A. mRNA 
expression profile for clone C on chromosome 18, including the transgene and 
endogenous genes DCC, MBD2 and uncharacterized locus 100287225.  B. mRNA 
expression profile for clone D, integrated on chromosome 5, including the transgene, 
AQPEP, COMMD10, SEMA6A and DTWD3.  C. mRNA expression profiles for clone E, 
integrated on chromosome 4, including the transgene, ARL9, SPINK2 and REST.  D. 
mRNA expression profile for clone F, integrated on chromosome 15, including the 
transgene and endogenous genes VPS33B, SV2B and SLCO3A1.  E. mRNA expression 
profile for clone G, integrated on chromosome 7, including the transgene, SEMA3E, 
SEMA3A, and SEMA3D.  F. mRNA expression profile for clone H, integrated on 
chromosome 14, including the transgene, TMEM121, IGHA2, IGHG2 and ADAM6.  G. 
mRNA expression profiles for clones I and J integrated on chromosome 21, including the 
transgene and endogenous genes BACH1, GRIK1 and CLDN8.  The black arrow indicates 
the promoter direction for the transgene.  Error bars indicate standard deviation from RT-
PCR triplicates. 
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2.3.2. Identification of transcriptional hot-spots in isolated, high-expressing clones 
Identifying the exact location of an integration event is greatly aided by high-
throughput sequencing techniques.  However, given the size of the human genome, this is 
an expensive approach.  Therefore, we employed a variety of low-throughput PCR-based 
methodologies, including TAIL PCR, inverse PCR and plasmid recovery based on 
genomic DNA to identify the integration loci for each of these ten clones.  The integration 
site was confirmed by PCR (further details are provided in the Supplementary Material 
of the publication175 for each clone). 
Using these PCR-based approaches, we were able to identify the integration loci of 
our ten GFP-expressing clone lines (Table 2-1 and Supplemental Table S1 of the 
publication175).  This information showed that the integration loci are distributed 
throughout the human chromosomes with half the integration events occuring in gene 
intronic regions.  The remainder of the integration events occurred further from the nearest 
protein-coding regions, with two integrations found in long non-coding RNA regions.  This 
is a surprising result and clearly demonstrates that regions outside of protein-coding 
sequence are hospitable towards heterologous transgene expression.  The clone with the 
highest mRNA expression levels had an integration in chromosome 14 in the IGHG2 gene.  
This region of the genome is rich in immunoglobulin proteins, which are spaced close 
together, yet not a region of particularly high expression for this particular cell line.  
Finally, two integration sites were each identified from duplicate, independent integration 
events.  Clones I and J both arose from integration into the GRIK1 gene on chromosome 
21 at the 13th intron and 12th intron respectively, and clones A and B both arose from 
integration into an unplaced genomic contig.  Unfortunately, very little information is 
available about this genomic contig, including its chromosome, because this is a region of 
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high redundancy.  Nevertheless, 8 unique genomic loci were identified from the 10 stable, 
high-expressing clones analyzed here.  
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Table 2-1:  High transcription integration loci are distributed throughout the genome.   
Clone Chr. Intron Nearest Gene Nearest Gene Function 
A   Unplaced genomic contig (3980bp)  
B   Unplaced genomic contig (3980bp)  
C 18 26 DCC Netrin 1 receptor 
D 5  SEMA6A, 28kb downstream Transmembrane domain 
E 4  SPINK2, 9kb upstream (in LOC105377668) Serine peptidase inhibitor 
F 15 1 SV2B Synaptic vesicle glycoprotein 
G 7  SEMA3A, 78kb downstream (in LOC101927378) Secreted neuronal protein 
H 14 3 IGHG2 Immunoglobulin heavy constant 
I 21 13 GRIK1 Glutamate receptor, neural 
J 21 12 GRIK1 Glutamate receptor, neural 
From ten stable, high expressing clones, we identified eight integration loci using PCR-
based low-throughput methodologies.  Each site was confirmed using primers matching 
the transgene and genomic locus, which produced a positive band but lack of band with 
wild-type gDNA.  Each locus is discussed in detail in Supplementary Material of the 
publication175. 
2.3.3. Expression mapping of hot spot loci reveal influence and impact of 
surrounding genes 
Next, we sought to evaluate the expression profile of surrounding protein coding 
regions in the various clones before and after transgene integration to determine both the 
benefits to transgene expression provided by the surrounding genomic DNA, as well as 
perturbations that may be caused by integration. Perturbations are specifically important in 
gene therapy applications, where ‘harmless’ integration loci must be chosen such that 
surrounding genes, especially oncogenes, are not inadvertently impacted.  Previous studies 
have demonstrated both modes of action with transgene expression155, 178.   
In this experiment, expression levels of protein coding genes were determined using 
RT-PCR with whole cell RNA for both the GFP-positive clone and wild-type HT1080.  
Expression of each gene was compared to ribosomal protein 11 (RPS11), a common human 
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housekeeping gene that is highly expressed at levels 4000-fold higher than the average 
gene (ranking it as the 117th most highly expressed gene based on a microarray study 
conducted by Shire Human Genetic Therapies).   
The resulting expression maps for all clones (excluding those integrated in the 
unplaced human genomic contig for which no information is available) are shown in 
Figure 2-3.  Universally, it is seen that protein coding sequences distantly located from the 
site of integration exhibit little to no difference between wild-type and GFP-positive clone 
transcripts indicating minimal expression perturbation caused by transgene integration.  
Here, we define minimal expression perturbation as being less than a 2-fold change in gene 
expression level.  Minimal, local transcriptional expression disruption is observed for 
clones C, E, F, and I (Figures 2-3A, 2-3C, 2-3D and 2-3G).  For the case of clone D 
(Figure 2-3B), expression in the GFP-positive clone of neighboring gene SEMA6A is 
elevated compared to the wild-type.  Finally, with the exception of the integration site for 
clone D and E, we see that expression of the transgene is significantly elevated relative to 
the surrounding genes, which in most cases are lowly expressed.  Thus, while these sites 
can enable high-level transcription, the transgene cassette is not simply hijacking a region 
of high transcription.  Collectively, these results indicate that the identified hot spot loci 
are indeed good integration loci with minimal impact to the expression of local genes.   
2.3.4. De novo targeting into GRIK1 12th exon/intron enables improved transgene 
expression 
Finally, we sought to demonstrate the impact of combining these high-transcription 
loci with site-specific genomic targeting techniques to speed the process of CLD and serve 
as an alternative to clonal screening.  We opted to use the CRISPR system which was 
recently demonstrated to be a flexible, highly efficient method for mammalian genome 
editing144, although delivery of large constructs via this method have not been previously 
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shown in human cell lines.  For this test, we selected the 12th exon-intron region of the 
GRIK1 gene on chromosome 21 as the target of choice as it exhibited high expression and 
was in a region identified independently in two clones.  Furthermore, site-specific 
integration at this locus was confirmed using primers found in Supplementary Material, 
Table S2 (61-63, 84-87) of the publication175. 
Initial tests to reconstitute high GFP expression with different transgene 
arrangements were conducted in HT1080 cells by delivering the pPG and pGP expression 
cassettes (Figure 2-1D) to this locus.  Targeted integrations to this GRIK1 locus were 
performed by transfecting the guide RNA (gRNA) construct along with the hCas9 and 
hrGFP/SEAP cassettes. The gRNA in this case encodes a crRNA-tracrRNA fusion 
transcript driven by the U6 polymerase III promoter modified to include a specific 23-
nucleotide region of homology to a distinct region in this locus.  This gRNA design was 
selected to minimize off-targeting effects using the criteria outlined by previous 
researchers144. Seventy-two hours after the transfection, cells were subjected to selection 
at MIC75 levels until viability recovered to greater than 90%.   
Compared to the controls with random integration, the targeted transfections to the 
GRIK1 locus in HT1080 resulted in a roughly 1.3- to 1.4-fold increase in GFP expression 
levels as measured via flow cytometry, at the stable bulk level (p < 0.001 when comparing 
their geometric mean difference) (Supplemental Figure S2a and S2b of the 
publication175).  Moreover, the population histograms are indicative of an overall shift in 
high expression, not a clear sub-population for these two transgene arrangements 
(Supplemental Figure S2c of the publication175).  To demonstrate the true potential of this 
site-specific integration, we isolated single cell clones with confirmed integration into the 
loci using a PCR-based approach179.  In this case, site-specific integration and isolation 
demonstrated a 3.1- to 3.9-fold improvement in geometric mean fluorescence (Figure 2-
 39
4A) when measured between 72 days and 110 days post-selection (p < 0.001 when 
compared to several clones with random integration for both constructs).  Based on the 
clones isolated from limited dilution cloning with our transgene integrated in the GRIK1 
locus, we estimate that the targeted integration efficiency is roughly <1% with the gRNA 
construct used.  These efficiencies are lower than previously reported values for other 
human cell types, but this is indeed the largest construct (6-kb) attempted for integration 
into the human genome144, despite recent work reporting a ~5-kb integration into HEK293 
and CHO with comparable efficiencies180 using the CRISPR/Cas system.   
Finally, we sought to demonstrate the capacity of site-specific integration into hot-
spot loci for a model secreted protein, SEAP, at the GRIK1 locus to verify that the 
improvements observed were not dependent/associated with the gene expressed.  Similar 
to the hrGFP study, HT1080 control cells were transfected with the pPS and pSP expression 
cassettes (Figure 2-1D) with similar controls.  Cultures were maintained for up to 120 days 
to account for any silencing that may occur in both populations (Supplemental Figures 
S2d-S2f of the publication175).  On average, the SEAP productivity was 1.3- to 1.4-fold 
higher for the targeted integration pools over that of random integration (Supplemental 
Figure S2g of the publication175) accounting for differences in heterogeneous bulk 
populations (Supplemental Figure S2h of the publication175).  This improvement is 
similar to the benefit in hrGFP expression observed when using targeted integrations at the 
GRIK1 locus.  Clonal populations were once again isolated and confirmed using PCR, and 
the site-specifically integrated clone exhibited a 2.4-fold increase in productivity (qp,random 
clones = 0.00956 ± 0.00298 compared to qp,specific clone = 0.0226 ± 0.0015, 95% CI, p < 0.001, 
confirming the increase in heterologous gene expression by specifically integrating a 
transgene into the GRIK1 locus (Figure 2-4B).  It should be noted that while the total 
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production of SEAP is low in this cell line, this is consistent with previous expression of 
this protein in this cell line. 
Figure 2-4:  Targeted integration into the GRIK1 loci results in elevated hrGFP and 
SEAP expression.   
 
 
 
  
 41
Figure 2-4, continued: 
A mammalian expression cassette expressing hrGFP or SEAP and puromycin was 
transfected into HT1080 cells in a random (control) and targeted fashion (Grik1B) using 
the CRISPR/Cas system. Following antibiotic selection, heterogeneous populations were 
evaluated and subsequently derived clonal populations by limited dilution cloning.  A. 
Flow cytometry was used to measure GFP expression.  Geometric mean fluorescence 
values of isolated hrGFP-expressing clones show a clear increase in GFP expression upon 
targeted integration into a transcriptional hot-spot.  Error bars represent 95% confidence 
interval of geometric mean from 3 clones (pPG) or 4 clones (pGP) isolated by limited 
dilution cloning.  B. SEAP productivity (pg/cell/day) of clonal (isogenic) populations 
transfected with the pSP expression cassette.  Site-specific integration into the 
transcriptional hot-spot in the GRIK1 locus supports a 2.4-fold increase in productivity 
when compared to random integration of the transgene.  Error bars represent 95% 
confidence interval of mean production from 3 clones (random, pSP) and 1 site-
specifically integrated clone (pSP). 
2.4. CONCLUSIONS 
By using an unbiased genome integration approach, we identify ten recombinant 
human cell lines with stable, single-copy, high-level heterologous gene expression and 
subsequently identify the corresponding integration loci. These results indicate the 
importance of non-protein coding regions for heterologous gene expression, despite the 
fact that previous studies have focused exclusively on exonic regions. Expression maps for 
each of these loci demonstrate negligible perturbations caused to the surrounding genes.  
Finally, we demonstrate that de novo, targeted integration at one of the identified loci, the 
12th exon of the GRIK1 gene on chromosome 21, results in superior expression compared 
to the standard, illegitimate integration approach.  This work provides a much needed 
cataloging of potential genomic hot spots that can be linked together with emerging 
genome editing tools.  Targeting these advantageous integration loci can significantly 
reduce the time, labor and materials associated with CLD.  Additionally, this approach (and 
specific targets identified) can be extended to other mammalian cell lines used for industrial 
protein production, including CHO and HEK293 and help speed CLD.  Critically, this work 
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demonstrates that the integration locus is an important component of our cellular 
engineering toolbox that we can leverage for fine-tuning gene expression.  
 43
Chapter 3: Inserting the message – characterizing transgene integration 
selectivity 
3.1. CHAPTER SUMMARY 
Due to the low success rate of identifying clonal populations with the transgene 
integrated at the correct locus in the work described in Chapter 2, we explored a cell line 
development strategy to improve upon that rate.  Our strategy will offer significant 
enrichment of the transgene containing population and simultaneously isolating 
integrations at the correct locus within that population by combining both positive and 
negative selection.  The characterization of this strategy described here focuses on using 
the CRISPR/Cas9 system for directing specific double strand breaks (DSBs) to facilitate 
the targeted integrations in mammalian host cell lines.  First, we confirmed the appropriate 
concentrations required for effective selection by determining MIC75 for each selection 
agent in each cell type.  Subsequently, adopting a co-targeting approach181 enabled us to 
validate gRNA designs for targeting a specific locus and characterize the frequency of DSB 
formation and repair at that locus by Sanger sequencing and quantitative PCR.  The work 
described in this chapter sets the foundation for the full characterization of our cell line 
development strategy. 
3.2. INTRODUCTION 
Transgene incorporation into the mammalian genome is routinely achieved through 
random integration facilitated by innate DNA repair mechanisms178.  This transgene 
integration process can be fundamentally divided into two steps: 1) the generation of a 
double strand break (DSB) and 2) the repair of the resulting break by homology-directed 
repair (HDR), microhomology-mediated end-joining (MMEJ), and/or non-homologous 
end-joining (NHEJ)182-184.  Since these DBSs can occur randomly in the host cell genome, 
the random integrations would require extensive screening to identify suitable transgene-
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expressing cell lines, increasing the time and material resources for this process185.  One 
approach to expedite this process was to establish pre-engineered cell lines with 
recombination/recognition sites for future integrations40, 41, 186-188. Alternatively, 
integration vectors derived from lentivirus or adenovirus can offer configurable directed 
integration189, 190 but with rather poor efficiency.  However, these pre-established sites may 
not be ideal depending on the application as we have shown in Chapter 2 that the integration 
site itself can significantly impact gene expression, limiting the utility of these engineered 
cell lines. 
We can exploit recent nuclease technologies such as ZFNs, TALENs, or the 
CRISPR/Cas9 system in order to programmatically introduce DSBs for transgene 
integration through the same innate DNA repair mechanisms191-193.  These nucleases offer 
directed DSB generation based on the DNA target, although they can be either DNA-
encoded (ZFN and TALEN) or RNA-guided (CRISPR/Cas9).  Due to this mode of target 
recognition, it is plausible that minimal mismatches to the target sequence would signal for 
nuclease activity, leading to off-target DSBs and adverse consequences.  Previous work 
indicated that the guide-RNA (gRNA) required for CRISPR/Cas9 functionality can 
influence DSB frequency at the target site, even though different gRNAs were designed 
based on the same protospacer motif (PAM) corresponding to a particular Cas9 enzyme64, 
144, 194.  Cleverly, by using a co-targeting approach to the hypoxanthine 
phosphoribosyltransferase (HPRT) gene and selection with 6-thioguanine (6-tG), the 
selected population was substantially enriched for DSB and repair activity at the target loci 
in a variety of mammalian cells181.  Therefore, this co-targeting approach can be 
incorporated into a cell line development strategy and/or used to screen gRNA designs. 
To further characterize the CRISPR/Cas9 system, the Cas9 nuclease derived from 
S. pyogenes (hereafter SpCas9) was critically evaluated for its on-target activity and off-
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target effects72, 146, 195-198 and subsequently, efforts to improve on-target activity were 
reported by engineering the enzyme itself93, 94, 199.  Alternatively, functional Cas9 enzymes 
derived from other species, such as N. meningitidis, recognize different PAMs and can be 
used to reduce off-target effects200.  Improvements to the Cas9 enzymes could certainly 
improve the generation of desired DSBs at the target locus with minimal cuts elsewhere in 
the genome, but the nuclease choice and its fidelity should not impact the innate DNA 
repair mechanism itself.  However, it was recently reported that the repair of DSBs induced 
by the CRISPR/Cas9 system is highly dependent on the protospacer sequence in the target 
site and is not purely random201.  Therefore, by shifting DNA repair towards HDR from 
the preferred NHEJ in mammalian cells202, it would be possible to favor more integrations 
at the desired locus.   
When the ability of the CRISPR/Cas9 system to mediate transgene integration was 
specifically investigated in CHO cells, the integration rate for a 3.7-kbp transgene varied 
between 7-28% depending on the target locus179.  The integration of an ~5-kbp transgene 
by NHEJ were rather low in HEK293 cells (0.17%) and CHO cells (0.45%) however180, 
indicating that these success rates are highly variable across target loci and even within the 
same cell types.  Other efforts tested the coupling of ZFN mRNA delivery146, 203 or 
CRISPR/Cas9 mRNA delivery with adeno-associated virus vectors99 to achieve reasonable 
levels of genome editing in a variety of key mammalian cell types. 
Ultimately, the interplay between the ability to generate precise on-target DSB and 
effective repair of the break with the transgene donor will dictate the integration process.  
Yet an efficient integration process still requires enrichment of the transgene containing 
and expressing population, and a stringent selection system could easily facilitate this 
enrichment204.  Unfortunately, a highly selective cell line development strategy alone does 
not necessarily imply that transgene integrations are at the desired locus (unless the loss-
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of-function due to insertion at the locus can be leveraged).  Therefore, the selectivity of a 
particular cell line development strategy comprised of both the enrichment for transfected 
cells and the isolation of the cell population with transgene integration at the desired locus 
need to be addressed simultaneously. 
To account for the selectivity in a cell line development strategy, we investigated 
options to facilitate our enrichment by coupling positive and negative selection and 
alternative nucleases with increased on-target activity.  We suspected that the two-pronged 
improvements will significantly favor the transfected cell population with transgene 
integration at the desired locus.  Following conventional practice, screening the transfected 
cell population with positive selection allows enrichment of the transgene containing 
population, but coupling this selection with negative selection could remove transgene 
integrations at undesired loci.  By increasing the propensity of the CRISPR/Cas9 system 
to induce DSBs at the desired locus, more DNA repair events could occur at that site, 
thereby increasing the likelihood of integrations at that the target site.   
3.3. RESULTS AND DISCUSSION 
3.3.1. Characterizing basal HDR rate and transgene designs 
For our cell line development strategy, combining positive and negative selection 
relies heavily on HDR and perhaps MMEJ to repair the DSB at the target site.  Any 
resulting NHEJ at the target site would be eliminated due to the negative selection marker 
present in our transgene.  Therefore, obtaining an estimate of the basal HDR rate without 
selection could serve as a baseline or a minimal expected rate of integration for our system 
into the desired locus.  We evaluated this basal HDR rate in HT1080 model cells using a 
dual reporter (SEAP and hrGFP) linked by an EMCV IRES205 transgene with 800-bp of 
flanking homology to the GRIK1 locus identified in Chapter 2 (Figure 3-1).  
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Figure 3-1: Transgene design for evaluating basal HDR rate in HT1080 cells targeting 
the GRIK1 locus. 
 
Coding sequences for secreted alkaline phosphatase (SEAP) and humanized Renilla 
green fluorescent protein (hrGFP) are linked by the EMCV IRES to enable bicistronic 
expression. 
We generated 3 heterogeneous bulk populations that expressed our dual reporter 
transgene without using selection pressure, and the resulting bulk populations contained a 
low proportion of cells expressing our transgene based on flow cytometry (Figure 3-2, 
left).  From these populations, we seeded 576 wells for limited dilution cloning and isolated 
5 populations that stably expressed hrGFP.  However, from these 5 populations, only 3 
were clonal populations as suggested by the histograms from flow cytometry (Figure 3-2, 
right); it is obvious that 2 of the populations are comprised of two distinct populations: 
untransfected and transgene expressing as represented by the bimodal distribution.  Based 
on the frequency of isolating these clonal populations with confirmed integration at the 
GRIK1 target site, the overall, basal HDR rate is ~0.5% in HT1080.  This HDR rate matches 
more closely with the integration rates previously reported in HEK293 and CHO cells for 
a ~5-kbp transgene180, and our transgene is ~5.6-kbp including the homology regions. 
Figure 3-2: Histograms from flow cytometry analysis evaluating basal homologous 
recombination in HT1080. 
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Figure 3-2, continued: 
(left) Histograms from flow cytometry analysis of 3 HT1080 heterogeneous bulk 
populations containing our dual reporter transgene.  (right) Histograms of 5 populations 
isolated by limited dilution cloning derived from the HT1080 bulk populations.  The 
clone numbering “x.y” denotes that the “y” clone isolated from bulk population “x”. 
These low rates in HT1080, HEK293, and CHO suggest that an optimized strategy 
could drastically improve the frequency of successful transgene integration.  In order to 
assess our combined positive and negative selection cell line development strategy, we 
created transgenes expressing the hrGFP reporter and Zeocin™ resistance204 linked by the 
same IRES element that are flanked by 800-bp homology to GRIK1/C. griseus Grik1 
(hereafter Cg.Grik1) on each side.  An additional expression cassette containing the 
negative selection marker based on the fusion of the S. cerevisiae-derived cytosine 
deaminase gene and the uracil phosphoribosyltransferase gene206-208 (sequence derived 
from pSELECT-zeo-Fcy::fur, InvivoGen, San Diego, CA) located downstream of the 3’ 
800-bp locus homology region (Figure 3-3).  Selection against the expression of this fusion 
gene with 5-fluorocytosine (5-fC) should eliminate cells with the transgene integrated 
anywhere besides the target locus. 
Figure 3-3: Transgene design for evaluating positive and negative selection in HT1080, 
HEK293, and CHO cells targeting the GRIK1/Cg.Grik1 locus. 
 
Coding sequences for the humanized Renilla green fluorescent protein (hrGFP) is linked 
by the EMCV IRES to Zeocin™resistance, enabling bicistronic expression. 
3.3.2. Determining effective concentrations of selection agents 
The positive selection, negative selection, and co-targeting selection require 
Zeocin™, 5-fC, and 6-tG selection respectively.  The effective concentration of these 
agents can vary across cell types, and we established working concentrations for our cell 
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line development strategy empirically by determining the maximum inhibitory 
concentration that kills 75% of the population (MIC75).  This determination for Zeocin™ 
and 6-tG was executed using wild-type (parental) host cells since Zeocin™ resistance or 
mutations to the HPRT1/C. griseus Hprt1 (hereafter Cg.Hprt1) locus are required for cell 
survival against these selection agents. 
We confirmed that the previously reported approximate concentrations of Zeocin™ 
required are sufficient for inducing robust cell death in HT1080 and HEK293 cells25.  We 
tracked the cell viability of 3 parental HT1080 (Figure 3-4) and HEK293 (Figure 3-5) cell 
lines subjected to 75 µg/mL Zeocin™ at day 0 and observed sufficient cell death in 7-10 
days with media replacement every 2-3 days.  Interestingly, a much higher selection 
concentration of Zeocin™ was required to achieve adequate killing of CHO cells within 
that same time period based on our data (Figure 3-6). 
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Figure 3-4: Confirmation of effective Zeocin™ selection in HT1080 cells 
 
Culture media replaced every 2 days.  Cell viability determined by ViCell XR (Beckman 
Coulter).  
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Figure 3-5: Confirmation of effective Zeocin™ selection in HEK293 cells 
 
Media replaced every 3 days.  Cell viability determined by ViCell XR (Beckman 
Coulter).  
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Figure 3-6: Confirmation of effective Zeocin™ selection in CHO cells 
 
Media replaced every 2 days.  Cell viability determined by ViCell XR (Beckman 
Coulter). 
Based on previous work181, we evaluated final concentrations of 6-tG at 5 µg/mL 
and 10 µg/mL in all 3 parental cell lines with the addition of 25 µg/mL for HT1080.  All 
concentrations tested were effective in these cell lines, with 10 µg/mL only showing a 
marginal benefit in HEK293 cells (Figures 3-7 to 3-9).  Therefore, we anticipated using 
the 5 µg/mL final concentration for 6-tG selection.  
0
20
40
60
80
100
0 2 4 6 8 10 12
V
ia
bi
lit
y 
(%
)
Time (days)
25μg/mL 50μg/mL 100μg/mL
200μg/mL 400μg/mL WT
 53
Figure 3-7: Confirmation of effective 6-tG selection in HT1080 cells 
 
Media replaced every 2 days.  Cell viability determined by ViCell XR (Beckman 
Coulter).  
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Figure 3-8: Confirmation of effective 6-tG selection in HEK293 cells 
 
Media replaced every 3 days.  Cell viability determined by ViCell XR (Beckman 
Coulter).  
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Figure 3-9: Confirmation of effective 6-tG selection in CHO cells 
 
Media replaced every 2 days.  Cell viability determined by ViCell XR (Beckman 
Coulter). 
However, in order to evaluate various concentrations of 5-fC required for effective 
selection, we would first need to generate cell lines containing the negative selection fusion 
gene in HT1080, HEK293, and CHO cell lines.  To obtain representative selection 
concentrations for 5-fC, we would need cell populations that contain a mixture of the entire 
transgene correctly integrated at the target site (removing the negative marker through 
HDR) and integrations due to NHEJ repair (retaining the negative marker), thus requiring 
the establishment of such cell lines prior to this analysis.  Nonetheless, it is expected that 
5-fC at 125-500 µg/mL is effective in mammalian cells expressing cytosine deaminase206, 
although this concentration may be even lower in our system given the superiority of the 
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yeast-derived cytosine deaminase variant in our fusion gene207 and the presence of both 
cytosine deaminase and uracil phosphoribosyltransferase can further increase 5-fC 
toxicity209. 
3.3.3. Qualifying gRNA designs in HT1080, HEK293F, and CHO-S cell lines 
To effectively use the CRISPR/Cas9 system, the corresponding gRNAs designed 
for various loci must be able to properly interact with tbe Cas9 enzyme to induce the DSB.  
We can leverage the co-targeting approach previously established181 in order to evaluate 
the extent at which a particular gRNA design would induce DSB activity at the desired 
locus (GRIK1/Cg.Grik1).  Previously, without the co-targeted editing of HPRT1/Cg.Hprt1 
and selection with 6-tG, it would be difficult to ascertain whether DSBs did not occur at 
the target site due to poor gRNA design, defunct Cas9 activity, or poor Cas9 expression in 
the particular cell type, implying that integrations would not be directed towards the target 
site. 
In order to estimate the editing frequency at the target locus using CRISPR/Cas9 
and a particular gRNA, we can recover the sequence of target locus with PCR.  Given the 
lower fidelity of Taq polymerase used to recover the sequence of the target locus, we first 
analyzed our recovery procedure using the WT/parental cell lines.  This analysis of the WT 
sequence informs us of the false-positive rate of arbitrarily detecting editing either as a 
mutation or indel at the target region.  We amplified the target regions of HT1080, 
HEK293, and CHO cells from their extracted genomic DNA.  These PCR products were 
sub-cloned into pCR™4-TOPO® TA vectors (Thermo Fisher Scientific) for sequence 
recovery by Sanger sequencing.  Based on this data (Table 3-1), the PCR/TOPO TA 
recovery method does not yield false estimates of indels, but introduces some mutations at 
the target regions (~3%). 
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Table 3-1: Estimated frequency of editing in HPRT1/Cg.Hprt1, GRIK1/Cg.Grik1, or 
AAVS1 locus from WT/parental HT1080, HEK293, and CHO cells. 
cell line target total colonies 
Indel 
count/freq 
Mutation 
count/freq 
indel+mutation 
count/freq 
WT 
count/freq 
HT1080 HPRT1 11 0 0.0% 0 0.0% 0 0.0% 11 100.0% 
HT1080 GRIK1 12 0 0.0% 1 8.3% 0 0.0% 11 91.7% 
HT1080 AAVS1 11 0 0.0% 0 0.0% 0 0.0% 11 100.0% 
HT1080 total 34 0 0.0% 1 2.9% 0 0.0% 33 97.1% 
HEK293 HPRT1 11 0 0.0% 0 0.0% 0 0.0% 11 100.0% 
HEK293 GRIK1 11 0 0.0% 0 0.0% 0 0.0% 11 100.0% 
HEK293 AAVS1 11 0 0.0% 1 9.1% 0 0.0% 10 90.9% 
HEK293 total 33 0 0.0% 1 3.0% 0 0.0% 32 97.0% 
CHO Grik1 11 0 0.0% 0 0.0% 0 0.0% 11 100.0% 
CHO Hprt1.1 10 0 0.0% 0 0.0% 0 0.0% 10 100.0% 
CHO total 21 0 0.0% 0 0.0% 0 0.0% 21 100.0% 
Counts determined by Sanger sequencing of PCR amplified/TOPO TA recovery.  The 
counts correspond to insertions/deletions (indel), mutations in the gRNA region, indel 
and mutations in the gRNA region, or the native wild-type (WT) sequence of the target 
region. 
We then quantified the frequency of genome editing at the GRIK1/Cg.Grik1 locus 
using our gRNA designs (GRIK1A, GRIK1B, GRIK1C, Cg.Grik1.1, Cg.Grik1.2) in 
HT1080, HEK293, and CHO cells, and as a control, at the AAVS1 locus using gRNAs 
previously described144 (AAVS1.T1 and AAVS1.T2) in HT1080 and HEK293 cells.  
Stable cell lines of each cell type were generated using the SpCas9144 in the Cas9 
expression vector used by Slaymaker, et al93 co-transfected with our target gRNA designs 
and HPRT1/Cg.Hprt1.1 gRNA in plasmid vectors (Addgene 41824).  We extracted gDNA 
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from each of these transformed populations after their recovery from selection with 5 
µg/mL 6-tG.  To estimate of the editing frequency at these loci in these Cas9-edited cell 
populations, we recovered the genomic sequence of the target region by PCR and 
confirmed the sequence by Sanger sequencing.  We found that our GRIK1B gRNA was 
particularly effective in HT1080 although we detected lower activity using the same gRNA 
in HEK293 (Table 3-2).  Likewise, we detected activity for both control gRNAs to AAVS1 
in HT1080, and corroborated previous findings that the T2 target is more effective than the 
T1 target144, yet neither targets were edited in HEK293 (Table 3-2).  Most importantly, by 
using this HPRT1/Cg.Hprt1 co-targeting approach, we confirmed that the Cg.Grik1.1 
gRNA was effective while the Cg.Grik1.2 gRNA was unfortunately a poor design (Table 
3-2).  Through this approach, we can attribute the lack of target locus editing (represented 
as minimal indels and indels with mutations in the target locus) is directly related to the 
gRNA design instead of nuclease activity since a functional Cas9 is required to edit 
HPRT1/Cg.Hprt1 to confer survival with 6-tG selection. 
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Table 3-2: Estimated frequency of editing in GRIK1/Cg.Grik1 or AAVS1 from 
HT1080, HEK293, and CHO cells after 6-tG selection. 
cell line target total colonies 
Indel 
count/freq 
Mutation 
count/freq 
indel+mutation 
count/freq 
WT 
count/freq 
HT1080 GRIK1A 21 8 38.1% 0 0.0% 0 0.0% 13 61.9% 
HT1080 GRIK1B 20 15 75.0% 0 0.0% 0 0.0% 5 25.0% 
HT1080 GRIK1C 8 4 50.0% 0 0.0% 2 25.0% 2 25.0% 
HT1080 AAVS1.T2 22 21 95.5% 0 0.0% 0 0.0% 1 4.5% 
HT1080 AAVS1.T1 22 14 63.6% 0 0.0% 0 0.0% 8 36.4% 
HEK293 GRIK1B 24 8 33.3% 2 8.3% 0 0.0% 14 58.3% 
HEK293 GRIK1C 23 3 13.0% 1 4.3% 0 0.0% 19 82.6% 
HEK293 AAVS1.T2 23 0 0.0% 0 0.0% 0 0.0% 23 100.0% 
HEK293 AAVS1.T1 20 0 0.0% 1 5.0% 0 0.0% 19 95.0% 
CHO Cg.Grik1.1 22 17 77.3% 1 4.5% 0 0.0% 4 18.2% 
CHO Cg.Grik1.2 24 2 8.3% 2 8.3% 1 4.2% 19 79.2% 
Counts determined by Sanger sequencing of PCR amplified/TOPO TA recovery.  The 
counts correspond to insertions/deletions (indel), mutations in the gRNA region, indel 
and mutations in the gRNA region, or the native wild-type (WT) sequence of the target 
region. 
In addition to verifying the edited genomic sequence by PCR and Sanger 
sequencing, we can qualitatively confirm that the target locus was edited and estimate the 
editing frequency in the target locus with quantitative PCR210.  Probes designed near and 
at the target site detect the abundance of the region (Figure 3-10), and the editing frequency 
can be estimated through a differential signal between the two probes.  This difference is 
due to the loss of signal from the probe corresponding to the target site that is subject to 
editing and repair by NHEJ.  Unlike the PCR/TOPO TA recovery method, this gene editing 
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frequency qPCR (GEF-qPCR210) assays the genomic DNA directly, avoiding any sampling 
bias selected for Sanger sequencing analysis. 
Figure 3-10:Depiction of qPCR probes near the target site (green) and at/spanning the 
target site (red). 
 
Primers (solid arrows) amplify the target region for GEF-qPCR while the primers slightly 
outside of the target region (arrows with lined fill) recover the sequence for TOPO TA 
cloning and Sanger sequencing analysis. 
Using the same genomic DNA analyzed with the PCR/TOPO TA recovery method, 
we first estimated the editing of the GRIK1 using the GRIK1B gRNA and AAVS1 locus 
using the AAVS1.T2 gRNA with GEF-qPCR as the threshold cycle (CT, equivalent to 
quantification cycle Cq) difference relative to the WT sequence in HT1080.  The measured 
change in threshold cycle (dCT) was significantly different for the GRIK1B target site in 
GRIK1 than the GRIK1A target site or the AAVS1 locus control, in addition to the parental 
WT sequence (Figure 3-11).  Similarly, the same differential was observed at the 
AAVS1.T2 site using the AAVS1.T2 gRNA while the adjacent AAVS1.T1 site and GRIK1 
sites were not impacted (Figure 3-12).  Similarly, the same measurements for the 
Cg.Grik1.1 gRNA target in Cg.Grik1 indicated that editing was clearly detected at the 
target site in CHO cells (Figure 3-13). 
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Figure 3-11:Estimated editing of GRIK1 at the GRIK1B target from HT1080 cell 
populations subjected to co-targeting and 6-tG selection based on dCT from 
GEF-qPCR. 
 
In comparison to the parental WT cells and other genomic DNA with edits at the AAVS1 
locus, the genome was edited in GRIK1 at the GRIK1B target site with the GRIK1B 
gRNA while no changes were detected using the GRIK1A gRNA.  
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Figure 3-12:Estimated editing of AAVS1 at the AAVS1.T2 target from HT1080 cell 
populations subjected to co-targeting and 6-tG selection based on dCT from 
GEF-qPCR.   
 
In comparison to the parental WT cells and other genomic DNA with edits at the GRIK1 
locus, the genome was edited in AAVS1 at the T2 target site with the AAVS1.T2 gRNA 
while no changes were detected using the AAVS1.T1 gRNA.  
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Figure 3-13:Estimated editing of Cg.Grik1 at the Cg.Grik1.1 and Cg.Grik1.2 targets 
from CHO cell populations subjected to co-targeting and 6-tG selection 
based on dCT from GEF-qPCR. 
 
In comparison to the parental WT cells (CAT-S), the genome was edited at Cg.Grik1 
with the Cg.Grik1.1 gRNA while marginal changes were detected using the Cg.Grik1.2 
gRNA. 
By establishing standard calibrations for the primers used in GEF-qPCR, we can 
also estimate the editing frequency from this data (Figures 3-14 to 3-16).  Collectively, 
these results suggest that GEF-qPCR is sufficiently sensitive to single nucleotide 
resolution, enabling precise interrogation of the target integration site.  
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Figure 3-14:Estimated editing of GRIK1 at the GRIK1B target from HT1080 cell 
populations subjected to co-targeting and 6-tG selection. 
 
In comparison to the parental WT cells and other genomic DNA with edits at the AAVS1 
locus, the genome was ~53% edited in GRIK1 at the GRIK1B target site with the 
GRIK1B gRNA while no changes were detected using the GRIK1A gRNA.  
 65
Figure 3-15:Estimated editing of AAVS1 at the AAVS1.T2 target from HT1080 cell 
populations subjected to co-targeting and 6-tG selection. 
 
In comparison to the parental WT cells and other genomic DNA with edits at the GRIK1 
locus, the genome was ~42% edited in AAVS1 at the T2 target site with the AAVS1.T2 
gRNA while no changes were detected using the AAVS1.T1 gRNA.  
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Figure 3-16:Estimated editing of Cg.Grik1 at the Cg.Grik1.1 and Cg.Grik1.2 targets 
from CHO cell populations subjected to co-targeting and 6-tG selection. 
 
In comparison to the parental WT cells (CAT-S), the genome was ~75% edited at 
Cg.Grik1 with the Cg.Grik1.1 gRNA while marginal changes (~10%) were detected 
using the Cg.Grik1.2 gRNA. 
3.4. CONCLUSIONS 
The work described in this chapter established the groundwork for a method to 
quantify the integration frequency at a target site mediated by CRIPSR/Cas9, estimating 
the selectivity of the transgene integration process.  This work facilitates the evaluation of 
Cas9 variants with higher fidelity on transgene integration and an assessment of a coupled 
positive and negative selection strategy to improve targeted integration selectivity.  It is 
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through an effective and precise generation of DSBs at the target site and subsequent repair 
with the transgene donor to that site that an integration process can be considered selective 
for cell line development.  While we observed the expected behavior when evaluating 
Zeocin™ selection conditions in HT1080, HEK293, and CHO cells, we observed a 
significant detriment to cell viability with 6-tG selection such that resistant populations 
were generated with only a single treatment instead of media replacement with 6-tG.  Even 
with the single treatment, these selected populations were still resistant to 6-tG at 5 µg/mL 
after recovery. 
Based on this toxicity, coupling both Zeocin™ and 6-tG selection in a cell line 
development strategy would be extremely taxing on the cells and we concluded that the 
co-targeting approach should be reserved for evaluating gRNA designs.  Furthermore, if 
cells are co-targeted for DSBs at HPRT1/Cg.Hprt1 and another locus, there would be an 
increased chance of undesired chromosomal rearrangements and/or transgene integration 
into the HPRT1/Cg.Hprt1 locus instead of the desired locus.  Even though a selective cell 
line development strategy incorporating negative selection should eliminate cells with 
integrations at other loci, including HPRT1/Cg.Hprt1, the additional DSB and repair at 
HPRT1/Cg.Hprt1 impose additional unnecessary strain on the cells since the target gRNA 
would already be validated for activity. 
Through the HPRT1/Cg.Hprt1 co-targeting approach181, we identified gRNA 
designs (GRIK1B and Cg.Grik1.1) that are effective in HT1080, HEK293, and CHO cells.  
We can also use this method to conclude that other gRNA targets (GRIK1A, GRIK1C, and 
Cg.Grik1.2) are poor designs for these particular cell types based on the induced DSB 
activity and resulting NHEJ repair.  Although we determined an effective selection 
concentration for 6-tG in HT1080, HEK293, and CHO cells, we observed much lower DSB 
activity for both GRIK1 and AAVS1 loci in HEK293 cells based on measurements by our 
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PCR/TOPO TA recovery method (Table 3-1).  In particular, the same GRIK1B gRNA 
showed lower activity in HEK293 than HT1080, suggesting that gRNA design may need 
to account for various cell types despite sharing the same genomic sequence.  However, it 
is also possible that the observed differences are manifestations of different transfection 
efficiencies between the two cell types.  Crucially, we did not measure any DSB activity 
at the AAVS1 locus in 6-tG resistant HEK293 cells, which conflicts with previous work 
describing the DSB activity at this locus144.  The AAVS1.T1 and AAVS1.T2 gRNA targets 
are commonly used as positive controls, thus further investigation with our HEK293 cells 
are necessary to clarify the lack of DSB activity and DNA repair at these sites. 
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Chapter 4: Creating the message – engineering synthetic promoters for 
high transgene expression3 
4.1. CHAPTER SUMMARY 
To establish precise control of gene expression in mammalian hosts, we need to 
investigate the local genetic elements that govern transcription in addition to specifying the 
integration loci of these elements.  Traditionally, promoter engineering enabled the 
transcriptional control required for bioproduction from mammalian hosts, focusing on 
achieving high expression levels.  Despite recent advances in improving titers for 
therapeutic proteins such as antibodies to the 10 g/L scale, these high yields can only be 
achieved in select mammalian hosts.  Regardless of the host or product, strong promoters 
are required to obtain these high levels of transgene expression.  However, the promoters 
employed to drive this expression are rather limited in variety and are usually either viral-
derived or screened empirically during vector design.  To begin to move away from viral 
parts, we employed a more systematic approach to identify and design new synthetic 
promoters using endogenous elements.  To do so, we established a workflow to design 
these elements by: (1) analyzing the transcriptomics profile of a specific cell line under a 
desired, representative cell culture condition, (2) identifying key genetic motifs using 
bioinformatics that can be used to rationally construct synthetic promoters, (3) building 
synthetic promoters using conventional DNA synthesis and molecular biology techniques, 
and (4) evaluating the performance of these synthetic promoters using model proteins.  The 
resulting promoters perform comparably to the hCMV IE promoter variants tested, but with 
endogenous components.  During this design-build-test cycle, we also investigated the 
                                                 
3 The content in this chapter can be found in a previously authored publication. JKC conducted the 
experiments and analyses, and wrote the chapter. 
Reprinted with permission from Cheng, J., & Alper, H. S. (2016). Transcriptomics-guided design of 
synthetic promoters for a mammalian system. ACS Synth Biol. Article ASAP. Publication Date (Web): 
June 7, 2016. DOI: 10.1021/acssynbio.6b00075. Copyright © 2016 American Chemical Society. 
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underlying design rules for transcription factor binding site arrangement in synthetic 
promoters.  Overall, this approach of using an ‘omics-guided workflow for designing 
synthetic promoters facilitates the construction of high expression vectors for immediate 
use in current production hosts. 
4.2. INTRODUCTION 
In recent years, select mammalian hosts have become potent vehicles for the 
production of heterologous, therapeutic antibodies and proteins with industrial titers 
reaching and exceeding 10 g/L scale211.  However, this capacity is not ubiquitous and is 
only possible in select hosts and for a subset of products, whereas difficult-to-express 
products still require intensive resources for their development212, 213.  Optimal 
heterologous protein expression from mammalian hosts requires fine-tuning many 
parameters213, 214 among which, the expression vector design plays a pivotal roles42. 
Inherently, one particular limitation in this field is the lack of genetic regulatory 
elements (namely, promoters) that can enable such high expression levels42.  This 
underdeveloped toolkit poses a clear challenge for engineering complex biotechnology 
applications that involve multiple reactions or pathways (e.g. a complete heparin 
pathway6).  Previously approaches for creating synthetic and hybrid promoters107, 215, 216 
employed both bottom-up and top-down approaches217, 218.  Additionally, collections of 
regulatory promoters exist to enable complex functionality such as multi-cistronic 
control219, epigenetic toggling220, and a mammalian oscillator circuit221.  Yet, the vast 
majority of promoter development has revolved around identifying, characterizing, and 
constructing hybrid promoters that are frequently viral-derived5, 222-224, thus resulting in 
synthetic parts that are susceptible to silencing225 with unreliable utility for long-term 
industrial processes.  To bypass stability issues, the commonly used cytomegalovirus 
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immediate-early [CMV IE] promoter was modified to include a CG-rich region (CpG 
island)226, 227 as well as alternative promoter variants228.  However, these modifications do 
not remove the viral nature of these promoters since methylation was observed at both CpG 
and non-CpG sites229 nor do they greatly expand the set of tools available.  As a result, a 
set of synthetic promoters (ideally non-virally derived) will be of high utility for 
mammalian cell engineering applications.     
This work seeks to establish a more systematic approach toward the rational design 
of synthetic promoter guided by high-throughput analysis such as microarray expression 
and RNA-seq.  The underlying premise for these designs is to incorporate distinguishing 
features (e.g. putative transcription factor binding sites, [TFBSs]) over-represented in high 
expression promoters and ideally absent in low or moderate expression.  A significant 
number of efforts (especially enabled by the ENCODE project230-232) have led to the 
cataloguing of transcription factors [TFs] and cognate TFBSs and their actions in vivo.  As 
a result, a variety of TF databases are available including the JASPAR database233 
(primarily used in the work described in this chapter), TRANSFAC234, MotifMap235, 
UniProbe236, and HOCOMOCO237 (among others) for H. sapiens.  While these databases 
contain a wealth of information that describes the endogenous expression program for a 
particular cell type, the use of these maps to prescribe transgene expression and design 
remains largely unexplored.   
Here, we describe and demonstrate a generalizable workflow for designing 
synthetic promoters based on representative microarray expression data of a mammalian 
production host (in this case, for the HT1080 fibrosarcoma host cell line, which is used to 
produce three globally, commercially available therapeutics135).   HT1080, in addition to 
other mammalian cell lines such as CHO and HEK293238 are important industrial hosts 
commonly used to produce protein therapeutics, such as insulin, antibodies, cytokines, 
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enzyme replacement therapies, and growth factors1.  Specifically, we use this expression 
data to identify TFBSs enriched in highly expressed promoters under desired conditions 
with the aid of a Gaussian Mixture Model [GMM] and bioinformatics.  Next, we designed 
synthetic promoter scaffolds based on these TFBSs and evaluated their performance with 
two model proteins.  The resulting promoters perform comparably to the hCMV IE 
promoter variants tested.  Finally, we briefly investigated possible design rules for TFBS 
arrangement by creating multiple variants of our synthetic promoters and evaluating their 
ability to drive the expression. 
4.3. RESULTS AND DISCUSSION 
In this work, we established and executed a generalizable workflow (Figure 4-1) 
to analyze large expression data sets (such as from microarray) and generate designs for 
synthetic promoters for a given cell type.  This workflow describes an expanded design-
build-test cycle that is highly accessible: (1) Design: expression data derived from 
representative cell culture conditions best reflect synthetic promoter application; (2) 
Design: large expression data sets inform the design process for synthetic promoters; (3) 
Build: conventional DNA synthesis and standard molecular biology techniques are used to 
build the synthetic promoter designs for expression vectors; and (4) Test: these expression 
vectors are transfected into the cell line of interest for evaluation.  Iterating upon this 
design-build-test cycle can further refine final designs and performance.  For this project, 
we applied this expanded D-B-T workflow for creating synthetic promoters to the 
mammalian host HT1080. 
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Figure 4-1:  Workflow to designing synthetic promoters from expression data. 
 
 
A generalized workflow is established through this work to go from bioinformatics 
analysis to design and testing of synthetic promoters. 
4.3.1. Processing and statistical modeling of gene expression data 
A microarray expression data set (Illumina) of the HT1080 cell line collected at 
four distinct time-points throughout a bioreactor fermentation under representative 
industrial process conditions (spanning growth and production phase) was provided by 
Shire Human Genetic Therapies.  Initially, this data comprising 48801 probes was pre-
processed using a logarithm transformation to normalize expression values and mapped to 
genes in the human genome.  Next, we modeled the expression data using a 3-component 
Gaussian Mixture Model (GMM) that assumed three populations of gene expression 
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existed in the data corresponding to high, moderate, and low expression.  The parameters 
describing the Gaussian components of this model (i, i, and i) were determined using 
an expectation-maximization algorithm239 with MATLAB software (Mathworks, R2014a).  
Qualitatively, this 3-component model adequately described the positively-skewed, log-
transformed data at all time-points (Figures 4-2A to 4-2D), and this model provided a 
quantitative means to assess the probability of any given measured expression value 
belonging to each of the three expression profiles (high, moderate, and low). 
Figure 4-2:  Processing of Microarray data using a Gaussian Mixture Model. 
A 
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Figure 4-2, continued: 
B 
 
C 
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Figure 4-2, continued: 
D 
 
GMM (blue) with three components (black, various patterns) and ksdensity 
approximation (red) of log-transformed expression data at time-point A) t1, B) t2, C) t3, 
and D) t4. 
Using this model, it was possible to evaluate expression profiles at each of the four 
timepoints and extract: (1) an expression threshold value (log-scale) that separated the 
“high” and “moderate” expression groups; (2) a false-positive probability associated with 
threshold (i.e. the probability that an expression value is incorrectly categorized as high 
expression); and (3) a false-negative probability associated with that threshold (i.e. the 
probability that an expression value is incorrectly categorized as low or moderate 
expression) (Table 4-1).  Moreover, we chose a rather conservative threshold such that the 
probabilities p(false-positive at threshold value) = p(fp)|th ൎ 0.001 was far less than p(false-
negative at threshold value) = p(fn)|th ൎ 0.11-0.13 across all time-points (Table 4-1).  As 
a result, if anything, this threshold “cut-off” value would underestimate the number of 
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constituents in the high expression group.  Similar sets of probabilities (Table 4-1) can be 
calculated across the other expression groups.  These probabilities have great power over 
arbitrarily selecting a cut-off for “high” expression.  For example, an arbitrary selection of 
the top 1% of available data (n = 488) as the “high expression group” would grossly 
underestimate membership for the group based the GMM with p(fp)|th ൎ 0.001  (n =  
6,499).  While the selection of discrete top m values would always be independent of using 
the statistical model, determining the members of the other expression groups (in this case, 
low and moderate), would not be as trivial especially for the skewed dataset observed 
(Figure 4-2).  Ultimately, this model was used to map gene expression (and ultimately 
promoter sequences) with expression levels.  While we chose the rational division of the 
microarray expression data into three groups representing discretized low, moderate, and 
high expression “groups”, the number of groups (components) in the GMM is easily 
modifiable for alternative experimental data. 
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Table 4-1:  Final Gaussian Mixture Model parameters. 
time 
point parameter 
low 
group 
moderate
group 
high 
group 
moderate-
high 
threshold
threshold 
p(fp)|th 
threshold 
p(fn)|th 
median 
p(fn)|m 
t1 
mean, μ 1.2395 1.6116 2.4971 
2.3704 1.00E-03 0.1141 0.0129 std. deviation, σ 0.1443 0.3047 0.6856 
probability, π 0.5759 0.1567 0.2674 
t2 
mean, μ 1.2325 1.5990 2.4879 
2.3602 9.99E-04 0.1153 0.0135 std. deviation, σ 0.1463 0.3056 0.6897 
probability, π 0.5728 0.1569 0.2704 
t3 
mean, μ 1.2087 1.5721 2.4746 
2.4095 1.00E-03 0.1257 0.0142 std. deviation, σ 0.1551 0.3346 0.7023 
probability, π 0.5662 0.1624 0.2714 
t4 
mean, μ 1.2070 1.5611 2.4496 
2.3563 1.00E-03 0.1257 0.0162 std. deviation, σ 0.1550 0.3198 0.7093 
probability, π 0.5643 0.1550 0.2808 
Parameters from each time point of a representative HT1080 culture fermented in a 
bioreactor are presented.  Final parameters are averaged from 10 independent 
optimizations of model parameters using an expectation-maximization algorithm. Values 
for the low, moderate, and high expression groups and the moderate-high threshold are in 
terms of the log(expression) from the microarray data set. 
4.3.2. Elucidating key TFBSs for representative strong promoters 
Using the GMM described above, we identified gene candidates based on their 
expression group and annotated their respective “promoter” regions with putative TFBSs 
using database-enabled bioinformatics.  Specifically, we selected non-ribosomal, coding 
sequences and mapped their promoter sequences to the annotated human genome 
(GRCh38.p2 assembly, NCBI).  For this test, we identified a subset of 20 of the most highly 
expressed genes across all time-points (Supporting Information Table S1a of the 
publication240), 20 genes with median level expression across all time-points (Supporting 
Information Table S1b of the publication240), and 20 randomly selected genes 
(Supporting Information Table S1c of the publication240) for further analysis.   
Mammalian promoters can vary greatly in size, ranging from 100-bp (base pair) scale to 
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over 1000-bp222, 241, 242.  Therefore, we performed our analysis based on two sizes: a 2000-
bp region and a 500-bp region preceding (in the 5’ direction of) the transcription start site 
(based on GRCh38.p2 assembly).  The goal of this analysis was to identify TFBSs enriched 
in the strong promoters found in the high expression group.  All DNA sequences were 
annotated for these putative TFBSs based on consensus sequences from the JASPAR 
database233 (vertebrates, H. sapiens only, Supporting Information Table S2 of the 
publication240) using the “ApE – A plasmid Editor” software, v2.0.47 for visualization and 
tabulation.  To account for native occurrences of putative TFBSs within a given 2000-bp 
region, we also analyzed up to 53 randomly selected 2000-bp regions from each human 
chromosome, which may include both intragenic and intergenic sequences.  Finally, a 
similar annotation of several commonly used viral-derived and endogenous promoters224, 
243 was performed for comparison purposes (Supporting Information Table S1d of the 
publication240).   
To identify enrichment of TFBSs amongst promoters belonging to specific 
expression groups, we chose to determine the frequencies of TFBSs as a ratio of the number 
of putative sites for each TFBS to the overall total number of TFBSs in each set.  Immediate 
comparisons of these frequencies between the 2000-bp annotations and 500-bp annotations 
suggest minor differences due to promoter length (Figure 4-3A).  More importantly, 
comparing these frequencies across promoters/promoter sets highlights differential 
enrichment for key TFBSs relevant to strong, measurable gene expression represented by 
the high expression group.  For example, the data suggest an overrepresentation of 
activating TFs such as the Sp/KLF families244 (Sp1, Sp2, and KLF5) and others also found 
in the hCMV IE gene enhancer222.  These distinguishing features form the design basis of 
synthetic promoters.  In addition to native promoters, comparisons were made with two 
conventional, viral-derived heterologous promoters used in research and large-scale 
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industrial applications (hCMV IE gene promoter and Simian Virus 40 [SV40] early 
promoter)243 and two commonly used endogenous promoters (from EEF1A1 and UbC)224, 
242, 243.  The putative TFBSs enriched in the high expression group encompass most of those 
annotated in the two viral-derived promoters (Figures 4-3B and 4-3C and Supporting 
Information Table S3a and S3b of the publication240) and, as expected, all of the putative 
TFBSs annotated in the two endogenous promoters (Figures 4-3D and 4-3E and 
Supporting Information Table S3c and S3d of the publication240). 
Collectively, we utilized these comparisons to define a list of putative TFBSs for 
the first design cycle to construct (build) synthetic promoters for subsequent testing.  We 
compared ~20% of the top frequencies (based on descending frequency as enriched in the 
high expression group) across the high, median, random, and chromosomal sets of genomic 
sequences.  TFBS frequency is defined as the ratio of the number of times a given TFBS 
is found within the specific sequence window (2000-bp or 500-bp) to all TFBSs found in 
the same window for a given annotated set (top, median, random, chromosomal region).  
The resulting putative TFBSs (Table 4-2) considered to be enriched in high expression 
promoters (green, higher frequencies found in the high/top expression set compared to 
other sets) or enriched in background (red, higher frequencies found in the chromosomal 
set compared to other sets) were selected to create synthetic promoters.  
 81
Figure 4-3: Distribution of TFBS frequencies across promoter regions. 
A 
 
B 
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Figure 4-3, continued: 
C 
 
D 
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Figure 4-3, continued: 
E 
 
(A) Heat maps of the frequencies of putative TFBSs in a select DNA (promoter) region 
annotated with the JASPAR database. top: TFBS heat map based on 2000-bp annotation. 
bottom: TFBS heat map based on 500-bp annotation. (B-E) Euler diagrams of TFBSs 
found in viral promoters compared to the subset of top promoters based on B) 2000-bp 
annotation of the promoter region and C) 500-bp annotation of the promoter region, and 
found in commonly used endogenous promoters compared to the subset of top promoters 
based on D) 2000-bp annotation of the promoter region, and E) 500-bp annotation of the 
promoter region. 
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Table 4-2:  Enriched TFBSs found across promoters. 
2000-bp 500-bp 
FOXC1 FOXC1
SP1 (short) SP1 (short)
FOXL1 MZF1_1-4
MZF1_1-4 ETS1 
ETS1 FOXL1
NFIC NFIC 
BRCA1 KLF5 
ZNF354C BRCA1 
HOXA5 ZNF354C 
SOX10 SPIB 
SPIB CREB (half)
HIF1A::ARNT HIF1A::ARNT
KLF5 HOXA5
CREB (half) SP1
FOXI1 SOX10
NFATC2 SP2
SP1 EHF 
EHF TFAP2C
SPI1 THAP1
SP2 ELK1
ELK1 FOSL2
SRY JUN (var.2)
THAP1 JUN::FOS 
 NF1 (consensus)
 STAT3
 YY1 
 
List of TFBSs found to be enriched in high expression groups/subset of top promoters 
(green text), in background expression (red text), and no particular set 
association/enrichment (black text) for both sequence lengths (2000-bp and 500-bp) 
annotated.  This enrichment is based on the TFBS frequency distribution found in 
Supporting Information Figure S1a and S1b of the publication240. 
4.3.3. Development and experimental testing of synthetic mammalian promoters 
using enriched TFBSs 
Leading to the final step of the design-build-test cycle, we created synthetic 
promoters based on the enriched TFBSs found in strong promoters and evaluated these 
promoters for their ability to drive reporter expression.  The central premise of these 
designs is that functional, synthetic promoters can be created by concatenating TFBSs 
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represented in strong promoters.  The corollary to this hypothesis is that weaker promoters 
will be created based on concatenations of TFBSs enriched in moderate or low expression 
and background datasets.  For this D-B-T cycle, we designed and synthesized three 
synthetic promoter variants (Figure 4-4) based on the TFBSs listed in Table 2 for 
subsequent testing.  Two of these variants (v1 and v2) were comprised of only TFBSs 
enriched in the high expression group (Table 4-2, green text) and the third variant, v3, was 
comprised of only TFBSs enriched in background (Table 4-2, red text).  Each of these 
designs involved randomly concatenating 19 TFBSs selected from the list (Table 4-2) and 
combining this element with the core region of hCMV IE promoter or the minimal region 
of the EF1α promoter from the H. sapiens EEF1A1 gene.  These TFBSs were selected 
based on their frequencies across the four frequency sets (top, median, random, and 
chromosomal, Supporting Information Figure S1a and S1b of the publication240): 
TFBSs with higher frequencies in the top promoter set (e.g. SP1) were included in variants 
v1 and v2 while TFBSs with higher frequencies in the chromosomal region or 
“background” (e.g. FOXC1) were included in variant v3.  In each of these cases, we used 
frequency to guide the approximate ratio of the most abundant sites (e.g. SP1 to MZF1_1-
4, FOXC1 to FOXL1). 
Moreover, we did not incorporate unenriched TFBSs (i.e. those with similar 
frequencies across all four datasets (Table 4-2, black text)) in the synthetic variants due to 
the lack of association with any particular frequency set.  Finally, we used the frequencies 
and ratios found in the 500-bp sequence window since the synthetic variants would be 
<500-bp.  After synthesis, we tested these designs via transient transfection driving the 
expression of both hrGFP and SEAP reporter proteins (linked by the encephalomyocarditis 
virus IRES245 as a bicistronic cassette) in the HT1080 cell line and we assayed for 
performance 48 hours post-transfection.  In comparison to our negative controls (promoter-
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less construct and HT1080 WT representing background expression levels), synthetic 
promoters v1 and v2 exhibited considerable functionality approaching reference (hCMV 
IE or full EF1α promoter) levels whereas variant v3 was barely functional (Figures 4-5A 
and 4-5B).  Furthermore, the synthetic promoter v1 seemed weaker than v2 when paired 
with hCMV IE promoter (Figures 4-5A and 4-5B); however, we did not observe this 
difference when pairing these synthetic promoters with the minimal EF1α promoter despite 
seeding the same number of TFBSs for both synthetic designs.  Annotation of the 
enhancer/proximal promoter region of these synthetic promoters using the same JASPAR 
database indicated that these 3 synthetic variants contained similar quantities of putative 
binding sites (53 for v1 and v2, 52 for v3; Supporting Information Table S4a to S4d of 
the publication240), thus the variable expression of both reporters reflecting the strength of 
these promoters were not due to a disparity in potential TFBSs.  These expression patterns 
suggest some context dependency of the core promoter region and the importance of TFBS 
ordering in promoter function.  Therefore, it is necessary to iterate through the workflow 
by incorporating TFBS arrangement considerations to further optimize synthetic promoter 
sequences.  Nevertheless, these results highlight the premise that combining TFBSs 
enriched in sequences correlated with strong expression can act as a potent 
enhancer/proximal promoter region and result in functional promoters when coupled with 
a core promoter element.  Furthermore, we have proven the corollary to the premise that 
coupling TFBSs enriched in background expression levels yielded a promoter sequence 
(v3) with minimal activity.  
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Figure 4-4: Schematic of synthetic promoter configurations used to drive dual-reporter 
expression. 
 
Pentagons represent putative TFBSs based on consensus sequence annotation using 
Supporting Information Table S2 of the publication240.  The reference sequence of 
human CMV promoter (dark green) is equivalent to accession M60321.1, nucleotides 1-
2105.  In particular, putative TFBSs in the synth.v1 and synth.v2 promoters (in shades of 
green encompassed by dark orange/brown box) reflect those sites that are enriched in the 
annotated promoter regions of highly expressed genes, whereas the putative TFBSs in the 
synth.v3 promoter (outline in shades of red encompassed by light orange box) reflect 
those sites that are enriched in an annotated region of minimal/background expression 
levels.    
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Figure 4-5: Transient expression of two reporter proteins in HT1080 cells at 48-h and 
HEK293F cells at 16-h post-transfection using synthetic promoter variants. 
A 
 
B 
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Figure 4-5, continued: 
C 
 
D 
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Figure 4-5, continued: 
A) Expression of model secreted protein, secreted alkaline phosphatase (SEAP) from the 
first cistron of our dual-reporter construct driven by promoters described in Figure 4-4.  
Values represent average specific productivity over 48-h from 3 independent 
transfections and error bars represent the 95% confidence interval of the average specific 
productivity.  B) Expression of model fluorescent protein (humanized Renilla green 
fluorescent protein, hrGFP) from the second cistron of our dual-reporter construct driven 
by promoters described in Figure 4-4. Values represent geometric mean fluorescence 
intensity from 3 independent transfections and error bars represent the 95% confidence 
interval of the geometric mean.  C) SEAP expression and D) hrGFP expression from a 
single transfection via nucleofection in HEK293F cells quantified at 16-h post-
transfection. 
To briefly assess whether synthetic promoter designs for a particular host cell line 
can function in another, we measured transient SEAP and hrGFP expression using the same 
expression vectors at 16-h post-transfection via nucleofection in HEK293F cells.  While 
the absolute expression levels were lower in HEK293F than HT1080 (compare Figures 4-
5A with 4-5C, 4-5B with 4-5D), the general trend of our synthetic promoters v1 and v2 
having comparable expression to the reference promoters (hCMV IE/pCMV and pEF1α) 
is maintained even in HEK293F cells (Figures 4-5C and 4-5D).  Interestingly, while this 
workflow specifically analyzed the native expression profile of HT1080 cells and used this 
analysis to design promoter sequences for driving expression in HT1080 cells, they were 
able to function properly in an alternate host cell line.  Both reference promoters showed 
comparable performance between the H. sapiens HT1080 and HEK293 cell lines224, 
therefore we expected some cross-functionality and that similar transcription factors are 
recruited to the reference and synthetic promoters in these cell lines.  Thus, this workflow 
can be readily applied to other host cell lines to generate functional de novo synthetic 
promoters using representative native expression data. 
Simply gaining insight into which TFBSs may yield functional de novo synthetic 
promoters is insufficient for obtaining optimal designs in a single D-B-T cycle since the 
arrangement of these binding sites (such as their spacing, orientation, and order or adjacent 
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binding sites) is poorly understood and difficult to establish a priori.  The large body of 
information found in transcription factor databases offers little insight into their overall 
arrangement (except potentially for known interactions, e.g. the AP-1 complex246).  
However, it is clear that the arrangement of the TFBSs used in a promoter can impact 
promoter activity as demonstrated in this work.  Previous attempts at creating synthetic 
promoters relied on concatenations of TFBSs whether with intentional5, 107 or random247 
arrangement of the TFBSs.  Furthermore, the spacing between TFBSs is known to 
influence promoter strength215.  Understanding the rules guiding TFBS arrangement will 
greatly optimize de novo promoter design and inform subsequent iterations of the D-B-T 
cycle. 
To briefly investigate how TFBS arrangement can impact promoter functionality, 
we created three synthetic variants of the conventional viral-derived hCMV IE promoter 
(M60321.1) that have altered spacing and order of its annotated putative TFBSs (Figure 
4-6A).  These promoter variants were randomly generated using a computational 
algorithm248 to contain 45% GC-content, approximately mimicking the overall GC-content 
found in the human genome and reference promoter sequence.  The three synthetic hCMV 
IE promoter variants (native, sequential, and random order) all have annotated TFBSs 
spaced 10-bp apart.  The reference hCMV IE promoter and its variants were used to drive 
the transient expression of the SEAP and hrGFP reporter proteins in HT1080 cells.  Based 
on the SEAP reporter expression 48 hours post-transfection, both spacing and order of 
TFBSs impacts promoter strength (Figure 4-6B).  Similarly, analyzing the geometric mean 
fluorescence intensity of the hrGFP reporter over the same 48-h period (Figure 4-6C) 
corroborates the trends observed with the SEAP reporter (Figure 4-6B).  
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Figure 4-6: Transient expression of two reporter proteins in HT1080 cells at 48-h post-
transfection using synthetic hCMV-IE promoter variants. 
A 
 
B 
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Figure 4-6, continued: 
C 
 
A) Schematic of synthetic hCMV-IE promoter variants used to drive our dual-reporter 
expression in this work.  Pentagons represent putative TFBSs based on consensus 
sequence annotation using Supporting Information Table S2.  The reference sequence of 
human CMV promoter (dark) is equivalent to accession M60321.1, nucleotides 1-2105.  
The 3 hCMV IE promoter variants with each TFBS spaced 10-bp apart exhibited reduced 
activity (light) and were constructed with the same identity and quantity of TFBSs as the 
reference sequence (dark). B) Expression of model secreted protein, secreted alkaline 
phosphatase (SEAP) from the first cistron of our dual-reporter construct driven by 
promoters described in A.  Values represent average specific productivity over 48-h from 
3 independent transfections and error bars represent the 95% confidence interval of the 
average specific productivity. C) Expression of model fluorescent protein (humanized 
Renilla green fluorescent protein, hrGFP) from the second cistron of our dual-reporter 
construct driven by promoters described in A. Values represent geometric mean 
fluorescence intensity from 3 independent transfections and error bars represent the 95% 
confidence interval of the geometric mean. 
Interestingly, the data suggest that the spacing between annotated TFBSs exhibited 
greater influence on promoter strength (compare native in light bar with reference in dark 
bar) than the particular arrangement of the TFBSs themselves (compare native, sequential, 
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random in light colored bars) (Figures 4-6B and 4-6C).  We selected the 10-bp spacing to 
represent an average of the spacing between annotated TFBSs in the reference hCMV IE 
promoter and to approximate nearly a full turn of the DNA helix to facilitate interaction of 
transcription factors with their cognate binding sites, although periodic expression may 
result from using tandem repeats of certain TFBSs249.  However, by creating a pre-defined 
static distance between putative TFBSs, it is likely that some synergistic interactions 
between TFs are disrupted246, 250, ultimately reducing the promoter strength.  The reduction 
in promoter length due to altered spacing between TFBSs does not fully account for its 
impact on promoter strength; the synthetic variants v1 and v2 (Figures 4-5A and 4-5B) 
were stronger than the hCMV IE promoter variants (Figures 4-6B and 4-6C) with an even 
shorter promoter sequence footprint overall (341-bp vs. 1301-bp for reference hCMV IE 
and 702-bp for hCMV IE variants).  Thus, the spacing, order, and composition of TFBSs 
are important for generating functional synthetic promoters and these parameters can be 
used to further tune the strength of synthetic promoters in subsequent cycles of the 
workflow described in this work.  For de novo synthetic sequences, it is straightforward to 
generate random designs as the first cycle and subsequent cycles of this workflow can 
investigate the spacing between TFBSs in these designs.  With the prevalence targeted 
genome editing tools and techniques251, the initial synthetic promoter designs can be 
refined with subsequent workflow cycles to obtain optimal functionality in the desired 
genomic context. 
4.4. CONCLUSIONS 
This work demonstrated the utility of an ‘omics guided workflow to create novel, 
synthetic promoters for a mammalian cell host.  These diverse, synthetic sequences 
comprise a suite of non viral-derived sequences, potentially reducing their susceptibility of 
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epigenetic silencing and increasing long-term stability.  By adjusting the TFBS 
composition and arrangement, a set of de novo promoters can be developed to properly 
tune the protein intermediates in a metabolic pathway of mammalian hosts as one of the 
tools governing transgene expression252.  Moreover, these synthetic promoters had an 
overall reduced sequence footprint compared to reference promoters, thus increasing the 
overall utility for applications such as (heterologous) metabolic pathway designs6 and gene 
delivery vector designs253, akin to efforts in reducing the regulatory sequence footprint in 
a conventional metabolic engineering host254.  It is possible to expand the combinatorial 
space in this work to enable many permutations of synthetic randomized concatenations of 
a particular set of TFBSs to be constructed and evaluated255.  Ultimately, this workflow 
incorporates contemporary high-throughput methodologies to construct functional 
promoter elements that can facilitate applications ranging from the study of fundamental 
processes to immediate use in large-scale industrial processes.  
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Chapter 5: Creating the message – alternative approaches to promoter 
engineering 
5.1. CHAPTER SUMMARY 
Chapter 4 established an approach to rationally create de novo promoters using 
endogenous expression information, but other promoter engineering approaches can 
exploit the endogenous sequences and their activity.  Traditionally, promoter engineering 
involved isolation and testing of segments of endogenous DNA sequences, which are often 
viral-derived.  These segments would be further dissected to identify essential and/or 
superfluous DNA regions for promoter activity through the expression of a reporter gene.  
This breakdown of promoter segments is typically comprised of an enhancer region, a 
proximal promoter region, and a core promoter region256.  The work described in this 
chapter investigated approaches to engineer these 3 regions to create hybrid promoters.  In 
doing so, we successfully generated hybrid promoter variants based on endogenous 
sequences that are comparable to a strong viral-derived promoter in expression and 
concomitantly revealed that the 5’ UTR, in particular the intron preceding the coding 
sequence, can drastically affect promoter strength in mammalian cells. 
5.2. INTRODUCTION 
As described in Chapter 4, a promoter typically includes the core promoter, 
proximal promoter, and distal enhancer elements.  Many previous efforts have explored 
the promoter activity of isolated putative promoter sequences that encompass all three 
elements in order to characterize their ability to drive heterologous gene expression222, 224, 
257-262.  To this end, only a handful of sequences are predominantly used based on the desire 
to drive high levels of expression224 and these sequences are often viral-derived.  However, 
the foreign nature of these viral-derived sequences can elicit cellular responses (e.g. 
silencing) that reduce or remove their transcriptional activity226, 229, leading to unstable 
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gene expression over time.  Nonetheless, the initial characterization of these promoters 
facilitated the subsequent derivatization to incorporate novel functionality such as response 
to heavy metals247, and paved the foundation for rational library screening approaches to 
identify stronger promoter variants5, 107, 215, 263.  Similar efforts utilizing both rational library 
screens and synthetic approaches created sets of sequences suitable for fine-tuned 
regulation of gene expression to enable metabolic engineering of microbial systems110, 111, 
248, 254, 264, and this work adapts some of these methodologies to create hybrid mammalian 
promoters. 
In particular, the core promoter region interacts with RNA polymerase II to 
facilitate downstream transcription and this region can be dissected into many critical 
components265, 266.  These components (TATA box, Initiator, general transcription factor 
binding sites such as TFIIB, TFIID, etc.) can be rationally combined to create synthetic 
core promoters with a substantial increase in activity compared to endogenous 
sequences267.  Therefore, we investigated the premise that functional core promoters can 
be synthetically created and that multiple core promoters could increase gene expression 
in the HT1080 mammalian host cell. 
To further expand the limited set of non-viral derived promoters that are functional 
in mammalian hosts, we adopted an alternative to the bioinformatics approach described 
in Chapter 4.  Again, by harnessing the native expression program, we can pinpoint 
precisely which genes are highly expressed and therefore explore their corresponding 5’ 
regulatory sequence responsible for the high expression levels.  The use of this guided 
approach is based on the same hypothesis in Chapter 4: highly expressed endogenous genes 
are controlled by strong promoters. 
The work described here is akin to previous work characterizing the functionality 
of commonly used promoters222, 224, 257-262 and require a fully sequenced genome.  However, 
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these regulatory regions are often poorly annotated at best in most host cell genomes, and 
the work described here explores some of these sequences and their ability to drive 
heterologous gene expression.  Another critical aspect of gene regulation in higher 
eukaryotes is the abundance of introns in their coding DNA sequences and in their 5’ UTR, 
and these introns can critically impact promoter functionality268-273.  By incorporating both 
native and synthetic intron sequences into promoter designs, we explored their impact on 
heterologous gene expression as an additional layer of control embedded within a 
promoter. 
5.3. RESULTS AND DISCUSSION 
5.3.1. Evaluating core promoter designs for increasing heterologous gene expression 
The previous rational design of a super core promoter was comprised of a variety 
of commonly used core promoter elements from the CMV-IE viral gene, adenovirus major-
late viral gene, and D. melanogaster sequences267.  Subsequent characterizations of 
additional core promoter elements suggest that novel core promoter designs can be tailored 
to specific applications to elicit the desired expression274-276.  While RNA polymerase II 
machinery is highly conserved across eukaryotic species, the elements of the core promoter 
and mode of transcription initiation by a specific core promoter can vary, especially in 
vertebrates266, 277. 
We revisited the design of the super core promoter and created a variant that 
included two additional elements that interact with TFIIB278 and three additional elements 
from the major histocompatibility complex (MHC) class I genes core promoter279 dubbed 
UCP shown below (Figure 5-1).  To assess the impact of coupling these two core 
promoters with an enhancer region, we generated 3 enhancer variants derived from the 
hCMV-IE enhancer (Figure 5-2).  We compared the ability of this novel core promoter 
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against the core promoter from the hCMV-IE gene (cpCMV) to drive gene expression in 
HT1080 cells by measuring the fluorescence intensity of the hrGFP reporter protein.  We 
quantified transient expression at 24h, 48h, and 72h post-transfection, and found 
insignificant differences between the UCP or cpCMV (Figure 5-3).  Furthermore, there 
were insignificant differences when these core promoter elements were coupled to the 
CMV enhancer variants (Figure 5-3).  As expected, since these two core promoters are 
statistically indistinguishable, the coupling of the hCMV-IE enhancer to either core 
promoter recapitulated the functionality of the full hCMV-IE promoter (pCMV, Figure 5-
3).  While this particular UCP core promoter design did not demonstrate an improvement 
over cpCMV in its ability to drive gene expression, the comparable expression suggested 
that some of these key elements are dispensible.  Therefore, future designs that would fully 
replace the viral-derived sequences can serve as alternatives if a particular application, such 
as for gene therapy or immunotherapy, requires an avoidance of viral-derived sequences. 
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Figure 5-1: Conserved elements of the core promoter derived from hCMV-IE (cpCMV) 
and the rationally designed UCP. 
 
Figure 5-2: Enhancer variants of the hCMV-IE gene used in conjunction to evaluate two 
core promoter designs. 
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Figure 5-3: Normalized geometric mean fluorescence intensity (gMFI) of hrGFP driven 
by two core promoter designs 
 
Core promoters along with their coupling with enhancer variants derived from hCMV-IE 
gene at 24h (light orange), 48h (orange), and 72h (brown) post-transfection. 
Inspired by the work in E. coli to boost gene expression through using tandem core 
promoters264, we explored the possibility of using multiple core promoters with defined 
TATA boxes and with/without initiator sequences to improve heterologous gene 
expression in mammalian production hosts.  It is expected that with the multiple initiator 
sequences in these core promoter variants that there would be multiple focused 
transcription start sites.  Despite this 5’ UTR heterogeneity, there would be a net increase 
of the transcript leading to increased expression levels when compared to a single core 
promoter.  Based on the extensive work that characterized the core promoter from the viral 
hCMV-IE gene, we created 6 additional multiple-core promoter variants from this well-
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studied sequence to incorporate permutations of including/excluding the initiator sequence 
(i.e. a transcription start site) for each additional core promoter sequence (Figure 5-4). 
Figure 5-4: Multiple core promoter variants evaluated for their transcription capacity.   
 
The extra gray right angle arrow corresponds to an expected transcription start site, 
denoted as “1” in the coded representation of the promoter. 
We transfected our model host cells, HT1080, with these core promoter variants 
driving the expression of our fluorescent model protein hrGFP.  Interestingly, our data did 
not suggest that the core promoter configurations had any impact on transient hrGFP 
expression as quantified by flow cytometry analysis 48h post-transfection (Figure 5-5).  
However, we analyzed the proportion of hrGFP expressing (positive) and non-expressing 
(negative) cells post-transfection, the data suggested that there was an increase in the 
proportion of cells that are expressing hrGFP (Figure 5-6).  By combining this approach 
with novel core promoter designs, this particular component of a promoter can be easily 
tailored to a particular application, and these core promoters can be independently coupled 
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to the enhancer regions produced by the Design-Build-Test workflow described in Chapter 
4. 
Figure 5-5: hrGFP transient expression measured from HT1080 cells 48h post-
transfection 
 
The average geometric mean fluorescence intensity (gMFI) is reported and accounting 
for the standard deviation in this measurement (represented by the error bars), there is no 
statistically significant difference when multiple core promoters are used to drive gene 
expression.  WT corresponds to the autofluorescence level from HT1080 cells. 
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Figure 5-6: The same samples from Figure 5-5 represented by the percentage of the 
analyzed cell population that is expressing hrGFP. 
 
By incorporating additional core promoter elements, a higher proportion of cells are 
expressing the reporter protein, albeit at the same expression level (see Figure 5-5).  WT 
corresponds to the autofluorescence level from HT1080 cells. *denotes p < 0.1 and 
**denotes p < 0.05 relative to the single core promoter (1x core). 
5.3.2. Rational design of endogenous hybrid promoters 
Although the core promoter region is essential for interacting with RNA 
polymerase II and basal transcription factors to facilitate transcription277, the proximal 
promoter/enhancer and distal enhancer regions harbor additional transcription factor 
binding sites that interact with the core region to boost transcriptional activity256.  By 
leveraging the expression data of the HT1080 cells analyzed in Chapter 4, we can screen 
endogenous 5’ UTR sequences from the same highly expressed genes for promoter activity.  
This is motivated by the same hypothesis that highly expressed genes have strong 
promoters responsible for driving that expression level.  Since conventionally used 
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promoter sequences vary from 500-bp to over 2000-bp224, we extracted versions of the 5’ 
UTR from 12 endogenous genes of the human genome (GRCh38.p2 build) that include 
approximately 500-bp or 2000-bp 5’ of the annotated TSS and 40-bp 3’ of the annotated 
TSS to include a portion of the first transcribed exon (see Supporting Information from 
publication240 described in Chapter 4), retaining the endogenous core promoter.  These 
putative promoters correspond to the regions annotated for bioinformatics analysis in 
Chapter 4. 
These putative sequences were cloned into the same vector used in Chapter 4 that 
would drive the expression of a secreted reporter protein (SEAP) and a fluorescent protein 
reporter (hrGFP) simultaneously.  We quantified the ability of these putative promoter 
sequences to drive gene expression transiently 48h post-transfection using an in-vitro assay 
for detecting SEAP production (NovaBrightTM SEAP Enzyme Reporter Gene 
Chemiluminescent Detection System 2.0, Invitrogen) and flow cytometry to measure 
fluorescence intensity (BD LSRII Fortessa, 200V).  To further evaluate the compatibility 
of these putative promoters with a well-characterized enhancer element, these endogenous 
promoter sequences were also coupled with the enhancer region from hCMV-IE (576-bp 
enhancer corresponding to 534-1109 from accession number M60321.1).  Despite the high 
expression of these endogenous genes in HT1080 as measured by microarray analysis 
(Shire Genetic Therapies), only a few of these 5’ UTR contained sequences capable of 
driving strong expression (Figures 5-7 and 5-8).  Only the promoter region from the 
previously characterized EEF1A1 gene261 and UBC gene269 demonstrated activity that is 
comparable to the viral hCMV-IE promoter (rpCMV.660).  
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Figure 5-7: Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by putative promoters derived from highly expressed genes. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates.  
The purple fill color denotes promoters with intron sequences included in the promoter 
region.  The numbers following the promoter name denotes the promoter length.  CMVe 
denotes promoter sequences with the hCMV-IE enhancer coupled, represented by the 
darker fill color.  Gray dotted line represents the expression level driven by the strong 
CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct.  
0.00
0.10
0.20
0.30
0.40
nu
ll
rp
C
M
V
.6
60
p
EE
F1
A
1.
13
56
p
EE
F1
A
1.
10
48
C
M
V
e.
p
EE
F1
A
1.
13
56
C
M
V
e.
p
EE
F1
A
1.
10
48
p
C
LU
A
P1
.2
00
0
p
C
LU
A
P1
.5
00
C
M
V
e.
p
C
LU
A
P1
.2
00
0
C
M
V
e.
p
C
LU
A
P1
.5
00
p
TP
T.
20
00
p
TP
T.
50
0
C
M
V
e.
p
TP
T.
20
00
C
M
V
e.
p
TP
T.
50
0
p
TU
BA
1B
.2
00
0
p
TU
BA
1B
.5
00
C
M
V
e.
p
TU
BA
1B
.2
00
0
C
M
V
e.
p
TU
BA
1B
.5
00
p
G
G
A
1.
50
0
C
M
V
e.
pG
G
A
1.
50
0
pL
A
IR
1.
50
0
C
M
V
e.
p
LA
IR
1.
50
0
p
UB
C
.1
77
8
p
UB
C
.1
31
0
C
M
V
e.
p
UB
C
.1
77
8
C
M
V
e.
p
UB
C
.1
31
0
p
V
IM
.2
00
0
p
V
IM
.5
00
C
M
V
e.
p
V
IM
.2
00
0
C
M
V
e.
p
V
IM
.5
00
p
F2
R.
50
0
C
M
V
e.
p
F2
R.
50
0
p
EI
F4
A
1.
77
6
p
EI
F4
A
1.
50
0
C
M
V
e.
p
EI
F4
A
1.
77
6
C
M
V
e.
p
EI
F4
A
1.
50
0
p
PG
K1
.1
00
0
p
PG
K1
.5
00
C
M
V
e.
p
PG
K1
.1
00
0
C
M
V
e.
p
PG
K1
.5
00
p
G
A
PD
H
.2
00
0
p
G
A
PD
H
.1
50
0
p
G
A
PD
H
.1
00
0
p
G
A
PD
H
.5
00
C
M
V
e.
p
G
A
PD
H
.2
00
0
C
M
V
e.
p
G
A
PD
H
.1
50
0
C
M
V
e.
p
G
A
PD
H
.1
00
0
C
M
V
e.
p
G
A
PD
H
.5
00
SE
A
P 
pr
od
uc
tiv
ity
, q
p
(p
g/
ce
ll/
d
a
y
 107
Figure 5-8: Transient hrGFP expression 48h post-transfection in HT1080 driven by 
putative promoters derived from highly expressed genes. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The purple fill color denotes promoters with intron 
sequences included in the promoter region.  The numbers following the promoter name 
denotes the promoter length.  CMVe denotes promoter sequences with the hCMV-IE 
enhancer coupled, represented by the darker fill color.  Gray dotted line represents the 
expression level driven by the strong CMV promoter and the red dotted line represents 
background expression/autofluorescence from a promoter-less construct. 
The results in Figures 5-7 to 5-8 suggest that most of the endogenous promoter 
sequences are activated by the CMV enhancer.  Therefore, despite already containing an 
endogenous enhancer region, these promoters can be further activated with an additional 
enhancer element.  We evaluated additional putative endogenous promoter sequences 
derived from the beta-actin promoter270, 280 and two ribosomal proteins identified from our 
microarray expression data set (RPL41 and RPLP2).  We also investigated pairings of a 
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subset of these endogenous promoters (from EEF1A1, UBC, RPL41, and RPLP2) with 
putative enhancer regions derived from EEF1A1, EIF4A1, or ACTB to create hybrid 
promoters using purely endogenous sequences.  Since the pEEF1A1.1048 promoter 
behaves like a minimal promoter that can be activated with a large dynamic range, we 
screened two additional endogenous elements that have been characterized as super-
enhancer elements from LMO1281 and a mutant variant of enhancer ID 176 (sequence found 
in Appendix B) from Lovén, et al that showed a strong signature for enhancer activity in 
multiple myeloma cells282.  The 182-bp enhancer region derived from ACTB coupled with 
2 EEF1A1 promoter variants (1048-bp “minimal” and 356-bp) resulted in hybrid promoters 
that exhibited comparable strength to the CMV promoter (Figures 5-9 and 5-10) using 
purely endogenous sequences.  The same enhancer region showed minimal influence when 
coupled with the ribosomal promoters; however, these endogenous promoters were able to 
drive gene expression at two distinct levels (Figures 5-9 and 5-10), suggesting that 
regulatory regions of ribosomal proteins can also be exploited.  Unfortunately, when two 
variants of the enhancer region from the 356-bp EEF1A1 promoter (308-bp and 156-bp) 
were coupled to the 1310-bp UBC promoter, the resulting hybrid promoters yielded no 
additional benefit to gene expression (Figures 5-9 and 5-10).  This data corroborates 
previous efforts in constructing hybrid promoters by coupling additional enhancer regions, 
but the high variation in functionality of these hybrid promoters maintains that this 
approach is extremely empirical.  
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Figure 5-9: Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by endogenous promoters and hybrid promoters with modified 
enhancers. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates.  
The purple fill color denotes promoters with intron sequences included in the promoter 
region.  The numbers following the promoter name denotes the promoter length.  Hybrid 
promoters with additional enhancer regions are represented by the darker fill color.  Gray 
dotted line represents the expression level driven by the strong CMV promoter and the 
red dotted line represents background expression/autofluorescence from a promoter-less 
construct.  
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Figure 5-10:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
other endogenous promoters and hybrid promoters with modified enhancers. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The purple fill color denotes promoters with intron 
sequences included in the promoter region.  The numbers following the promoter name 
denotes the promoter length.  Hybrid promoters with additional enhancer regions are 
represented by the darker fill color.  Gray dotted line represents the expression level 
driven by the strong CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct. 
Based on the expression of our reporters with promoters derived from EIF4A1 
(Figures 5-7 and 5-8), critical analysis of the endogenous sequence revealed an extended 
5’ UTR before the start codon.  Thus, we wanted to explore the contribution of the 5’ UTR 
on promoter activity and designed additional hybrid promoters that contained extended 5’ 
UTR regions.  Specifically, we assessed permutations of promoters derived from LAIR1, 
F2R, PGK1, and EIF4A1 that included the full length of their endogenous 5’ UTR up to 
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the corresponding start codon in these genes based on their relatively poor ability to drive 
reporter expression (Figures 5-7 and 5-8).  Given the benefit of coupling the CMV 
enhancer to these promoters, we wanted to verify that the 5’ UTR extension is 
complementary to the activation by the enhancer region 5’ of the transcription start site. 
The transient hrGFP and SEAP expression 48h post-transfection from these hybrid 
promoters with 5’ UTR modifications suggest that the promoter strength can be improved 
by incorporating a suitable 5’ UTR, but there is also context dependency with regards to 
the enhancer region (Figures 5-11 and 5-12).  For example, the enhancer and 5’ UTR can 
be cooperative (e.g. CMV enhancer with 636-bp EIF4A1 promoter compared with the 500-
bp variant), yet the same hybrid promoter with the extended 5’ UTR is not influenced by 
the addition of the 308-bp or 156-bp enhancer variants derived from EEF1A1.   Increasing 
the 5’ UTR by itself is insufficient to generate hybrid promoters that are comparable to the 
CMV promoter without incorporating an additional enhancer region.  The improved 
activity from incorporating the native 5’ UTR (Figures 5-11 and 5-12) suggests that the 
putative promoters showed minimal activity (Figures 5-7 and 5-8) because they were no 
longer in the appropriate genomic context when employed in a transient expression vector.  
This is further corroborated by the EEF1A1- and UBC-derived promoters that include their 
first intron as a 5’ UTR showing significant activity (Figures 5-7 and 5-8).  Thus, the 
genomic context is indeed important when hijacking endogenous sequences for gene 
regulatory function.  
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Figure 5-11:Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by hybrid promoters with modified 5’ UTR. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates.  
The purple fill color denotes promoters with intron sequences included in the promoter 
region.  The orange fill color denotes promoters with extended 5’ UTR.  Numbers 
following the promoter name denotes the promoter length.  CMVe denotes promoter 
sequences with the hCMV-IE enhancer coupled, represented by the darker fill color.  
Gray dotted line represents the expression level driven by the strong CMV promoter and 
the red dotted line represents background expression/autofluorescence from a promoter-
less construct.  
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Figure 5-12:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
hybrid promoters with modified 5’ UTR. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The purple fill color denotes promoters with intron 
sequences included in the promoter region.  The orange fill color denotes promoters with 
extended 5’ UTR.  Numbers following the promoter name denotes the promoter length.  
CMVe denotes promoter sequences with the hCMV-IE enhancer coupled, represented by 
the darker fill color.  Gray dotted line represents the expression level driven by the strong 
CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct. 
5.3.3. Promoter redesign with introns 
Along the same vein as incorporating a native 5’ UTR to modulate promoter 
activity, we showed that the endogenous promoters with introns (EEF1A1- and UBC-
derived) and their hybrid derivatives are the predominant ones that exhibited comparable 
functionality to the strong CMV promoter (Figures 5-7 to 5-10).  Therefore, we suspected 
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that the presence of an intron was responsible for the strong promoter activity since using 
the EEF1A1 enhancer regions were insufficient to elicit this effect (Figures 5-9 to 5-12).  
Given the significant DNA footprint that introns typically occupy, it is expected that these 
sequences would contain additional transcription factor binding sites that can activate or 
repress gene expression283.  It was previously shown that the intron A and its variants from 
the CMV promoter can drastically affect its strength273, 284.  In the case of the GAPDH 
promoter variants, which we expected should have strong promoter activities, sequence 
analysis revealed that the endogenous gene locus contained a 240-bp intron prior to the 
start codon found in the second exon.  Therefore, we created additional GAPDH promoter 
variants with the same 5’ enhancer regions and included this first intron and flanking exons.  
We also rationally combined this GAPDH endogenous intron and flanking exons with 
some of the putative promoters derived from GGA1, LAIR1, and F2R that showed 
negligible activities originally (Figures 5-7 and 5-8) and subsequently detectable activities 
when their 5’ UTR were extended (Figures 5-11 and 5-12).  Furthermore, we created an 
additional EIF4A1 promoter variant with the same GAPDH intron 1 and flanking exons. 
When the previous GAPDH promoter variants were coupled to its cognate intron 1, 
we observed increases in gene expression as expected (Figures 5-13 and 5-14).  However, 
pairing the GAPDH intron 1 with other endogenous promoters resulted only in a modest 
increase in promoter strength (Figures 5-13 and 5-14), suggesting that the improvement 
observed with the GAPDH promoters with the intron is unlikely to be dictated by additional 
activating transcription factor binding sites within the intron and flanking exons.  It is 
possible that these other promoters contain similar binding sites to those found in the 
GAPDH intron 1 and flanking exons, resulting in insignificant contributions.  Due to the 
improvements observed when the GAPDH promoters were coupled with its cognate intron, 
we also evaluated two additional variants by combining the 500-bp GAPDH promoter with 
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the EEF1A1 intron 1 with its flanking exons or the hCMV-IE intron A with its flanking 
exons.  Interestingly, despite both introns demonstrating an increase in promoter activity 
when paired with their cognate promoters, they negatively impacted the GAPDH promoter 
(Figures 5-13 and 5-14). 
Figure 5-13:Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by hybrid promoters with modified introns. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates.  
The purple fill color denotes promoters with intron sequences included in the promoter 
region.  The numbers following the promoter name denotes the promoter length.  Gray 
dotted line represents the expression level driven by the strong CMV promoter and the 
red dotted line represents background expression/autofluorescence from a promoter-less 
construct.  
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Figure 5-14:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
hybrid promoters with modified introns. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The purple fill color denotes promoters with intron 
sequences included in the promoter region.  The numbers following the promoter name 
denotes the promoter length.  Gray dotted line represents the expression level driven by 
the strong CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct. 
Lastly, we investigated a few additional hybrid promoter variants that utilized the 
GAPDH intron 1 with other enhancer regions (based on data found in Figure 5-13 and 5-
14) to drive gene expression as quantified by the hrGFP and SEAP reporters (Figures 5-
15 and 5-16).  Interestingly, the combination of these two major regulatory regions showed 
an inconsistent interplay: the addition of the enhancer regions did not always increase gene 
expression (e.g. GAPDH variants with CMV enhancer).  In fact, the 500-bp GAPDH hybrid 
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promoter with GAPDH intron 1 was not affected by the 3 distinct enhancers coupled to this 
particular promoter (Figures 5-15 and 5-16).  However, a hybrid promoter based on the 
500-bp EIF4A1 promoter with GAPDH intron 1 showed a marked increase when it was 
coupled to the CMV enhancer (Figures 5-15 and 5-16).  Based on these results, it is 
difficult to identify which element is dominant when they are used in conjunction.  Instead, 
permutations of these elements derived from endogenous sequences must be evaluated 
empirically at this time as clear design rules for hybrid promoters cannot be elucidated 
from this data. 
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Figure 5-15:Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by hybrid promoters with modified enhancers and introns. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates.  
The purple fill color denotes promoters with intron sequences included in the promoter 
region.  The numbers following the promoter name denotes the promoter length.  Hybrid 
promoters with additional enhancer regions are represented by the darker fill color.  Gray 
dotted line represents the expression level driven by the strong CMV promoter and the 
red dotted line represents background expression/autofluorescence from a promoter-less 
construct.  
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Figure 5-16:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
hybrid promoters with modified enhancers and introns. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The purple fill color denotes promoters with intron 
sequences included in the promoter region.  The numbers following the promoter name 
denotes the promoter length.  Hybrid promoters with additional enhancer regions are 
represented by the darker fill color.  Gray dotted line represents the expression level 
driven by the strong CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct. 
Based on these inconsistent benefits to gene expression, we wanted to verify the 
impact of using an intron with the CMV promoter as previously reported273, 284.  We 
designed hybrid promoter variants of the CMV promoter that contained the EEF1A1 or 
GAPDH intron 1 and their flanking exons in addition to the endogenous variant with the 
hCMV-IE intron A.  We measured transient reporter expression of SEAP and hrGFP driven 
by this particular set of CMV hybrid promoters and found that the introns had no impact 
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on promoter activity (Figure 5-17 and 5-18).  Thus, it is unlikely that any observed benefits 
are due to these regions hosting additional transcription factor binding sites that activate 
transcription. 
Figure 5-17:Transient SEAP productivity (expression) 48h post-transfection in HT1080 
driven by CMV hybrid promoters with intron variants. 
 
Error bars represent 95% CI of SEAP productivity from 3 or more biological replicates. 
The numbers following the promoter name denotes the promoter length.  Gray dotted line 
represents the expression level driven by the strong CMV promoter and the red dotted 
line represents background expression/autofluorescence from a promoter-less construct.
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Figure 5-18:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
CMV hybrid promoters with intron variants. 
 
Error bars represent standard deviation of geometric mean fluorescence intensity from 3 
or more biological replicates.  The numbers following the promoter name denotes the 
promoter length.  Gray dotted line represents the expression level driven by the strong 
CMV promoter and the red dotted line represents background 
expression/autofluorescence from a promoter-less construct. 
Another suggested mechanism is that the splicing machinery can stimulate 
transcription machinery, leading to successful gene expression285.  To further evaluate this 
finding, we designed a synthetic minimal intron (iS1) based on conserved sequence 
elements (Figure 5-19) and the EEF1A1 pyrimidine-rich region and flanking exons 
(Figure 5-20).  This intron is devoid of any putative transcription factor binding sites based 
on the sequences from JASPAR database233, 286, allowing us to interrogate the impact of 
intron processing on gene expression directly. 
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Figure 5-19:Typical intron structure with approximate consensus sequence based on 
nucleotide frequencies. 
 
Reproduced from Stevens lecture, BIO 395J Fall 2013, The University of Texas at 
Austin. 
Figure 5-20:Sequence of synthetic intron iS1 based on conserved sequences and a 19-bp 
pyrimidine-rich region from EEF1A1 flanked by the EEF1A1 exons 1 and 2. 
 
With such a minimal sequence, it is unclear whether the splicing machinery would 
be able to properly process this mRNA given the size of the spliceosome287.  Therefore, we 
screened additional “ultra-short” introns found in the human genome to exploit the minimal 
sequence space and minimize the potential of these sequences to harbor transcription factor 
binding sites.  The splicing of the 56-bp intron from HNRNPH1 and the 43-bp intron from 
ESRP2 were confirmed287, and we also built test constructs based on the 10 shortest introns 
that were identified by Piovesan, et al288.  The processing of the 49-bp intron of NDOR1 
found in this data set288 was also experimentally verified previously287.  These 12 minimal 
endogenous introns were also flanked by the EEF1A1 exons 1 and 2 to maintain genomic 
context consistency and consistency in the final 5’ UTR of the reporter mature mRNA. 
…CAG gttactaactttttttcttccatttcag GTG… 
3’ splice site 5’ splice site 
exon 1 exon 2 Pyrimidine-rich region 
branch point 
branch consensus 
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We compared the ability of the CMV promoter with and without each of these 
minimal introns to drive gene expression as quantified by our hrGFP reporter.  As a positive 
control, we included the EEF1A1 intron 1 flanked by its endogenous exons.  The control 
promoter without an intron had the native exons replaced by the EEF1A1 exons 1 and 2 for 
context consistency.  Interestingly, these minimal introns exhibited significantly different 
effect on gene expression (Figure 5-21).  These hybrid promoters with minimal introns 
cover almost a 3-fold dynamic range, further highlighting the need for empirical screening 
of endogenous sequences to identify desirable elements for a particular application. 
Figure 5-21:Transient hrGFP expression 48h post-transfection in HT1080 driven by 
CMV hybrid promoters with intron variants in a single replicate. 
 
Error bars represent 95% CI of geometric mean fluorescence intensity.  The numbers 
following the promoter name denotes the promoter length.  Gray dotted line represents 
the expression level driven by the strong CMV promoter and the purple solid line 
represents the expression from the CMV promoter coupled to the native intron 1 from 
EEF1A1. 
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5.4. CONCLUSIONS 
Rational and library-based promoter engineering approaches have been 
demonstrated to yield strong components107, 110, 111, 215, 247, 248, 254 and characterization of 
endogenous genes led to the exploitation of these regulatory sequences to drive 
heterologous gene expression, especially in mammalian cells222, 224, 258, 261, 269, 289.  Through 
integrating an additional layer of classification based on endogenous expression levels, we 
can narrow down the desired sequence space screened in order to generate strong hybrid 
promoters.  Overall, by evaluating several of the elements that regulate transcription at the 
promoter level, we constructed hybrid promoters solely relying on endogenous sequences 
that drove a wide range of expression levels, relieving the dependence on viral-derived 
elements.  Most importantly, to address the goal of replacing strong viral-derived elements, 
we were able to construct a hybrid promoter (pEEF1A1.350.Gi1) that exhibited 
comparable activity (1.1-fold) to the strong CMV promoter.  Although this hybrid promoter 
required slightly larger sequence footprint relative to the CMV promoter (770-bp vs. 660-
bp), it required substantially less sequence footprint than the strongest endogenous 
promoter evaluated from EEF1A1 (770-bp vs. 1356-bp). 
The use of multiple core promoters in mammalian cells did not result in the same 
level of improvement in gene expression previously observed in E. coli264, but we were 
able to increase the percentage of transfected cells that expressed our transgene.  This 
suggested that the multiple core promoter elements were in fact functional based on the 
increase in percentage of transgene expressing cells.  Furthermore, this repetitive core 
promoter architecture can be extrapolated for other applications such as creating a hybrid 
core promoter that would be functional across multiple cell types by combining multiple 
core promoters unique to these cell types. 
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In evaluating endogenous promoters and designing hybrid promoters in the more 
traditional fashion of exploring enhancer regions, we observed stark differences between 
many of our designs.  Many of the endogenous promoters could not drive gene expression, 
suggesting a high dependence on genomic context for their activity.  It is unclear whether 
this context is a result of chromatin organization to govern expression290 or if a more 
comprehensive inclusion of the local regulatory sequence is required for promoter activity.  
However, incorporating additional genomic context through an extended 5’ UTR yielded 
increased promoter activity, suggesting that this is a viable approach to generate hybrid 
promoters for mammalian cell types.  Also, endogenous enhancers did not exhibit a 
consistent activation when paired with other endogenous promoters, indicating that more 
fundamental design rules are required.  This was further exemplified when these enhancer 
regions were coupled to promoters with extended 5’ UTR or introns. 
With regards to the minimal introns, the variable gene expression observed (Figure 
5-21) cannot be solely attributed to whether the intron processing was experimentally 
confirmed since the hybrid promoters with introns derived from NDOR1, ESRP2, and 
HNRNPH1 are distinctly different.  Nonetheless, the resulting hybrid promoters were only 
comparable to the promoter without an intron, confirming the lack of benefit observed 
when the CMV promoter was coupled with its cognate intron A in our data (Figures 5-17 
and 5-18).  This data suggests that the intron could be a superfluous element for the CMV 
promoter to drive gene expression based on the data with an underlying assumption.  The 
impact on transcription could be masked if the translation machinery is saturated, thus any 
increase in mRNA abundance would not increase protein levels.  However, there were 
instances where protein levels were significantly lower than our control promoter without 
an intron, but it is unclear from protein expression data alone whether this is due to lower 
mRNA abundance or ineffective processing of mRNA due to these introns. 
 126
Ultimately, through our investigation of the putative promoter structure in the 
mammalian genome, we revealed that the core promoter, enhancer, and 5’ UTR can 
drastically influence gene expression in a combinatorial, yet currently unpredictable, 
manner.  The inconsistent interplay between these elements recapitulated the need for 
empirical and systematic evaluation of each element.  Through these efforts, we gained 
some insight into the design rules and impact of each element on gene expression that 
collectively could lead to de novo rational promoter design for target expression levels. 
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Chapter 6: Prolonging the message – engineering terminators for high 
transgene expression 
6.1. CHAPTER SUMMARY 
Many of the previous efforts to boost transgene expression in mammalian hosts 
focus on the promoter element, as described in Chapters 4 and 5.  Understandably, the 
promoter is the element responsible for generating mRNA and therefore the primary driver 
for gene expression.  However, the terminator (3’ UTR) of the transgene can also modulate 
gene expression by controlling the stability of the transgene mRNA and exerting influence 
on post-transcriptional processing such as intron splicing291-293.  Akin to the work described 
in Chapters 4 and 5 to replace viral promoters with endogenous and synthetic components, 
we generated rational endogenous and synthetic terminators that are comparable in terms 
of tuning gene expression and require less sequence footprint relative to a standard viral 
counterpart.  Ultimately, this novel set of terminators expanded our genetic toolkit for 
engineering mammalian host cells. 
6.2. INTRODUCTION 
The terminator of any coding sequence is often overlooked with minimal emphasis 
during transgene design, especially in mammalian cells, as exemplified by the common 
usage of viral derived terminators294.  In order to generate rational designs of terminators, 
we require an understanding of the essential elements that comprise a functional terminator.  
Significant efforts have characterized various viral and endogenous terminators295-301, 
resulting in a suggested generic structure for this particular element302.  This generic 
structure is comprised of an upstream sequence element (USE), the highly conserved 
hexameric polyadenylation signal (PAS), a cleavage/polyadenylation site, and the 
downstream sequence element (DSE) (Figure 6-1). 
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Figure 6-1: Generic structure of mammalian terminators as described by Proudfoot302. 
 
USE represents the upstream sequence element based on a consensus sequence303, PAS 
represents the highly conserved hexameric polyadenylation signal300, and DSE represents 
the downstream sequence element304. 
These key regions in the terminator have similar structure to yeast terminators that 
were previously exploited to design synthetic terminators for S. cerevisiae and showed 
functionality in another yeast Y. lipolytica305, suggesting that synthetic designs based these 
conserved regions of the terminator are broadly functional.  Along the same vein, 
combining the endogenous element from the human gastrin gene with the viral SV40 
terminator improved reporter gene expression at the transcript level in 3 model mammalian 
cell lines, affirming some modularity to these elements306.  While it was unclear from this 
work what mechanism was directly responsible for the increased mRNA levels, this work 
suggested that terminators can be rationally designed to influence gene expression in 
mammalian cells, much like the previous efforts in yeast305.  More importantly, 
transcription termination can improve gene expression regardless of the promoter in 
yeast305, 307 and mammalian cells292, indicating that the terminator design can be orthogonal 
to the promoter engineering efforts described in Chapters 4 and 5. 
Previous studies characterized some of these key elements of the terminator and 
identified their impact on post-transcriptional regulation308.  The most highly conserved 
element is the hexameric PAS, with minimal deviation from the AAUAAA consensus300, 
309.  The USE was reported to contain sequences that interact with splicing factors, and 
these interactions promote 3’ end formation303.  Likewise, the consensus sequence for the 
DSE was essential for 3’ end formation301, 304, 310, 311. Despite the generic structure of 
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mammalian terminators, it was suggested that some of these elements are dispensable312.  
In the absence of the hexameric PAS, other USEs can direct the recognition of the 
appropriate polyadenyation site and poly(A) addition313, 314.  In fact, a synthetic sequence 
comprised of only the PAS and DSE spaced 22- to 23-bp apart was sufficient to terminate 
transcription315.  Therefore, we adopted a similar approach in exploiting the key elements 
found in the conserved terminator structure for rational designs305 to create and 
subsequently evaluate a set of novel endogenous and synthetic mammalian terminators.  
The expanded availability of characterized mammalian terminators facilitates the 
replacement of viral-derived sequences and offer additional tools to fine-tune gene 
expression in these cells. 
6.3. RESULTS AND DISCUSSION 
6.3.1. Rational design and evaluation of endogenous and synthetic terminators 
It was previously reported that many housekeeping genes have mRNA with 
relatively long half-lives316, suggesting that the terminators of these genes have sequences 
in their 3’ UTR that confer this attribute.  In addition, some of these genes (e.g. EEF1A1, 
GAPDH, and ACTB) are also among the most highly expressed in the genome based on 
our microarray expression data analyzed in Chapter 4.  Therefore, we first explored variants 
of the 3’ UTR from these three genes as terminators and evaluated their impact on the 
expression of the fluorescent reporter hrGFP.  Terminator sequences from EEF1A1, 
GAPDH, and ACTB were selected based on approximations of the key terminator elements 
previously described, most notably the USEs and DSEs (Table 6-1).  These sequences are 
not fully annotated in the genome, thus variants were selected and evaluated similar to 
previous characterization work with promoter identification and verification.  We also 
evaluated a terminator derived from the 3’ UTR of the non-coding RPL41 gene as an 
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alternative to key housekeeping coding genes (Table 6-1).  As a control, we also conducted 
a truncation analysis of the commonly used SV40 terminator to estimate the effects of the 
USEs and DSEs and terminator impact on hrGFP expression (Table 6-1).
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Table 6-1: Table of native/endogenous terminator sequences with putative spacer regions in lower case. 
terminator sequence 5’ > 3’ length Notes 
f.SV40pA 
CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAccattataagctgc
AATAAAcaagttaacaacAAcaattgcattcatttTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGG
TTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA 
222 SV40 late terminator 
m.SV40pA.1 TGTAAccattataagctgcAATAAAcaagttaacaacAAcaattgcattcatttTATGTTTC 62 "minimal" SV40 late terminator, minimal USE, minimal DSE 
m.SV40pA.2 TGTAAccattataagctgcAATAAAcaagttaacaacAAcaattgcattcatttTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTT 92 
"minimal" SV40 late terminator, 
minimal USE, short DSE 
m.SV40pA.3 
CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAccattataagctgc
AATAAAcaagttaacaacAAcaattgcattcatttTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGG
TTTTTT 
192 "minimal" SV40 late terminator, full USE, short DSE 
m.SV40pA.4 
TGTGATGCTATTGCTTTATTTGTAAccattataagctgcAATAAAcaagttaacaacAAcaattgcattcattt
TATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCT
ACAAATGTGGTA 
142 "minimal" SV40 late terminator, short USE, full DSE 
T.EEF1A1.1 TGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTTTCTTTT 71 EEF1A1 terminator, short USE, short DSE 
T.EEF1A1.2 
TGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTTTCTTTTAACAGTT
ACTATGTTGGAATTGGTTACAAATTTTGGAGTGGATTTCAAAAGTGAGAGCTAACTT
CAGTTGATTTCAAGGTAGTGCTTGGCTTTTTTTGTTTA 
173 EEF1A1 terminator, short USE, long DSE 
T.EEF1A1.3 TGTGAAACCCAGTGTCTTAGACAACTGTGGCTTGAGCACCACCTGCTGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTTTCTTTT 117 
EEF1A1 terminator, long USE, 
short DSE 
T.EEF1A1.4 
TGTGAAACCCAGTGTCTTAGACAACTGTGGCTTGAGCACCACCTGCTGGTATtcattacaa
acttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTTTCTTTTAACAGTTACTATGTTGGA
ATTGGTTACAAATTTTGGAGTGGATTTCAAAAGTGAGAGCTAACTTCAGTTGATTTC
AAGGTAGTGCTTGGCTTTTTTTGTTTA 
219 EEF1A1 terminator, long USE, long DSE 
T.GAPDH.1 TGTCATGTACcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagGGTCTGGGGCAGAGGGGAGGGAAGCTGGGCTTGTGTC 99 GAPDH terminator, short USE 
T.GAPDH.2 
TGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCTTGTCATGTACcatcA
ATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagGGTCTGGGGCAGAGGGGAGGGAAGCT
GGGCTTGTGTC 
142 GAPDH terminator, long USE 
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Table 6-1, continued: 
terminator sequence 5’ > 3’ length Notes 
T.ACTB.f 
GCGGACTATGACTTAGTTGCGTTACACCCTTTCTTGACAAAACCTAACTTGCGCAGA
AAACAAGATGAGATTGGCATGGCTTTATTTGTTTTTTTTGTTTTGTTTTGGTTTTTTTT
TTTTTTTTGGCTTGACTCAGGATTTAAAAACTGGAACGGTGAAGGTGACAGCAGTCG
GTTGGAGCGAGCATCCCCCAAAGTTCACAATGTGGCCGAGGACTTTGATTGCACAT
TGTTGTTTTTTTAATAGTCATTCCAAATATGAGATGCGTTGTTACAGGAAGTCCCTTG
CCATCCTAAAAGCCACCCCACTTCTCTCTAAGGAGAATGGCCCAGTCCTCTCCCAAG
TCCACACAGGGGAGGTGATAGCATTGCTTTCGTGTAAATTATGTAATGCAAAATTTT
TTTAATCTTCGCCTTAATACTTTTTTATTTTGTTTTATTTTGAATGATGAGCCTTCGTG
CCCCCCCTTCCCCCTTTTTTGTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCC
CTGGGAGTGGGTGGAGGCAGCCAGGGCTTACCTGTACactgacttgagaccagttgAATAAAag
tgcacaccttaaaaatGAggccaagtgtgacTTTGTGGTGTGGCTGGGTTGGGGGCAGCAGAGGGTG
AACCCTGCAGGAGGGTGAACCCTGCAAAAGGGTGGGGCAGTGGGGGCCAACTTGT
CCTTACCCAGAGTGCAGGTGTGTGGAGATCCCTCCTGCCTTGACATTGAGCAGCCTT
AGAGGGTGGGGGAGGCTCAGGGGTCAGGTCTCTGTTCCTGCTTATTGGGGAGTTCC
TGGCCTGGCCCTTCTATGTCTCCCCAGGTACCCCAGTTTTTCTGGGTTCACCCAGAGT
GCAGATGCTTGAGGAGGTGGGAAGGGACTATTTGGGGGTGTCTGGCTCAGGTGCCA
TGCCTCACTGGGGCTGGTTGGCACCTGCATTTCCTGGGAGTGGGGCTGTCTCAGGGT
AGCTGGGCACGGTGTTCCCTTGAGTGGGGGTGTAGTGGGTGTTCCTAGCTGCCACGC
CTTTGCCTTCACCTATGGGA 
1065 
ACTB reference sequence (same for 
both mRNA variants), full USE 
sequence prior to PAS, long DSE 
T.ACTB.1 
GCGGACTATGACTTAGTTGCGTTACACCCTTTCTTGACAAAACCTAACTTGCGCAGA
AAACAAGATGAGATTGGCATGGCTTTATTTGTTTTTTTTGTTTTGTTTTGGTTTTTTTT
TTTTTTTTGGCTTGACTCAGGATTTAAAAACTGGAACGGTGAAGGTGACAGCAGTCG
GTTGGAGCGAGCATCCCCCAAAGTTCACAATGTGGCCGAGGACTTTGATTGCACAT
TGTTGTTTTTTTAATAGTCATTCCAAATATGAGATGCGTTGTTACAGGAAGTCCCTTG
CCATCCTAAAAGCCACCCCACTTCTCTCTAAGGAGAATGGCCCAGTCCTCTCCCAAG
TCCACACAGGGGAGGTGATAGCATTGCTTTCGTGTAAATTATGTAATGCAAAATTTT
TTTAATCTTCGCCTTAATACTTTTTTATTTTGTTTTATTTTGAATGATGAGCCTTCGTG
CCCCCCCTTCCCCCTTTTTTGTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCC
CTGGGAGTGGGTGGAGGCAGCCAGGGCTTACCTGTACactgacttgagaccagttgAATAAAag
tgcacaccttaaaaatGAggccaagtgtgacTTTGTGGTGTGGCTGGGTTGGGGGCAGCAGAGGGTG
AACCCTGCAGGAGGGTGAACCCTGCAAAAGGGTGGGGCAGTGGGGGCCAAC 
700 
ACTB reference sequence (same for 
both mRNA variants), full USE 
sequence prior to PAS, 100-bp DSE 
after poly(A) site 
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Table 6-1, continued: 
terminator sequence 5’ > 3’ length Notes 
T.ACTB.2 
GCGGACTATGACTTAGTTGCGTTACACCCTTTCTTGACAAAACCTAACTTGCGCAGA
AAACAAGATGAGATTGGCATGGCTTTATTTGTTTTTTTTGTTTTGTTTTGGTTTTTTTT
TTTTTTTTGGCTTGACTCAGGATTTAAAAACTGGAACGGTGAAGGTGACAGCAGTCG
GTTGGAGCGAGCATCCCCCAAAGTTCACAATGTGGCCGAGGACTTTGATTGCACAT
TGTTGTTTTTTTAATAGTCATTCCAAATATGAGATGCGTTGTTACAGGAAGTCCCTTG
CCATCCTAAAAGCCACCCCACTTCTCTCTAAGGAGAATGGCCCAGTCCTCTCCCAAG
TCCACACAGGGGAGGTGATAGCATTGCTTTCGTGTAAATTATGTAATGCAAAATTTT
TTTAATCTTCGCCTTAATACTTTTTTATTTTGTTTTATTTTGAATGATGAGCCTTCGTG
CCCCCCCTTCCCCCTTTTTTGTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCC
CTGGGAGTGGGTGGAGGCAGCCAGGGCTTACCTGTACactgacttgagaccagttgAATAAAag
tgcacaccttaaaaatGAggccaagtgtgacTTTGTGGTGTGGCTGGGTTGGGGG 
637 
ACTB reference sequence (same for 
both mRNA variants), full USE 
sequence prior to PAS, 37-bp DSE 
after poly(A) site 
T.ACTB.3 
TTGCTTTCGTGTAAATTATGTAATGCAAAATTTTTTTAATCTTCGCCTTAATACTTTT
TTATTTTGTTTTATTTTGAATGATGAGCCTTCGTGCCCCCCCTTCCCCCTTTTTTGTCC
CCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGTGGAGGCAGCC
AGGGCTTACCTGTACactgacttgagaccagttgAATAAAagtgcacaccttaaaaatGAggccaagtgtgacTTT
GTGGTGTGGCTGGGTTGGGGGCAGCAGAGGGTGAACCCTGCAGGAGGGTGAACCCT
GCAAAAGGGTGGGGCAGTGGGGGCCAAC 
333 
ACTB reference sequence, short 
USE sequence prior to PAS for both 
mRNA variants, 100-bp after 
poly(A) site 
T.ACTB.4 
TTGCTTTCGTGTAAATTATGTAATGCAAAATTTTTTTAATCTTCGCCTTAATACTTTT
TTATTTTGTTTTATTTTGAATGATGAGCCTTCGTGCCCCCCCTTCCCCCTTTTTTGTCC
CCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGTGGAGGCAGCC
AGGGCTTACCTGTACactgacttgagaccagttgAATAAAagtgcacaccttaaaaatGAggccaagtgtgacTTT
GTGGTGTGGCTGGGTTGGGGG 
270 
ACTB reference sequence, short 
USE sequence prior to PAS for both 
mRNA variants, 37-bp after poly(A) 
site 
T.RPL41.f 
ACCGCTAGCTTGTTGCACCGTGGAGGCCACAGGAGCAGAAACATGGAATGCCAGAC
GCTGGGGATGCTGGTACAAGTTGTGGGACTGCATGCTACTGTCTAGAGCTTGTCTCA
ATGGATCTAGAACTTCATCGCCCTCTGATCGCCGATCACCTCTGAGACCCACCTTGC
TCATAAACAAAATGCCCATGTTGGTCCTCTGCCCTGGACCTGTGACATTCTGGACTA
TTTCTGTGTTTATTTGTGGCCGAGTGTAACAACCATATAATAAAtcacctcttccgctgttttagctg
aagaattaaatCAtcttgtctattaTGTTTTTTATGGTTCCATCGGGTGGGGGTTTTCTGTCATTAGA
GTTTGCCCTGTCACTACCTGTGCTATGGAGGGTATCAAAGCTATA 
408 
RPL41 reference sequence, full USE 
sequence prior to PAS, 100-bp after 
poly(A) site 
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Table 6-2: Table of synthetic terminator sequences 
terminator sequence 5’ > 3’ length Notes 
Tm.synth.1 TGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCTTGTCATGTACcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTGTGTTTT 113 
GAPDH long USE, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, DSE 
consensus 
Tm.synth.2 TGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCTTGTCATGTACcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTCTGTGTGTTGGTTTTTTGTGTG 128 
GAPDH long USE, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, 
Levitt consensus 
Tm.synth.3 
TGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCGCACCTTGTCATGTACcatcA
ATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTGTGTTTTTCTGTGTGTTGGTTTTTTGT
GTG 
136 
GAPDH long USE, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, 
DSE+Levitt consensus 
Tm.synth.4 TGTAATGTAATGTAATGTAAcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagGGTCTGGGGCAGAGGGGAGGGAAGCTGGGCTTGTGTC 109 
4x USE consensus, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, 
GAPDH DSE 
Tm.synth.5 TGTAATGTAATGTAATGTAAcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTGTGTTTT 80 
4x USE consensus, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, DSE 
consensus 
Tm.synth.6 TGTAATGTAATGTAATGTAAcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTCTGTGTGTTGGTTTTTTGTGTG 95 
4x USE consensus, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, 
Levitt consensus 
Tm.synth.7 TGTAATGTAATGTAATGTAAcatcAATAAAgtaccctgtgctcaaccagtTActtgtcctgtcttattctagTGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 103 
4x USE consensus, GAPDH spacer 
1, GAPDH spacer 2, GAPDH 
poly(A) site, GAPDH spacer 3, 
DSE+Levitt consensus 
Tm.synth.8 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtTATGTGTTTT 56 
4x USE consensus, GAPDH spacer 
2, GAPDH poly(A) site, DSE 
consensus 
Tm.synth.9 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtTATCTGTGTGTTGGTTTTTTGTGTG 71 
4x USE consensus, GAPDH spacer 
2, GAPDH poly(A) site, Levitt 
consensus 
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Table 6-2, continued: 
terminator sequence 5’ > 3’ length Notes 
Tm.synth.10 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtTATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 79 
4x USE consensus, GAPDH spacer 
2, GAPDH poly(A) site, 
DSE+Levitt consensus 
Tm.synth.11 TGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTGTGTTTT 71 
EEF1A1 short USE, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, DSE 
consensus 
Tm.synth.12 TGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTCTGTGTGTTGGTTTTTTGTGTG 86 
EEF1A1 short USE, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, 
Levitt consensus 
Tm.synth.13 TGGTATtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 94 
EEF1A1 short USE, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, 
DSE+Levitt consensus 
Tm.synth.14 
TGTAATGTAATGTAATGTAAtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggca
TTTCTTTTAACAGTTACTATGTTGGAATTGGTTACAAATTTTGGAGTGGATTTCAAA
AGTGAGAGCTAACTTCAGTTGATTTCAAGGTAGTGCTTGGCTTTTTTTGTTTA 
187 
4x USE consensus, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, 
EEF1A1 long DSE 
Tm.synth.15 TGTAATGTAATGTAATGTAAtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTGTGTTTT 85 
4x USE consensus, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, DSE 
consensus 
Tm.synth.16 TGTAATGTAATGTAATGTAAtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTCTGTGTGTTGGTTTTTTGTGTG 100 
4x USE consensus, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, 
Levitt consensus 
Tm.synth.17 TGTAATGTAATGTAATGTAAtcattacaaacttgctcactacAATAAAtgaattttaagctttAAgatgaagtggcaTGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 108 
4x USE consensus, EEF1A1 spacer 
1, EEF1A1 spacer 2, EEF1A1 
poly(A) site, EEF1A1 spacer 3, 
DSE+Levitt consensus 
Tm.synth.18 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttAATGTGTTTT 51 
4x USE consensus, EEF1A1 spacer 
2, EEF1A1 poly(A) site, DSE 
consensus 
Tm.synth.19 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttAATCTGTGTGTTGGTTTTTTGTGTG 66 
4x USE consensus, EEF1A1 spacer 
2, EEF1A1 poly(A) site, Levitt 
consensus 
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Table 6-2, continued: 
terminator sequence 5’ > 3’ length Notes 
Tm.synth.20 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttAATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 74 
4x USE consensus, EEF1A1 spacer 
2, EEF1A1 poly(A) site, 
DSE+Levitt consensus 
Tm.synth.21 TGTAATGTAATGTAATGTAAAATAAAagtgcacaccttaaaaatGATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 77 
4x USE consensus, ACTB spacer 2, 
ACTB poly(A) site, DSE+Levitt 
consensus 
Tm.synth.22 TGTAATGTAATGTAATGTAAAATAAAagtgcacaccttaaaaatCATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 77 
4x USE consensus, ACTB spacer 2, 
poly(A) site consensus, DSE+Levitt 
consensus 
Tm.synth.23 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtCATGTGTTTT 56 
4x USE consensus, GAPDH spacer 
2, poly(A) site consensus, DSE 
consensus 
Tm.synth.24 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtCATCTGTGTGTTGGTTTTTTGTGTG 71 
4x USE consensus, GAPDH spacer 
2, poly(A) site consensus, Levitt 
consensus 
Tm.synth.25 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtCATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 79 
4x USE consensus, GAPDH spacer 
2, poly(A) site consensus, 
DSE+Levitt consensus 
Tm.synth.26 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttCATGTGTTTT 51 
4x USE consensus, EEF1A1 spacer 
2, poly(A) site consensus, DSE 
consensus 
Tm.synth.27 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttCATCTGTGTGTTGGTTTTTTGTGTG 66 
4x USE consensus, EEF1A1 spacer 
2, poly(A) site consensus, Levitt 
consensus 
Tm.synth.28 TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttCATGTGTTTTTCTGTGTGTTGGTTTTTTGTGTG 74 
4x USE consensus, EEF1A1 spacer 
2, poly(A) site consensus, 
DSE+Levitt consensus 
Tm.synth.29 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtCACGTGTTATTCATAAGCATT 67 
4x USE consensus, GAPDH spacer 
2, poly(A) site consensus, MC4R 
DSE312 
Tm.synth.30 TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaaccagtCAGTTGTGTGTGTTG 61 
4x USE consensus, GAPDH spacer 
2, poly(A) site consensus, #7 DSE 
from Pérez Cañadillas, et al (CstF-
64 RRM)317 
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Since previous work demonstrated that rationally designed synthetic terminators 
are functional in eukaryotes305, 315, we used the generic mammalian terminator structure 
(Figure 6-1) as a scaffold and created 30 permutations (Table 6-2) by filling the spacer 
sequences with endogenous sequences from EEF1A1, GAPDH, and ACTB.  We also 
explored putative USEs and DSEs from these endogenous genes in addition to their 
consensus sequences302, as well as two DSEs identified in other reports312, 317.  Lastly, 
variants were created using the polyadenylation site consensus dinucleotide ‘CA’ instead 
of the native site from EEF1A1, GAPDH, and ACTB to evaluate the impact of this key 
terminator element. 
These terminators were paired with a moderate strength promoter characterized in 
Chapter 5 and derived from EIF4A1 (636-bp promoter pEIF4A1.636) to drive hrGFP 
reporter expression.  We quantified the impact of the various terminators on gene 
expression by measuring the transient hrGFP expression 48h post-transfection in HT1080 
cells.  Of the 4 truncated variants of the SV40 terminator, only m.SV40pA.1 affected gene 
expression negatively relative to the full length terminator (f.SV40pA) (Figure 6-2).  
Based on these results (Figure 6-2), we identified endogenous terminator sequences that 
are functional and influence gene expression to different extents, with 3 (T.GAPDH.2, 
T.ACTB.3, and T.ACTB.4) that were obviously comparable to the full length 222-bp SV40 
terminator (f.SV40pA).  From our 30 synthetic variants, the Tm.synth.13 terminator was 
clearly indistinguishable from the full length SV40 terminator (f.SV40pA) in terms of its 
impact on hrGFP expression (Figure 6-2).  Overall, 14 of our 30 synthetic terminators 
comprised solely of endogenous and consensus sequences behave comparably to the SV40 
terminator based on this expression data (Figure 6-2). 
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Figure 6-2: Transient hrGFP expression 48h post-transfection with various terminators 
in HT1080 cells 
 
Expression reported as average geometric mean fluorescence intensity (gMFI) in 
arbitrary units.  Error bars represent the 95% CI of the average gMFI from at least 3 
independent transfections. 
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6.3.2. Full replacement of viral components with endogenous/synthetic elements 
Based on the comparability of gene expression levels from several endogenous and 
synthetic terminators to the SV40 terminator (Figure 6-2), we established that these novel 
terminators are suitable replacements for the viral-derived sequence.  We compared hrGFP 
expression between several transgene designs to further evaluate the possibility of 
completely replacing strong viral-derived regulatory elements.  Our transgene containing 
viral-derived elements use the common strong CMV promoter coupled to the SV40 
terminator while our endogenous and synthetic variants use the strong endogenous 
promoter (pEEF1A1.1356) with our 3 terminators T.GAPDH.2, T.ACTB.4, and 
Tm.synth.13.  When we measured transient hrGFP expression 48h post-transfection, the 3 
fully endogenous/synthetic constructs were comparable to, and 1.9x stronger 
(Tm.synth.13) than, the viral-derived construct, indicating that we can obtain high transient 
transgene expression in HT1080 without relying on viral-derived components (Figure 6-3 
and Table 6-3). 
Most importantly, we identified endogenous and synthetic terminator variants that 
resulted in comparable gene expression relative to the common SV40 terminator 
(T.GAPDH.2, T.ACTB.3, T.ACTB.4, and Tm.synth.13, Figures 6-2 and 6-3).  
Interestingly, these novel variants were either 1.5x larger (333-bp) or nearly 2.4x smaller 
(94-bp) in sequence length (Tables 6-1 and 6-2) relative to the viral terminator (222-bp), 
indicating that a particular sequence length was not necessary for strong terminator activity.  
Furthermore, the 63-bp reduction in the DSE between T.ACTB.3 and T.ACTB.4 resulted 
in negligible impact on gene expression (Figure 6-2), suggesting that the 24-bp G/T-rich 
DSE from ACTB was sufficient.  However, when comparing the other 3 ACTB-derived 
terminators with an extended 555-bp USE (T.ACTB.f, T.ACTB.1, and T.ACTB.2, Figure 
6-2), the reduction of the corresponding DSE from the 452-bp or 87-bp version to the 24-
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bp version resulted in much lower gene expression (compare T.ACTB.2 with other ACTB-
derived terminators, Figure 6-2).  Even within this small group of terminator sequences 
derived from the same endogenous sequence, the variable expression highlights that these 
key elements of a terminator have significant interplay. 
Figure 6-3: Comparison of strong viral-derived elements with fully 
endogenous/synthetic elements for regulating gene expression. 
 
Transient hrGFP expression 48h post-transfection in HT1080 cells reported as average 
geometric mean fluorescence intensity (gMFI) in arbitrary units.  Error bars represent the 
95% CI of the average gMFI from at least 3 independent transfections. rpCMV 
corresponds to reference CMV promoter, pEEF1A1 corresponds to full length 1356-bp 
promoter derived from EEF1A1. 
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Table 6-3: Fully endogenous/synthetic genetic elements compared with viral-derived 
elements based on hrGFP expression. 
terminator pair expression difference padjusted 
rpCMV.f.SV40pA-HT1080.WT 2.032 0.000 
rpCMV.f.SV40pA-pEEF1A1.no.terminator 0.605 0.000 
rpCMV.f.SV40pA-pEEF1A1.f.SV40pA -0.411 0.000 
rpCMV.f.SV40pA-pEEF1A1.T.GAPDH.2 -0.016 1.000 
rpCMV.f.SV40pA-pEEF1A1.T.ACTB.4 -0.156 0.275 
rpCMV.f.SV40pA-pEEF1A1.Tm.synth.13 -0.282 0.003 
rpCMV corresponds to reference CMV promoter, pEEF1A1 corresponds to full length 
1356-bp promoter derived from EEF1A1.  Statistical significance determined by 
ANOVA and Tukey’s HSD post-hoc testing.  Expression difference corresponds to the 
difference of log mean hrGFP expression of the particular terminator relative to SV40. 
6.3.3. Confirming terminator functionality under different genomic context 
While we designed these synthetic variants based on the generic mammalian 
terminator structure and therefore they should be independent of the gene/transgene they 
regulate, we wanted to confirm that their functionality remains comparable under two 
additional genomic contexts.  We examined a subset of our endogenous and synthetic 
terminator designs for their ability to modulate the expression of secreted alkaline 
phosphatase (SEAP), a secreted reporter protein, and also their interplay with a stronger 
promoter (1356-bp promoter pEEF1A1.1356 derived from EEF1A1, commonly regarded 
as EF1) to regulate hrGFP expression. 
We observed similar trends in SEAP expression to our previous hrGFP data 
(Figure 6-4).  With this subset of terminators, we obtained 11-fold dynamic range of 
expression, which is greater than the 5.7-fold range measured with our hrGFP reporter 
(Figure 6-2) for this same subset.  Interestingly, the ACTB-derived terminator (T.ACTB.4) 
was only minimally influenced by this change in preceding coding sequence and remained 
comparable to the SV40 terminator, but the GAPDH-derived terminator (T.GAPDH.2) was 
only half as functional (Figure 6-4).  Also, the synthetic terminator Tm.synth.19 behaved 
comparably to the SV40 terminator based on SEAP expression but not hrGFP expression 
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(compare Figure 6-2 and 6-4), suggesting some interaction between terminators and 
preceding coding sequence.  Based on the SEAP reporter, only Tm.synth.19 and 
Tm.synth.20 were comparable to SV40 in terms of gene expression (Figure 6-4). 
Figure 6-4: Transient SEAP expression 48h post-transfection with terminator subset in 
HT1080 cells 
Expression reported as average specific productivity in pg/cell/day.  Error bars represent 
the 95% CI of the specific productivity from at least 3 independent transfections. 
When we replaced the moderate strength promoter (pEIF4A1.636) with the strong 
endogenous promoter (pEEF1A1.1356), our dynamic range of hrGFP expression was 
reduced to approximately 3.5-fold, essentially half of the range measured previously with 
our moderate strength promoter (Figure 6-5).  However, a reduction in the expression 
range is expected since the mRNA generation rate of stronger promoters can overwhelm 
the degradation rate, consequently saturating the system.  This pairing also revealed some 
additional context dependency on gene expression, most notably the weaker gene 
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expression associated with the endogenous terminators T.GAPDH.2 and T.ACTB.4 
(Figure 6-5), mimicking the same observations with the SEAP reporter (Figure 6-4).  
However, under the context of a strong promoter (reflected by the marked increase in 
gMFI, compare Figures 6-2 and 6-5), 8 of the 12 synthetic terminators were comparable 
to the SV40 terminator based on gene expression levels (Figure 6-5). 
Figure 6-5: Transient hrGFP expression 48h post-transfection in HT1080 cells when 
terminators are coupled to a strong endogenous promoter 
Expression of various terminators with a strong promoter (pEEF1A1.1356) as average 
geometric mean fluorescence intensity (gMFI) in arbitrary units.  Error bars represent the 
95% CI of the average gMFI from at least 3 independent transfections. 
6.3.4. Dissecting the key composition of mammalian terminators 
The variable influence on gene expression by the terminator sequence affirmed the 
ability of the 3’ UTR to tune gene expression and suggested that the key elements of these 
terminators can be dissected to reveal their contributions to this regulation.  We compared 
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hrGFP and SEAP expression within a subset of these synthetic terminators, specifically 
interrogating the effects of spacer 2 (between the PAS and the polyadenylation site), the 
polyadenylation site, and the DSE sequence independently and between their interactions.  
This subset is comprised of Tm.synth.8-10, 18-20, and 23-28 (Table 6-2), which contains 
permutations of these three key terminator elements. 
Analysis of the transient hrGFP expression driven by the moderate strength 
promoter (pEIF4A1.636) using ANOVA followed by Tukey’s HSD post-hoc testing 
revealed that the DSE can significantly impact terminator functionality and gene 
expression (p < 0.001).  Synthetic DSE sequences were clearly functional from the 
expression data (Figures 6-2 to 6-5) and they were stronger than the DSE consensus (Table 
6-4).  A broader ANOVA across the entire terminator subset revealed that the interactions 
between these three key elements in the terminator significantly impact gene expression 
(Table 6-5).  Likewise, the same analyses conducted on the SEAP expression data and 
hrGFP expression data driven by the strong endogenous promoter revealed the same 
critical impact of the DSE and the interaction of these three key elements on gene 
expression (Table 6-5). 
Table 6-4: Differential expression between a particular DSE and the DSE consensus 
from ANOVA analysis with Tukey’s HSD post-hoc testing based on hrGFP 
expression driven by the pEIF4A1.636 promoter. 
pairwise comparison differential expression padjusted 
Levitt-consensus 0.140 0.035 
MC4R-consensus 0.220 0.002 
CstF64.RRM-consensus 0.271 0.000 
consensus+Levitt-consensus 0.570 0.000 
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Table 6-5: ANOVA analysis with Tukey’s HSD post-hoc testing of the spacer 2, 
polyadenylation site, and DSE impact on gene expression in conjunction 
with two promoter strengths. 
pEIF4A1.636-hrGFP pEIF4A1.636-SEAP pEEF1A1.1356-hrGFP 
Factor/interaction p-value Factor/interaction p-value Factor/interaction p-value 
spacer.2 0.033 spacer.2 0.000 spacer.2 0.116 
PA.site 0.919 PA.site 0.755 PA.site 0.539 
DSE <2.20E-16 DSE 3.351E-08 DSE 1.08E-12 
spacer.2:PA.site 9.96E-11 spacer.2:PA.site 4.94E-05 spacer.2:PA.site 0.527 
spacer.2:DSE 0.349 spacer.2:DSE 0.022 spacer.2:DSE 0.035 
PA.site:DSE 0.779 PA.site:DSE 0.503 PA.site:DSE 9.01E-05 
spacer.2:PA.site:DSE 2.52E-10 spacer.2:PA.site:DSE 1.23E-03 spacer.2:PA.site:DSE 0.361 
Analysis corresponds to hrGFP expression driven by the pEIF4A1.636 promoter, SEAP 
expression driven by the pEIF4A1, and hrGFP expression driven by the pEEF1A1.1356 
promoter. 
We briefly investigated the interactions between these key elements that could 
guide subsequent terminator design.  Based on the expression data, the DSE itself can 
drastically impact the resulting gene expression in a sequence-dependent manner and the 
DSE consensus sequence alone is sufficient for terminator activity (Figures 6-2, 6-4, and 
6-5).  While the DSE consensus was functional as a terminator element, we observed 
significantly stronger gene expression with other synthetic DSEs, suggesting that a 
consensus sequence may not be optimal (Table 6-4).  These observations were 
recapitulated between the endogenous terminators and its synthetic variants with different 
DSEs (compare T.EEF1A1.1, T.EEF1A1.2, Tm.synth.11, Tm.synth.12, and Tm.synth.13, 
Figure 6-2), and the resulting gene expression again did not correlate with the DSE 
sequence length.  Interestingly, the synthetic DSEs in this terminator context yielded 
stronger gene expression than the endogenous EEF1A1 DSEs, yet the same effect was not 
observed with GAPDH-derived sequences (compare T.GAPDH.2, Tm.synth.01, 
Tm.synth.02, and Tm.synth.03, Figure 6-2). 
Likewise, changing the endogenous USE sequence to the consensus 4x repeat did 
not result in a consistent impact on gene expression based on EEF1A1-derived (compare 
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T.EEF1A1.2, T.EEF1A1.4, and Tm.synth.14) and GAPDH-derived (compare 
T.GAPDH.1, T.GAPDH.2, and Tm.synth.04) sequences (Figure 6-2).  Collectively, the 
data corroborates previous bioinformatics analyses suggesting that the DSE has a greater 
impact on polyadenylation processing than the USE318.  In addition, changing the 
endogenous polyadenylation site to the dinucleotide consensus sequence had no 
measurable impact on gene expression (Table 6-5), further highlighting the suboptimal 
nature of a consensus sequence of a terminator element.  Although, certain combinations 
of the spacer between the PAS and polyadenylation site (spacer 2), the polyadenylation 
site, and the DSE had significant impact on gene expression, this impact was masked when 
expression was driven by a strong promoter (Table 6-5).  These results revealed that the 
impact of the terminator on gene expression can be tailored through these particular 
elements. 
6.4. CONCLUSIONS 
In this work, we generated and characterized the impact of 12 endogenous and 30 
synthetic terminator variants on their ability to modulate gene expression.  Critically, all of 
these variants were functional, and many variants required significantly reduced sequence 
space compared to a common, strong viral terminator.  For the initial evaluation of these 
terminators, we opted to use a moderate strength promoter in order to observe a greater 
dynamic range in gene expression due to changes in the terminator.  As a regulatory 
element, the terminator should ideally function in a predictable manner regardless of the 
preceding coding sequence or the relative strength of the promoter driving that particular 
transcript.  However, our subsequent characterizations of a subset of these endogenous and 
synthetic terminators with an alternate reporter and stronger promoter showed that these 
terminators do exhibit some context dependency (compare Figure 6-2, 6-4, and 6-5).  The 
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relative measured gene expression levels between terminators were inconsistent when the 
protein reporter was changed, but a large dynamic range in expression was maintained.  
This is expected since the terminator elements should fine-tune gene expression, whereas 
the promoter element responsible for generating mRNA was unchanged.  This is further 
corroborated by the compression of this dynamic range when a subset of our terminators 
were coupled to a strong endogenous promoter (Figure 6-5).  Previous work in our group 
reported similar findings in S. cerevisiae, where the terminator exerted greater influence 
on gene expression when paired with lower-strength promoters307. 
The premise of engineering novel terminators for high gene expression 
predominantly aims to replace the viral-derived components with endogenous and 
synthetic counterparts that are comparable in terms of their impact on gene expression.  
Based on the work for replacing the promoter with synthetic de novo designs (Chapter 4) 
and with endogenous variants (Chapter 5), the replacement of viral terminators with the 
endogenous and synthetic terminators characterized in this work enables a full conversion 
of viral-derived regulatory sequences to purely endogenous and synthetic sequences.  This 
replacement was not detrimental to gene expression, but instead we achieved comparable 
or stronger expression using an endogenous promoter and terminator (Figure 6-3).  
However, much like the promoter engineering and characterization described in Chapters 
4 and 5, terminator engineering still requires empirical characterization in mammalian cells 
even when using a generic structure as a scaffold based on the context dependency 
observed in this work.  The dissection of several key elements in terminators affirmed the 
interaction between these elements (Table 6-5), but design rules for predictive terminator 
design to achieve a certain expression level were not evident from this work.  Similar to 
previous efforts in yeast305, 307, this work expanded the set of characterized terminators 
available for tuning gene expression.  Ultimately, the ability to use a terminator as an 
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additional regulatory element to modulate transgene expression facilitates the transition 
from mammalian cell engineering for solely high transgene expression to engineering 
metabolic pathways and other applications that require precise control of gene expression.
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Chapter 7: Conclusions and Major Findings 
The engineering of mammalian host cells over the past several decades 
predominantly focused on industrial biotechnology and basic research applied to human 
health and disease.  The advent of recombinant protein production in model organisms and 
mammalian cell types drastically changed the landscape of healthcare, simultaneously 
exposing the complex cellular and molecular biology of mammalian cells.  The clinical 
and industrial successes of these bioengineered products fundamentally relied on many of 
the genetic elements governing gene expression that were derived from virology work.  
The extensive and prolonged use of these viral-derived elements revealed a critical 
limitation in addition to their inherent immunogenic potential: the sequences were 
eventually recognized as foreign elements and silenced226, 229, 319, reducing the robustness 
required of viable industrial processes.  Furthermore, many of cellular engineering efforts 
focused primarily on increasing gene expression or enabling applications for high gene 
expression with little regard for potential applications. 
The work described in this dissertation aims to shift the mindset away from treating 
mammalian cells solely as recombinant protein factories and facilitates the exploration of 
their complex metabolism and cell biology for other therapeutic applications and medical 
needs.  This was accomplished by developing the approaches and methods that enable 
extensive control of gene expression in these cell types while removing the dependence on 
viral-derived elements for these tasks.  This work can be immediately applied to current 
protein production applications in mammalian cells, but most importantly, the sufficiently 
generic methods and approaches can greatly benefit the growing number of metabolic 
engineering and immune cell engineering applications. 
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By using an unbiased genome integration approach, our work in Chapter 2 revealed 
that the gene locus/integration site can act as one of the levers for tuning expression.  We 
identified ten recombinant human cell lines with stable, single-copy, high-level 
heterologous gene expression and subsequently their corresponding integration loci.  These 
results indicated the importance of both non-protein coding regions and exonic regions for 
heterologous gene expression.  Expression maps for each of these loci also demonstrated 
negligible perturbations caused to the surrounding genes by our transgene integration.  
Lastly, we demonstrated that de novo, targeted integration at one of the identified 
“transcriptional hot-spots” resulted in superior expression compared to the standard, 
illegitimate (random) integration approach.  This work provided a much needed cataloging 
of potential genomic hot spots for gene expression and an easily adaptable approach to 
seek out other loci that can be linked together with emerging genome editing tools.  
Relating to immediate applications, the targeting of these advantageous integration loci can 
significantly reduce the time, labor and materials associated with cell line development for 
therapeutic protein production.  This approach (and the specific targets identified) can be 
extended to other mammalian cell lines used for industrial protein production, including 
CHO and HEK293 and help speed their development processes.  Given our measured 20-
fold dynamic range in transcriptional activity based on this limited set of integration sites, 
an extensive characterization of additional loci can enable facile exploitation of the 
integration site as an additional layer of gene regulation. 
To truly utilize an integration locus for controlling gene expression, clonal cell 
populations must be easily generated and isolated that contain the desired integration.  The 
work in Chapter 3 set the groundwork for improving the success of specific, targeted 
integrations.  We verified a locus co-targeting approach181 for validating gRNA target sites 
and corroborated the coordination of these gRNA with Cas9 to induce targeted DSBs by 
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Sanger sequencing and qPCR methods.  A thorough characterization of this integration 
process is essential for incorporating pathways and complex expression programs 
associated with metabolic engineering and immune cell engineering in addition to gaining 
insight into the critical parameters that govern this process for cell line development. 
In our work, we explored two avenues to engineer promoters, the key element that 
drives transcription.  First, we demonstrated the utility of an ‘omics guided workflow to 
create novel, synthetic promoters for a mammalian cell host in Chapter 4.  By applying this 
generic workflow, we can develop a set of de novo promoters to properly tune the levels 
of protein intermediates in a metabolic pathway through adjusting the TFBS composition 
and arrangement.  Moreover, these synthetic promoters had an overall reduced sequence 
footprint compared to reference promoters, thus increasing the overall utility for 
applications such as (heterologous) metabolic pathway designs6 and gene delivery vector 
designs253, akin to efforts in reducing the regulatory sequence footprint in a conventional 
metabolic engineering host254.  The synthetic promoters designed in a single iteration of 
our workflow for high expression were comparable to a strong viral-derived and 
endogenous promoter, highlighting the potential of replacing viral-derived elements.  
Importantly, replacing viral-derived elements with these diverse, synthetic sequences 
would potentially reduce their susceptibility of epigenetic silencing and increase their long-
term stability, which are two key attributes required in metabolic engineering and immune 
cell engineering applications. Ultimately, this workflow incorporates contemporary high-
throughput methodologies to construct functional promoter elements that can facilitate a 
myriad of applications ranging from the study of fundamental processes to immediate use 
in large-scale industrial processes. 
Second, we explored a more traditional approach of evaluating putative regulatory 
regions derived from segments of endogenous sequences to create hybrid promoters in 
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Chapter 5.  We found that the core promoter element can be rationally engineered and 
expanded with repeats to achieve a certain level of functionality in a specific cell type, but 
the major regulation in gene expression was due to the enhancer region, corroborating the 
findings in Chapter 4.  Our data revealed that the concomitant introns found in endogenous 
promoters correlated with strong expression, yet they were not necessary for strong 
expression.  This was exemplified by our 546-bp hybrid promoter (ACTBe.182-
pEEF1A1.356) containing sequences derived from ACTB and EEF1A1 that was 
comparable to the 660-bp viral promoter, which was further improved by adding the 
GAPDH intron 1 (ACTBe.182-pEEF1A1.350.Gi1).  Interestingly, the 182-bp ACTB-
derived enhancer did not impact gene expression relative to its variant containing the 
GAPDH intron 1 (pEEF1A1.350.Gi1), indicating that the enhancer and intron were not 
purely additive in their effect on gene expression.  Subsequent hybrid promoters containing 
short endogenous introns or a synthetic intron showed that the intronic region can further 
modulate promoter activity.  Nonetheless, we created a set of hybrid promoters with 
expression levels ranging from minimally detectable expression to strong expression 
characteristic of a viral promoter.  Some of these hybrid promoters were comparable to if 
not stronger than a strong viral promoter, expanding the ability to tune gene expression 
without viral-derived elements.  Critically, this work highlighted the strong impact on gene 
expression by the intronic region in mammalian cells, and their impact warrants further 
characterization of the mechanisms responsible. 
Lastly, many of the previous efforts around terminators focused on understanding 
the critical key elements that comprise this essential regulatory region in mammalian cells 
and other eukaryotic systems.  Single, one-off, synthetic variants were reported for 
mammalian cells315 and yeast320 yet terminators were not systematically studied to harness 
their potential for modulating gene expression levels until this work in mammalian cells 
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and recently in yeast305, 307.  We designed and evaluated a panel of endogenous and 
synthetic terminators, many of which exhibited a similar impact on gene expression as a 
commonly used viral terminator.  Under the control of a weak promoter, the terminator can 
impact net gene expression by 11-fold while under the control of a strong promoter, this 
impact is reduced to 3.5-fold.  Nonetheless, our data suggests that terminators can still 
significantly impact the resulting expression levels regardless of promoter strength.  
Finally, we examined a full replacement of viral-derived components for both the promoter 
and terminator and found that our endogenous and synthetic variants were comparable at 
regulating gene expression, and one particular variant was 1.9-fold stronger than the fully 
viral-derived combination.  Similar to the TFBS composition impact on promoter strength, 
our analysis of the key elements that comprise terminators revealed that they are the drivers 
for the differential impact on the final gene expression.  Therefore, our data indicates that 
terminators are additional tools for fine-tuning expression in mammalian cells, and we can 
rationally engineer them by specifying the key elements that comprise terminators.  
Collectively, by selecting the transgene integration site, specifying an appropriate 
promoter strength for transcriptional activity, and regulating that transcript with an 
engineered terminator, we have an unprecedented ability to systematically control gene 
expression in mammalian cells.  Without doubt, these approaches and methods enabled the 
replacement of viral-derived elements and can be readily adapted to a variety of 
mammalian cell types used in current applications.  The multiplexing capability of these 
approaches and methods, along with the conversion away from viral-derived sequences, 
moves mammalian cell engineering forward in the metabolic engineering and immune cell 
engineering fields where precise and prolonged gene expression programs are required for 
their success. 
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In the broader sense, this work addresses several key challenges facing established 
and nascent mammalian cell engineering applications as therapeutics.  The influence of the 
integration site on gene expression highlighted in our work strictly emphasizes the need 
for targeted transgene integrations into the host cell genome instead of relying on 
integrations into random loci.  Not only can targeted integrations expedite cell line 
development for therapeutic protein production by reducing screening efforts, it can also 
build in additional quality assurance and quality control into the process from a federal 
regulation perspective (“Quality by Design”).  Our work described in Chapter 2 established 
a straightforward approach to identify potential integration sites, which can be combined 
with high-throughput sequencing technologies to build a larger catalog of beneficial 
integration sites.  Concurrently, adoption of our endogenous/synthetic promoter and 
terminator elements from Chapters 4-6 can culminate into a transgene design capable of 
driving extremely high protein expression without the use of viral-derived elements, 
potentially escaping epigenetic silencing of the transgene over time.  Furthermore, this 
avoidance of viral-derived elements with robust activity is especially critical to in vivo 
applications such as immunotherapies/adoptive cell therapies so that a predictable medical 
benefit in patients can be maintained.  Thus, the work described in this dissertation has 
immediate impact on a clinically- and commercially-relevant industry and emerging 
technologies.  
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Chapter 8: Proposals for future work 
This work expanded the ability to fine tune gene expression in mammalian hosts, 
and in doing so, created endogenous and synthetic genetic elements that can replace viral-
derived regulatory elements with comparable impact on gene expression.  In this chapter, 
additional considerations and unanswered questions along with potential future studies in 
these topics are discussed. 
In Chapter 2, we established a set of genomic loci that function as transcriptional 
hot-spots through our genome-wide screening approach.  We isolated clonal populations 
with stable, strong hrGFP expression through FACS, with the underlying assumption that 
the clones with the highest expression levels correspond to integrations sites that favor 
transcription.  We verified that the clonal populations contained a single copy of our 
reporter and identified the transgene integration sites in these clonal populations with low-
throughput methods.  Even within our set of characterized integration sites, two of the loci 
were unplaced, clearly highlighting a challenge in our approach and suggesting 
opportunities for subsequent studies. 
For example, we can exploit the maturation of high-throughput sequencing (HTS) 
technologies to improve our success in identifying integration sites.  While it would still 
be difficult to identify the integrations sites that are located in heavily repeated sequences 
such as short and long interspersed sequences (SINEs and LINEs)321 with HTS techniques, 
it would be possible to gain additional insight into these integration sites with a large 
enough sample set.  If high expression cell populations contain preferential integration 
sites, the classification or other attributes of these loci can facilitate subsequent de novo 
targeting of favorable sites.  Given the high transcriptional activity associated with these 
identified loci, preferential recovery of integrations at these sites may also be biased by the 
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local chromatin remodeling at these loci as a result of DNA repair322.  In addition, extensive 
cataloguing of these sites may reveal loci that are prone to DSBs with implications on 
cellular health323.  Lastly, these transcriptional hot-spots can be evaluated in other cell lines 
to confirm that the impact on gene expression is maintained. 
In Chapter 3, we laid most of the groundwork to enable a thorough assessment of 
targeted transgene integration into common mammalian host cells.  A highly selective 
targeted integration and screening process would effectively isolate cell populations with 
the desired transgene(s) integrated at the target locus while an efficient process would 
incorporate as much of the donor template as possible.  By taking an approach that should 
reduce the formation of DSBs and remove unwanted integrations at off-target loci, we 
would be able achieve a highly selective and efficient process.  We verified that Zeocin™ 
is a highly selective agent for common mammalian host cells but we have yet to confirm 
the expression cytosine deaminase-uracil phosphoribosyltransferase fusion gene serves as 
an effective negative selection marker that responds to 5-fluorocytosine206, 209 for removing 
integrations at undesired loci.  An effective negative selection agent is imperative to this 
combination approach and requires thorough characterization. 
Previous work demonstrated that multiple gRNAs targeting the same locus 
drastically improved gene silencing79, suggesting that we can exploit this approach to 
increase the propensity for DSBs at the target site and subsequently improve the frequency 
of successful integrations through DNA repair.  This putative improvement can still be 
combined with high-fidelity variants of the Cas9 nuclease responsible for DSB formation.  
Alternatively, the delivery of the Cas9 enzyme can be supplied either as mRNA or in its 
protein form324 to reduce potential off-target activity due to the prolonged Cas9 nuclease 
expression when supplied as an expression vector.  Interestingly, it was reported that HDR 
is favored over NHEJ in transcriptionally active chromatin325, hinting that the combined 
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positive and negative selection approach is viable.  Still, it is unclear whether the recovered 
cell populations from coupled selections would arise from a single cell or many cells that 
survived the selection pressures, warranting additional studies to fully investigate the 
integration efficiencies with this approach. 
In Chapter 4, we established a workflow based on a Design-Build-Test paradigm 
that enabled de novo generation of promoters capable of driving high levels of gene 
expression.  Through a single iteration of our workflow, we achieved our goal of designing 
synthetic promoters that were capable of driving high gene expression and were 
comparable to a strong viral-derived promoter.  However, there are several avenues to 
explore and dissect our synthetic designs.  For one, the workflow essentially represents a 
bottom-up approach to building functional genetic elements, but we can now apply a top-
down approach to remove the transcription factor binding sites systematically to 
understand which of those building blocks were essential.  This would address whether the 
number of putative sites available or the specific combination of sites were necessary for 
our observations.  Furthermore, once the necessary and sufficient building blocks are 
identified, an exhaustive library of sequences containing permutations of those building 
blocks can explore the spacing and arrangement relationship between them in depth. 
In Chapter 5, we explored additional promoter designs that could be viable for 
regulating gene expression in mammalian hosts.  This chapter considered rational designs 
based on known synthetic sequences or mimicking traditional promoter characterization 
by examining a segment of the 5’ UTR of highly expressed genes.  However, superfluous 
sequences are likely included in promoter designs that simply take a segment of DNA 
sequence to confer promoter activity, which was common practice until de novo designs.  
Thus, employing a rational and a library screening approach in conjunction can identify 
novel sequences that would exhibit the desired functional characteristics, as demonstrated 
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previously in our research group in S. cerevisiae248, 254.  Applying this approach to the core 
promoter region is particularly important to building fully synthetic regulatory elements 
for mammalian hosts and replacing all viral-derived sequences.  In Chapters 4 and 5, the 
promoter engineering work primarily focused around designs for the proximal and distal 
enhancer regions.  The multiple core promoter exploration along with the rational core 
promoter work here and previously reported in literature267 suggest that particular element 
is highly tunable despite its essential interactions with basal RNA polymerase II machinery.  
Lastly, the minimal improvements in gene expression may not fully reflect the promoter 
strength if the translational machinery is saturated due to high levels of mRNA.  Therefore, 
it would be an important confirmation to measure transcript levels with qPCR to verify 
whether the promoter strength was impacted by our designs. 
In Chapter 6, we exploited the native structure of mammalian terminators to isolate 
putative endogenous terminators and to guide our synthetic designs.  This work affirmed 
that the terminator can also tune gene expression in a sequence dependent manner, and we 
are able to achieve levels of gene expression using fully endogenous/synthetic elements 
that are comparable to expression driven by viral-derived elements.  While these 
components showed minor context dependency (differences based on preceding coding 
sequence and promoter strength), it is crucial to demonstrate that these designs are 
functional in other mammalian cell types.  Since our terminator designs are derived from 
endogenous and/or consensus sequences, we expect comparable behavior in other 
mammalian cell types based on the highly conserved machinery326. 
Critically, it is implied that the differential expression is likely due to the 
termination efficiency (lack of terminator read-through/stopping transcription) based on 
the comparison of gene expression between any terminator used and our no-terminator 
control.  However, with our diverse set of terminator designs and their distinct permutations 
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of key elements within the terminator, it would be interesting to characterize whether the 
measured gene expression correlates with termination efficiency and/or the mRNA half-
life.  These results would reveal mechanistic insight into terminator function and 
simultaneously offer additional design parameters.  For example, it would be possible to 
design a terminator with some termination inefficiency to enable polycistronic messages 
or that selectively tunes mRNA abundance with a specific half-life. 
In closing, the studies demonstrated in this work provide some of the stepping 
stones necessary to truly push mammalian cell engineering away from being solely 
therapeutic protein factories and towards a new era of applications such as metabolic 
engineering and immunotherapy.  We have yet to fully tap their potential in these 
applications where precise control of gene expression is inherently and critically tied to 
their success.  In doing so, these future directions can uncover a deeper understanding of 
the cellular and molecular biology governing these cells, catalyzing new iterations of 
design approaches and methods to address ongoing medical needs.  
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Chapter 9: Materials and Methods 
9.1. COMMON METHODS USED IN THIS WORK 
9.1.1. Plasmid construction 
Plasmids were generated by standard molecular biology techniques: restriction 
enzyme digestion, agarose gel DNA electrophoresis extraction, ligation, Gibson Assembly.  
Alternatively, plasmids were assembled using the In-Fusion cloning kit (Clontech). 
9.1.2. Growth and media conditions 
A suspension-adapted and serum-free HT1080 cell line, provided by Shire 
Pharmaceuticals and established from ATCC CCL-121, was used for all experiments.  
Cells were grown in CD 50/50 media, passaged every 48–72 h and seeded at 3 x 105 viable 
cells/mL. CD 50/50 contains 50% CD-CHO and 50% CD-293 (Invitrogen) with 4 mM 
glutamine and pH of 7.2. Cell viability, concentration, and size were measured using a 
Beckman Coulter ViCell. Shake flasks were maintained at 37°C, 5% CO2, humidity above 
80% and 125 rpm. Plasmids were propagated in Escherichia coli DH10β or Stellar strains 
using lysogeny broth with ampicillin at 37°C. 
9.1.3. HT1080 transient transfections 
To establish transient expression cultures, three batches of 12 x 106 viable cells 
were re-suspended in RPMI-1640 media (0.75 mL per cuvette) and transfected each with 
50 μg of plasmid DNA (harboring our dual-reporter expression cassette with various 
promoters) using a 4 mm electroporation cuvette and Gene Pulser XCell (BioRad) at 350 
V and 950 μF of capacitance. 
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9.1.4. Quantification of GFP expression 
GFP expression profiles were determined using flow cytometry.  1.0 – 2.0 x106 
cells were pelleted and suspended in sterile 1x DPBS 48-h post-transfection.  These cell 
suspensions were analyzed using the BD LSRII Fortessa (UT Institute of Cellular and 
Molecular Biology Core Facility) with the following parameters: 340V FSC, 176V SSC, 
GFP voltages vary from 180V to 260V to obtain a suitable distribution within the 
quantification window.  25,000-30,000 events were collected from a subpopulation that 
represented live cells (as determined by gating WT cells) and these live cells were divided 
between GFP- or GFP+ by setting a threshold such that 1% of the WT cells are considered 
GFP+ as an approximation of autofluorescence.  All other samples were analyzed using the 
same gate for live cell subpopulation and threshold for GFP+ cells.   
9.1.5. Quantification of SEAP expression 
The supernatant obtained from centrifugation to pellet cells was sampled for 
analysis using the NovaBrightTM Secreted Placental Alkaline Phosphatase (SEAP) Enzyme 
Reporter Gene Chemiluminescent Detection System 2.0 (Invitrogen). 
9.1.6. Genomic DNA extraction  
Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit 
(Promega) from 3.5 x 106 cells per sample.  This gDNA can be used to confirm the number 
of transgene copies or further digested with a restriction enzyme to facilitate qPCR 
analysis. 
9.1.7. Data analysis 
Data analysis for expression data conducted using MS Excel and R: The R Project 
for Statistical Computing versions 3.0.0 to 3.3.0. 
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9.2. CHAPTER 2 SPECIFIC 
The methods corresponding to this chapter can be found in a previously authored 
publication: Cheng, J. K., Lewis, A. M., Kim, D. S., Dyess, T., & Alper, H. S. (2016). 
Identifying and retargeting transcriptional hot spots in the human genome. Biotechnol J, 
11(8), 1100–1109. DOI: 10.1002/biot.201600015.  Copyright © 1999 - 2016 John Wiley 
& Sons, Inc. 
9.2.1. Plasmid Construction 
Several key plasmid designs were used as shown in Figure 2-1.  The pIRES-hrGFP 
plasmid (Figure 2-1A) was constructed through modification of pIRES-hrGFP-1a 
(Stratagene). The Zeocin™ resistance gene was amplified from pSV40-zeo2 (Invitrogen).  
The pHL-GFP plasmid (Figure 2-1B) was provided by Shire Pharmaceuticals.  The 
pAML-Zeo plasmid (Figure 2-1C) was constructed as previously described 25.  pCMV-
hrGFP-IRES-puro (pGP), pCMV-puro-IRES-hrGFP (pPG), pCMV-SEAP-IRES-puro 
(pSP), and pCMV-puro-IRES-SEAP (pPS) plasmids (Figure 2-1D) were derived from 
pAML-Zeo plasmid by replacing the Zeocin™ resistance gene for the puromycin 
resistance gene, and the hrGFP gene for the secreted alkaline phosphatase (SEAP) gene.  
This final set of vectors (Figure 2-1D) was designed for loci retargeting.  The detailed 
construction of these plasmids, including specific primers, is described further in 
Supplementary Material and Methods of the publication175.   
9.2.2. Cell line development 
Plasmid DNA was extracted from 150 mL of E.coli DH10β culture using the 
Qiagen HiSpeed Maxi Prep kit, digested at 37°C, and purified by phenol-chloroform 
extraction. To establish stable, green fluorescent protein (GFP) expressing cells, three 
batches of 12 x 106 viable cells were re-suspended in RPMI-1640 media (0.75 mL per 
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cuvette) and transfected with 50 μg of pIRES-hrGFP DNA using a 4 mm electroporation 
cuvette and Gene Pulser XCell (BioRad) at 350 V and 950 μF of capacitance. Transfection 
efficiencies were typically 80%. Cells were transferred to CD 50/50 media and recovered 
48 hours before selection pressure was applied.  Concentrations of 50, 100 and 250 μg/ml 
of Zeocin™ were used to establish the HT1080 libraries.  Selective pressure was 
maintained until culture viability was above 90%. 
9.2.3. Sterile FACS to isolate high hrGFP expression population 
After stable cell selection was completed (approximately 15-25 days), cells were 
prepared for flow cytometry sorting and analysis.  For each sort, 300,000 cells of the top 
10-15% of the population (based on GFP expression) were isolated using a FACSAria.  
This population was transferred to a six well plate and split every 24-48 hours, expanding 
the population until another sort was feasible.  This process was iterated twice to ensure 
stringent selection and sustained expression. 
9.2.4. Single Cell Cloning 
Single cell clones were established from the Zeocin™-resistant cell culture pools 
using dilution cloning. GFP fluorescence profiles of each clone were examined using flow 
cytometry.  The copy number of GFP integrants was determined for each clone as 
previously described41.  Detailed single cell cloning procedures are described further in 
Supplementary Materials and Methods of the publication175.  
9.2.5. Methods for identifying integration loci 
Low-throughput methodologies for identifying integration loci rely on approaches 
that both isolate and amplify genomic DNA adjacent to the transgene.  We utilized three 
primary approaches to identify the integration sites in our high expression clones: TAIL 
PCR, inverse PCR and plasmid recovery.  TAIL PCR utilizes three interlaced PCR 
 164
reactions to amplify genomic fragments adjacent to the integrated transgene.  Long 
primers, specific to the integrated sequence flanking the gDNA, along with an arbitrary, 
degenerate primer of 12-16 base pairs in length are used in each PCR reaction.  Based on 
previous reports, we adapted a methodology that uses three interlaced PCR reactions to 
enrich the flanking genomic DNA fragment 327-330.  This methodology was used to 
successfully identify the integration loci for clones A, B, C, H, I and J, and further details 
for each clone can be found in Supplementary Material of the publication175.  A second 
approach, inverse PCR, was adapted from previous reports149, 150, 161, 162, 331.  This approach 
was used to successfully identify the integration locus for clone E and further details are 
discussed in Supplementary Material of the publication175.  The third approach, plasmid 
recovery, provided better capture and recovery of genomic fragments, thereby increasing 
our coverage of the human genome.  This approach was used to successfully identify the 
integration loci for clones D, F and G, and further details are discussed in Supplementary 
Material of the publication175. 
9.2.6. RNA extraction, cDNA synthesis, and quantitative PCR 
Whole cell RNA was extracted using the RiboPure kit (Ambion) at 5 x 106 cells per 
sample.  RNA was converted to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems).  Relative mRNA expression for genes of interest 
was measured and compared to a common housekeeping gene, RPS11.  The primer pairs 
for each gene can be found in Supplementary Material, Table S2, (1-56) of the 
publication175 and were designed using PrimerExpress software to ensure consistent primer 
lengths, amplicon lengths, GC content and melting temperatures, and minimal secondary 
structures across all primer pairs.  Roche SYBR Green 2x master mix was used to prepare 
samples in triplicate and a standard deviation of less than 0.5 CT units was imposed to 
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ensure consistent primer efficiency across pairs.  The ViiA™ 7 Real-Time PCR System 
(Applied Biosystems) and software was used to run qPCR and analyze results.  Melt-curves 
were reviewed for all primer pairs to ensure formation of a single product and no random 
binding and amplification occurred.  The comparative CT method was used to normalize 
measurements relative to RPS11, a highly expressed ribosomal gene.  After normalizing to 
RPS11, relative mRNA expression across genes of interest was calculated using the 
comparative CT method.  A log fold change greater than 2 was considered statistically 
significant. 
9.2.7. Genomic DNA extraction and copy number quantification 
Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit 
(Promega) from 3.5 x 106 cells per sample and used to confirm the number of transgene 
copies.  Roche SYBR Green 2x master mix was used to prepare samples in triplicate.  The 
ViiA™ 7 Real-Time PCR System (Applied Biosystems) and software was used to run RT-
PCR and analyze results.  Copy number was measured based on a standard curve of each 
primer pair for a particular gene (Supplementary Material, Table S2, 78-83 of the 
publication175) compared to a common housekeeping gene, RPPH1. 
9.2.8. Site-Specific Retargeting 
The hCas9 plasmid, previously constructed by the Church group 144, was obtained 
from Addgene (41815). Two gRNA constructs were designed following recommendations 
from the Church group 144 and used to generate stable cell lines expressing hrGFP and 
SEAP (Figure 1d).  The construction of these gRNA sequences, Grik1A and Grik1B, are 
described in detail in Supplementary Material and Methods of the publication175.   
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9.3. CHAPTER 3 SPECIFIC 
9.3.1. MIC75 determination 
The maximum inhibitory concentrations for a particular selective agent was 
determined by subjecting healthy parental cells to a range of concentrations.  Typically, 3 
cultures were tested at each concentration and compared to the parental cells maintained 
under standard conditions.  The impact of the selection pressure is monitored 6-12 days 
until the cultures reached a vital minimum viability threshold. 
9.3.2. Sequence recovery by TOPO TA Cloning and Sanger sequencing 
Genomic DNA from Cas9 edited cell populations were extracted using the standard 
method.  The gDNA from various cell populations were amplified with region-specific 
primers to recover the target locus and subcloned into the pCR™4-TOPO® TA vector 
following manufacturer’s protocol.  The resulting products were transformed into E. coli 
TOP10 cells and plated on LB + 50 µg/mL Kanamycin + 20 µg/mL X-Gal plates.  White 
colonies were selected and grown in liquid culture containing 50 µg/mL Kanamycin or 100 
µg/mL ampicillin overnight.  The plasmids from the confluent cultures were isolated by 
miniprep and submitted for Sanger sequencing using the T3 primer. 
9.3.3. Quantitative PCR with custom designed probes 
Using the same gDNA extracted for sequence recovery by TOPO TA Cloning and 
Sanger sequencing (described above), the edited regions were analyzed using quantitative 
PCR with custom design probes for the target loci.  Prior to qPCR, 1 µg of gDNA was 
digested with NruI in 50 µL reaction (per gDNA) to reduce structure.  The digested gDNA 
were analyzed with the iTaq™ Universal Probes Supermix (Bio-Rad) based on 
manufacturer’s thermal cycling protocol.  600nM of each primer and 300nM of each probe 
was used per reaction. 
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9.4. CHAPTER 4 SPECIFIC 
The methods pertaining to this chapter can be found in a previously authored 
publication: Cheng, J., & Alper, H. S. (2016). Transcriptomics-guided design of synthetic 
promoters for a mammalian system. ACS Synth Biol. Article ASAP. Publication Date 
(Web): June 7, 2016. DOI: 10.1021/acssynbio.6b00075. 
9.4.1 Processing of gene expression data 
Microarray data from the Illumina platform representing the growth of HT1080 WT 
cells under representative (industrial) bioreactor conditions was transformed with a 
logarithmic function in MS Excel and modeled using a 3-component Gaussian Mixture 
Model (GMM) using MATLAB software (Mathworks, R2014a).  The GMM was 
generated by an expectation-maximization algorithm332 to identify parameters (μ, σ, π) that 
described the 3 Gaussian components comprising the model.  The parameters were 
randomly seeded (within the bounds of the values in the data set) 10 times independently, 
and each “run” of the algorithm had at least 50 iterations to identify converged parameter 
values for the entire log-transformed data set at each time point (t1-t4).  Using the final 
parameters from each component, false-positive and false-negative estimates were 
calculated at a particular threshold expression value (th) using equations found in the 
Supporting Information of the publication240.  In addition, the probability of that a 
particular expression value (e.g. median value of data set) could belong to a specific 
expression group (i.e. component of GMM representing high, moderate, or low expression 
group) can be determined using these finalized parameters. 
9.4.2. Annotation and analysis of candidate promoter sequences 
The JASPAR database233 containing TFBS consensus sequences was adapted (full 
list of sequences used found in Supporting Information Table S2 of the publication240) 
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as a feature list in ApE, A plasmid Editor, v2.0.47 software.  This procedure enables rapid 
annotation of any sequence length in both sense and anti-sense TFBS orientations.  The list 
of putative sites in a particular sequence of interest is stored as a CSV file using MS Excel 
and then parsed using R: The R Project for Statistical Computing to tabulate all putative 
sites across promoter regions for comparison.  The total putative sites are subsequently 
analyzed in MS Excel to determine TFBS frequencies. 
Similarly, 2000-bp chromosome regions were annotated using the same process as 
candidate promoter sequences.  The chromosome regions were selected at random (MS 
Excel, random number generator) and the number of chromosome regions selected 
reflected the relative size of the chromosomes: 10 regions were selected as a minimum 
(corresponding to the size of chromosome 21) and the number of regions were increased 
based on the chromosome’s size relative to chromosome 21 (up to 53 regions for 
chromosome 1, Supporting Information Table S5 of the publication240). 
9.4.3. Plasmid construction 
Plasmids were constructed by a combination of standard molecular biology 
techniques (restriction enzyme cloning, Gibson assembly, In-Fusion HD cloning kit).  The 
essential elements required for plasmid propagation in E.coli (origin, beta-lactamase) from 
pUC19 were sub-cloned with the conventional SV40 late terminator and multiple cloning 
sites (EcoRI, NotI, NheI, PmeI, XbaI, and NsiI) using Gibson assembly to generate the base 
vector (Supporting Information Figure S2a of the publication240).  Subsequently, the 
SEAP, IRES, and hrGFP sequences were sub-cloned from other plasmids into these 
cloning sites (Supporting Information Figure S2b of the publication240).  The region 5’ 
to the start codon of the human CMV immediate-early gene (M60321.1, nucleotides 1-
2105) was synthesized and supplied in a pUC57 vector (GenScript); this entire length is 
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considered the “reference” promoter in this work.  Promoter variants were synthesized as 
dsDNA gBlocks (IDT).  The reference promoter and its variants were cloned between the 
NotI and NheI sites immediately 5’ of the SEAP CDS.  To evaluate the synthetic proximal 
promoter/enhancer region, sequences were synthesized as Ultramer oligonucleotides and 
annealed (IDT) and cloned between the NotI and EcoRI (5’ of NotI) sites.  For direct 
comparison to the reference promoter and its variants, the hCMV IE core promoter region 
(joining exon 1 and 2: 1110-1264…2089-2105, 172-bp total) was retained from the 
reference promoter and cloned between the NotI and NheI sites.  Alternatively, the minimal 
(Supporting Information Figure S2c of the publication240) and full-length variants of the 
promoter derived from the EEF1A1 gene (EF1a) were sub-cloned from genomic DNA 
extracted from HT1080 WT cells using primers found in (Supporting Information Table 
S6 of the publication240).  Plasmid DNA was extracted from 150 mL of DH10β culture 
using the Qiagen HiSpeed Maxi Prep kit or the Zymo Research ZymoPURE Maxi Prep kit, 
and further purified by ethanol precipitation. 
Synthetic promoter elements used in variants synth.v1, v2, and v3 (Supporting 
Information Figures S2d-S2f of the publication240) were cloned between the EcoRI and 
NotI sites 5’ of the core promoter (between the NotI and NheI sites) using primers found in 
Supporting Information Table S6 of the publication240.  hCMV IE promoter variants 
were generated using the “synthprom” algorithm248 with 45% GC content to approximate 
the overall human genome and reference promoter sequence and dsDNA fragments were 
constructed as gBlocks gene fragments (IDT).  These fragments were amplified using 
primers found in Supporting Information Table S6 of the publication240 and cloned 
between the NotI and NheI sites in the dual-reporter expression vector (Supporting 
Information Figure S2b of the publication240).  Three variants were generated to vary 
TFBS arrangement found in the hCMV IE promoter: native, sequential, and random 
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variants.  The native variant (Supporting Information Figure S2g of the publication240) 
contained the same TFBS arrangement as the reference sequence.  The sequential variant 
(Supporting Information Figure S2h of the publication240) contained TFBSs arranged in 
a grouped manner (e.g. multiple instances of a TFBS were placed adjacent to each other or 
sequentially from 5’ to 3’).  Lastly, the random variant (Supporting Information Figure 
S2i of the publication240) contained TFBSs arranged randomly. 
9.4.4. Transfections 
Transient transfections for HT1080 were conducted based on protocol described 
above.  Transient transfections for HEK293 were conducted by nucleofection using the 
Nucleofector™2b device (Lonza Biologics) with the Nucleofector® Kit V (Lonza 
Biologics). 
9.5. CHAPTER 5 SPECIFIC 
None. 
9.6. CHAPTER 6 SPECIFIC 
None. 
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Appendix A: Primers and gBlocks® Gene Fragments 
A.1. COMMON PRIMERS USED IN THIS WORK 
Table A1: Primers used for Sanger sequencing to confirm plasmid construction 
Primer notes sequence 
S1 pCMV variant 5' ⇒ 3' ATCCGCTAGCGATTACGCCAAGCTC 
S2 region between HgHB/IRES 3' ⇒ 5' AGTCGTCGAGGAATTGCTATTATTT 
S3 HgHB 5' ⇒ 3' CAGAAGCGCGGCCGTCTGGACCGAT 
S4 SV40 late poly(A) 5' ⇒ 3' GCTTTATTTGTGAAATTTGTGATGCTATTGC 
S5 IRES 5' ⇒ 3' ACATGCTTTACATGTGTTTAGTCGA 
S6 SV40 late poly(A) 5' ⇒ 3' AAAAAAATGCTTTATTTGTGAAATTTGTGATGC 
S7 IRES 3' ⇒ 5' CAATATGGTGGAAAATAACATATAGACAAACGCAC 
S8 pSEAP2-basic plasmid 5' ⇒ 3' GGTACCGAGCTCTTACGCGTGCTAG 
S9 SV40 late poly(A) 3' ⇒ 5' GCATTTTTTTCACTGCATTCTAGTTGTGGT 
S10 F1 origin 3' ⇒ 5' GTTCTTTAATAGTGGACTCTTGTTCCAAACTGG 
S11 SEAP 5' ⇒ 3' AGGTGGAGGCCGAAAGTACATGTTT 
S12 ColE1 origin TTCGCCACCTCTGACTTGAGC 
S13 core pCMV 5' ⇒ 3' AGGTCTATATAAGCAGAGCTCGTTTAGTGA 
S14 core pSV40 5' ⇒ 3' CCTCTGAGCTATTCCAGAAGTAGTGAGG 
S15 hrGFP 5' ⇒ 3' GCACCGCCTGGAGAAGACCT 
S16 mStraw 5' ⇒ 3' CATCGTCGGCATCAAGTTGGACATC 
S17 hrGFP 3' ⇒ 5' CTCCAGGTTCACCTTGAAGCTCATGAT 
S17b hrGFP 3' ⇒ 5' GTTCACCTTGAAGCTCAT 
S18 pCMV 5' ⇒ 3' CCCATTGACGCAAATGGGCG 
S19 AmpR 5' ⇒ 3' CTCTCAAGGATCTTACCGCTGTTGA 
S20 TB 3' ⇒ 5' TGTTTTGATGGAGAGCGTATGTTAG 
S21 ColE1 origin 5' ⇒ 3' AGGATTAGCAGAGCGAGGTATGTAG 
S22 AmpR 3' ⇒ 5' GCCCTCCCGTATCGTAGTTATC  
S23 AmpR 5' ⇒ 3' GCTCGTCGTTTGGTATGGCTTC  
S24 SEAP 3' ⇒ 5' TTCTCCTCCTCAACTGGGATGATG 
S25 CMV enhancer 3' ⇒ 5' CGTAAGTTATGTAACGCGGAACTCCA 
S26 CMViA 3' ⇒ 5' ATGGATTAGTAATGGAAAGTATCGTCACC  
S27 ref pCMV 5' ⇒ 3' GCTATTGGCCATTGCATACGTT 
S28 CMV enhancer 5' ⇒ 3' AATCAACGGGACTTTCCAA 
S29 CMV iA 5' ⇒ 3' CAGACATAATAGCTGACAGAC 
S30 TB 5' ⇒ 3' ACTAACATACGCTCTCCATCAAA 
S31 pCLUAP1 5' ⇒ 3' CTTCATTTGCATATTAGCCATCC 
S32 pGAPDH.2000 5' ⇒ 3' GAAAGGCAATCCCAGAAAGG 
 172
Table A1, continued: 
Primer notes sequence 
S33 pPGK1 5' ⇒ 3' GCTTCTGGGAATAACATCACC 
S34 Grik1B 3' homology 5' ⇒ 3' TTACCTAGGACTTCCACCTAAT 
S35 fcy1.fur1 5' ⇒ 3' CTTCAAAGTGGGACCAGAAG 
S36 fcy1.fur1 5' ⇒ 3' CTACACCATCATCAGGAACAAG 
S37 HBB terminator 5' ⇒ 3' GCATCTGGATTCTGCCTAATAA 
S38 pVIM 5' ⇒ 3' GGGACTACAGAACACCTACA 
S39 pEEF1A1 5' ⇒ 3' CGGAGCTGAGAGTAATTCATAC 
S40 pTPT 5' ⇒ 3' CCAAGGGTTGCATTCTTACTC 
S41 pTUBA1B 5' ⇒ 3' GGGTGGTTCCCTAACATTC 
S43 pUBC 5' ⇒ 3' CTGCCACGTCAGACGAA 
S44 pGAPDH.2500 5' ⇒ 3' CTACCAGCATTTGTGGGAA 
S45 pGAPDH.3000 5' ⇒ 3' ATTAGCCGGGCGTATTG 
S46 pF2R.2000 5' ⇒ 3' GCCTCTGATCGTACTTTCTC 
S47 GAPDH exon 1 3' ⇒ 5' CTGCGGGCTCAATTTATAG 
S48 Grik1B 3' homology 3' ⇒ 5' ggatgcgtgtgacaaagatag 
S49 hCas9 5' ⇒ 3' GCCTGTCTGAGTTGGATAAAG 
S50 hCas9 5' ⇒ 3' GACACCACCATAGACAGAAAG 
S51 hCas9 5' ⇒ 3' GAGACAAGCAGAGTGGAAAG 
S52 hCas9 5' ⇒ 3' TCGAGGAAGTCGTGGATAAG 
S53 hCas9 5' ⇒ 3' ACGGCCTGTTTGGTAATC 
S54 hCas9 5' ⇒ 3' GATTCTCCTACAGTCGCTTAC 
S55 hCas9 5' ⇒ 3' GCAGATATACCCGCAGAAAG 
S56 hCas9 5' ⇒ 3' CAACTGCCTGAGAAGTACAA 
S57 hCas9 3' ⇒ 5' CCTTGTACTCGTCCGTAATG 
S58 GAPDH exon 1 5' ⇒ 3' CTATAAATTGAGCCCGCAG 
S58b GAPDH exon 1 5' ⇒ 3' CCCGGTTTCTATAAATTGAGC 
S59 pACTB.2387 5' ⇒ 3' CGTGACTGTTACCCTCAAA 
S60 pACTB.2387 5' ⇒ 3' CGTTCCGAAAGTTGCCTT 
S61 hSpCas9 (PX165) 3' ⇒ 5' CCCTTAAACCCTTACCTCTTG 
S62 hSpCas9 (PX165) 3' ⇒ 5' GCTGTCCACCAGTTTCTT 
S63 hSpCas9 (PX165) 5' ⇒ 3' GAGCAAGAGGTAAGGGTTTAAG 
S64 hSpCas9 (PX165) 5' ⇒ 3' CATCTACCACCTGAGAAAGAAA 
S65 hSpCas9 (PX165) 5' ⇒ 3' CTGCCTGAGAAGTACAAAGAG 
S66 hSpCas9 (PX165) 5' ⇒ 3' CATACCACGATCTGCTGAAA 
S67 hSpCas9 (PX165) 5' ⇒ 3' GATCGAAGAGGGCATCAAAG 
S68 hSpCas9 (PX165) 5' ⇒ 3' AAGAGCGAGCAGGAAATC 
S69 hSpCas9 (PX165) 5' ⇒ 3' GCCACTATGAGAAGCTGAAG 
S70 hSpCas9 (PX165) 5' ⇒ 3' CATTGTCTGAGTAGGTGTCATT 
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Table A1, continued: 
Primer notes sequence 
S71 hSpCas9 (PX165) CAG promoter 3' 
⇒ 5' CTCACCTCGACCATGGTAATA 
S72 hSpCas9 (PX165) CAG promoter 5' 
⇒ 3' CCTTATGGGACTTTCCTACTTG 
S73 IRES-hrGFP/mStraw junction 3' ⇒ 5' CTTGCTCACCATCATTATCATCG 
S74 EMCV IRES (middle) 5' ⇒ 3' CCACGTTGTGAGTTGGATAG 
Table A2: Primers for constructing base expression vector/plasmid 
Primer notes sequence 
g187 bac-transcription blocker, 5' ⇒ 3' ACATTTCCCCGAAAAGTGCCACCTGACGTCGATATCAATAAA
g188 transcription blocker-base+pA, 3' ⇒ 5' 
TTGCGGCCGCTTTTTTCCTTCGGAATTCCGCCTTAATT
AAG 
g189 transcription blocker-base+pA, 5' ⇒ 3' 
ATTTCTCTCCTTAATTAAGGCGGAATTCCGAAGGAAAA
AAG 
g190 base+pA-bac, 3' ⇒ 5' TGGCCTTTTGCTGGCCTTTTGCTCACATGTTACCACATTTGTAGAGG
g191 base+pA-bac, 5' ⇒ 3' AGTAAAACCTCTACAAATGTGGTAACATGTGAGCAAAAGGCCAGCAA
g192 bac-transcription blocker, 3' ⇒ 5' AAATAAAGATATTTTATTGATATCGACGTCAGGTGGCACTTTTCG
207b replace EcoRV with AscI, 5' ⇒ 3' TTGGCGCGCCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTG 
208b replace EcoRV with AscI, 3' ⇒ 5' TTGGCGCGCCAAAGGTGGCACTTTTCGGGG 
A.2. CHAPTER 2 SPECIFIC 
Relevant primer sequences can be found in the Supplementary Information of our 
publication: Cheng, J. K., Lewis, A. M., Kim, D. S., Dyess, T., & Alper, H. S. (2016). 
Identifying and retargeting transcriptional hot spots in the human genome. Biotechnol J, 
11(8), 1100–1109. DOI: 10.1002/biot.201600015.  Copyright © 1999 - 2016 John Wiley 
& Sons, Inc. 
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A.3. CHAPTER 3 SPECIFIC 
Table A3: PCR primers for creating expression vectors with homology regions 
Primer notes sequence 
293 bac - TB...SV40pA (AscI) for adding site homology regions, 5' ⇒ 3' GAGCAAAAGGCCAGCAAAAGG 
294 bac - TB...SV40pA (AscI) for adding site homology regions, 3' ⇒ 5' TACCACATTTGTAGAGGTTTTACTTGCTTT 
295 (GRIK1B) 5' homology to TB...SV40pA (AscI) vector, 5' ⇒ 3' CAAATAGGGGTTCCGCGCA 
296 (GRIK1B) 5' homology to TB...SV40pA (AscI) vector, 3' ⇒ 5' CACACAAAAAACCAACACACAGATGTA 
297 (GRIK1B) 3' homology to TB...SV40pA (AscI) vector, 5' ⇒ 3' GGAGGTGTGGGAGGTTTTTTAAAGC 
298 (GRIK1B) 3' homology to TB...SV40pA (AscI) vector, 3' ⇒ 5' CAGCAACGCGGCCTTTTTACG 
538 TB-rpCMV.660...SV40pA for adding site homology regions, 5' ⇒ 3' AATAAAATATCTTTATTTTCATTACATCTGTGTGTTGG 
539 bac - {fcy:fur} - (AscI) for adding site homology regions, 3' ⇒ 5' GGCGCGCCAAAGGTGG 
299 fcy1:fur1 gBlock A 5' ⇒ 3' CTAAAGTATATATGAGTAAACTTGGTCTGACAGG 
300 fcy1:fur1 gBlock A 3' ⇒ 5' TCCCTCAAAGTTCTCATTGGTGTC 
301 fcy1:fur1 gBlock B 5' ⇒ 3' CAGAAGCAGATTGTGGAGACTGA 
302 fcy1:fur1 gBlock B 3' ⇒ 5' ACTGGGGCCAGATGGTAAG 
g380 GRIK1B 3' homology - fcy1:fur1 A 5' ⇒ 3' 
gtcaggcatatggtatagaaaatttttccaggatGAGTAATTCATACAAAAG
GACTCGCC 
g381 GRIK1B 5' homology - fcy1:fur1 B 3' ⇒ 5' 
tttcagaaccatggcctgtggtcacttaatGGCGCGCCTGCCAAGTGCATT
AGCTGTTTG 
Table A4: gBlocks® Gene Fragments (IDT) for creating expression vectors with 
homology regions 
fragment sequence 
AAVS1.T2 gRNA 
TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGT
ACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTG
CATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTA
AACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTT
GGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTA
CCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGG
ACGAAACACCGGGGCCACTAGGGACAGGATGTTTTAGAGCTAGAAATAGC
AAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTC
GGTGCTTTTTTTCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTA 
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Table A4, continued: 
fragment sequence 
GRIK1B 5' homology 
CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTTTGGCGCGC
Cattaagtgaccacaggccatggttctgaaaacaaatttaaaacaaatcaaaaggaaattatgaatttgaaattctgcagtgag
gcatgctatgtagttaatactaatgtgtaccactaggcctggaccagtataattccaaatgtatgccttgtctcttcctttaggatca
tgatttttccccgtggactattcgaaaaacatctaatacactccaaattcagctctacattttgttcactaatttgttcagccttgcaat
ccctttcatgcattacaaaatcgctagaccaccacttagactccttctaaccatctgtccatacaaaccccttgaaggcaagtcac
ccctcttttttgtgtctcccacaggacctaacgacacaatatcttgacattgtagttactatgcaacaagtgtgtgtcacattcgtcg
ctacttggtggggtaaatacttgggatgagtgaacctttctttacagttcatctagttgttcagtaatatggaaatgaatgaaaact
cagaagaattcagtagacatagagctgaggagtacaattccagctgaccaatttgcctataaataagaagtctggtaaatattaa
cgtctcaaggctctttgcactttgcccaccaaagctgtaagtttatgactatggcctttactcttttggtttgaagcttttgtgattaat
tgttgggttttctgcattgctcagcaggttttggttttgctggtgtcctgtgtgtttctctgatatttacagactgtttctgttaactacca
caggtttacacAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGT
GTG 
GRIK1B 3' homology 
GGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAC
TCGAGccatgcaaccctgactcagacgtggtggaaaacaattttactttactaaatagtttctggtttggagttggagctctc
atgcagcaaggtacaccggttgcctatctttgtcacacgcatcccacagtgtgctgacaggctttcatgctggtaaactccacc
atgaagctagagggtaggatgaaacaccatctcaggaacttaagaaaatagcaacggactttctagccggttttgaagatgaa
gcaaaaccaatgacctatatggaactcccttgctatatatctaaaatagcacttctatcaagcaataaatacaaattttcctgtggg
tagcaaaagataaggtaccttagaaatcgtttacaaatttgcatagatggagatgttggtcttctccttctcagccataactccacg
agtcagcagtttaaaggagcgggatctaaatcctttggagattaaattcactgagattcttccaattgccaaccttacctaggact
tccacctaattactactctggcaaaccctactgagattcatttcagcctcccagtaacttttcacaatctccctcaattggtaaccat
agcaacaataaactgtaggagttggggaaataaaatttggccatagaaatgtaatatattttatacatttcctatgaattcggggat
tctgcttttgtagtgggggaagggggagctattttaacctttggaagaactccatttcttttgtgattttttttttcagcttcaatgtcag
gcatatggtatagaaaatttttccaggatGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTA
AAAAGGCCGCGTTGCTG 
AAVS1.T2 5' homology 
CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTTTGGCGCGC
Cctgctttctctgacctgcattctctcccctgggcctgtgccgctttctgtctgcagcttgtggcctgggtcacctctacggctgg
cccagatccttccctgccgcctccttcaggttccgtcttcctccactccctcttccccttgctctctgctgtgttgctgcccaaggat
gctctttccggagcacttccttctcggcgctgcaccacgtgatgtcctctgagcggatcctccccgtgtctgggtcctctccgg
gcatctctcctccctcacccaaccccatgccgtcttcactcgctgggttcccttttccttctccttctggggcctgtgccatctctcg
tttcttaggatggccttctccgacggatgtctcccttgcgtcccgcctccccttcttgtaggcctgcatcatcaccgtttttctggac
aaccccaaagtaccccgtctccctggctttagccacctctccatcctcttgctttctttgcctggacaccccgttctcctgtggatt
cgggtcacctctcactcctttcatttgggcagctcccctaccccccttacctctctagtctgtgctagctcttccagccccctgtca
tggcatcttccaggggtccgagagctcagctagtcttcttcctccaacccgggcccctatgtccacttcaggacagcatgtttgc
tgcctccagggatcctgtgtccccgagctgggaccaccttatattcccagggccggttaatgtggctctggttctgggtactttt
atctgtcccctccaccccacagtAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGG
TTTTTTGTGTG 
AAVS1.T2 3' homology 
GGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAC
TCGAGtgacagaaaagccccatccttaggcctcctccttcctagtctcctgatattgggtctaacccccacctcctgttagg
cagattccttatctggtgacacacccccatttcctggagccatctctctccttgccagaacctctaaggtttgcttacgatggagc
cagagaggatcctgggagggagagcttggcagggggtgggagggaagggggggatgcgtgacctgcccggttctcagt
ggccaccctgcgctaccctctcccagaacctgagctgctctgacgcggccgtctggtgcgtttcactgatcctggtgctgcag
cttccttacacttcccaagaggagaagcagtttggaaaaacaaaatcagaataagttggtcctgagttctaactttggctcttcac
ctttctagtccccaatttatattgttcctccgtgcgtcagttttacctgtgagataaggccagtagccagccccgtcctggcaggg
ctgtggtgaggaggggggtgtccgtgtggaaaactccctttgtgagaatggtgcgtcctaggtgttcaccaggtcgtggccg
cctctactccctttctctttctccatccttctttccttaaagagtccccagtgctatctgggacatattcctccgcccagagcagggt
cccgcttccctaaggccctgctctgggcttctgggtttgagtccttggcaagcccaggagaggcgctcaggcttccctgtccc
ccttcctcgtccaccatctcatgcccctggctctcctgccccttccctacaGAGCAAAAGGCCAGCAAAAG
GCCAGGAACCGTAAAAAGGCCGCGTTGCTG 
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Table A4, continued: 
fragment sequence 
Cg.Grik1.A 5' homology 
CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTTTGGCGCGC
Cacgggtttaaattccattccatttaaacttttgacttgtgaatttatgactaagaaagaaaagatgggcatgtctatctatggaaat
gcatttgttaaaacaagtctgagttcttgtgaaggtccctgttaactcgacaaggtttagagtcatctaggagacacatctcttgac
atgtctgtgaagatgtttcctgacaggcttggatgaggagggaaggccctgaaggtgagatgcatcttcctataggctggggc
tgtagacttaataaaaaggaaaaagcaatacaaaagtggacaaagttagtagggcacagagttcagtgttctttgtttccttact
gcagatacactgtgactgttgccccaagttcctgtccccaagctccccacacctgatggaatatactcttaactatgccactgca
aacccgttagcccttaaattgcttctaatcagttatttgattacatcaatgagtaggtaactaatataggctccttattcttcactctttt
caggaaaatggtgtgtccattctttggaagaagtgtattcatggcaaagaagctccatttagaccctatttctgtcttcttttgagaa
ctggctagaaactctattgctgttgttttctattcctgtgtgtttcatcctaccatctaccttcatggtggagttcaccagcacgaacg
cttatcagcagactgtgggatgcaagtgacaaaatgggcaaccggtgtaccttgctgcatgagagctccaactccaaaccag
aaactatttagcaaagtgaaattAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGT
TTTTTGTGTGAATCGATAGTACTAACATACGCTCTCCATC 
Cg.Grik1.A 3' homology 
GGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAC
TCGAGgtgtaaacctgtgataattgacagaaacagtttgtaaacatcagatacacagatgaaccagaggaaaagctgctg
agcaatgcagaaaacccaacaactgagcagaagcaattgcttctggattgggaaagtcactgggcaaatactcactagcttct
tacttcagagtcaaacccattagtggctaggatggcactcctcagacctctatccactgaattctgagtttccaatcattcacatttt
actgagcaactagacaactataaagaaaagttcctgcatctcaagttttgactctagcaaggtacaagagaggcatggaatga
atgattacatggttgagcttttatgttgctagttgctgtgagggtcaggtgctctccagagacattatggttccatgaacagacact
atacagagtctagcatttcacaaataatgtagaataaagaaaaaaaatgaacaaaaaagaagggatggatttgagagtatatc
gcttatttcaaagatactatatagaatccttcaatgaaaaggcaaattttaaatttaggagtatcatggcccaggtataggtatata
ctatatgtactaatatagtataatggcattaacttcaaggctcacagtgggaaattagaagctcatgcttcccttttgatatattatta
attggatggttttctgaattatgccctgaagtcatataatcagcaactctggttaggtgtgcaaagtgttttctgtggcaccattatt
gctctacctccaagaagccatggctgtaagtttctggGAGCAAAAGGCCAGCAAAAGGCCAGGAA
CCGTAAAAAGGCCGCGTTGCTG 
fcy1:fur1 A 
GATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTT
TAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGGAGTAATTC
ATACAAAAGGACTCGCCCCTGCCTTGGGGAATCCCAGGGACCGTCGTTAAA
CTCCCACTAACGTAGAACCCAGAGATCGCTGCGTTCCCGCCCCCTCACCCG
CCCGCTCTCGTCATCACTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTG
CCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG
GGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAA
CTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGG
AGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTATGGTCAC
AGGAGGCATGGCTTCAAAGTGGGACCAGAAGGGCATGGACATTGCCTATG
AGGAGGCTGCTCTGGGCTACAAGGAGGGAGGGGTCCCAATTGGTGGCTGC
CTCATCAACAACAAGGATGGCAGTGTCCTGGGCAGGGGCCACAACATGAG
GTTCCAGAAGGGCAGTGCCACCCTGCATGGGGAGATCAGCACCCTGGAGA
ACTGTGGCAGGCTGGAGGGCAAGGTCTACAAGGACACCACTCTGTACACCA
CCCTCAGCCCTTGTGACATGTGCACAGGGGCCATCATCATGTATGGCATTCC
CAGGTGTGTGGTGGGAGAGAATGTCAACTTCAAGTCAAAAGGAGAGAAGT
ACCTCCAGACCAGGGGCCATGAGGTGGTTGTGGTGGATGATGAGAGGTGC
AAGAAGATTATGAAGCAGTTCATTGATGAGAGACCCCAGGACTGGTTTGAG
GACATTGGGGAGGCCTCTGAGCCCTTCAAGAATGTGTACCTCCTCCCCCAG
ACCAACCAACTCCTGGGACTCTACACCATCATCAGGAACAAGAACACCACC
AGGCCAGACTTCATCTTCTACAGTGACAGGATCATCAGGCTCCTGGTGGAG
GAGGGCCTCAACCACCTCCCTGTGCAGAAGCAGATTGTGGAGACTGACACC
AATGAGAACTTTGAGGGA 
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Table A4, continued: 
fragment sequence 
fcy1:fur1 B 
CAGAAGCAGATTGTGGAGACTGACACCAATGAGAACTTTGAGGGAGTGTCT
TTCATGGGCAAGATTTGTGGGGTGTCCATTGTGAGGGCTGGGGAGAGCATG
GAGCAGGGCCTGAGGGACTGTTGCAGGAGTGTGAGGATTGGCAAGATCCT
GATCCAGAGGGATGAGGAGACTGCCCTGCCCAAGCTGTTCTATGAGAAGCT
CCCTGAAGACATCTCTGAGAGGTATGTCTTCCTCCTGGACCCCATGCTGGCA
ACTGGAGGCTCTGCAATCATGGCCACTGAGGTGCTCATCAAGAGGGGAGTC
AAGCCTGAGAGGATCTACTTCCTCAACCTCATCTGCTCAAAGGAGGGCATT
GAGAAGTACCATGCTGCCTTCCCTGAAGTGAGGATTGTCACTGGGGCTCTG
GACAGGGGCCTGGATGAGAACAAGTACCTGGTCCCTGGCCTGGGAGACTTT
GGGGACAGATACTACTGTGTCTAAGCTCGCTTTCTTGCTGTCCAATTTCTAT
TAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGA
AGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGC
AATGATGTATTTAAATTATTTCTGAATATTTTACTAAAAAGGGAATGTGGG
AGGTCAGTGCATTTAAAACATAAAGAAATGAAGAGCTAGTTCAAACCTTGG
GAAAATACACTATATCTTAAACTCCATGAAAGAAGGTGAGGCTGCAAACA
GCTAATGCACTTGGCATTACCAATGCTTAATCAGTGAGGCACCTATCTCAG
CGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGAT
AACTACGATACGGGAGGGCTTACCATCTGGCCCCAGT 
Table A5: PCR primers for amplifying target regions 
Primer notes sequence 
Grik1-
gDNA-F inside GRIK1 3' homology, 3' ⇒ 5' 
GAAATGGAGTTCTTCCAAAGGTTAAAATAGCTCCCCCT
TC 
Grik1-
gDNA-R inside GRIK1 5' homology, 5' ⇒ 3' 
GGTTTGAAGCTTTTGTGATTAATTGTTGGGTTTTCTGCA
T 
593 AAVS1 confirmation_F144 TATATTCCCAGGGCCGGTTA 
594 AAVS1 confirmation_R144 ACAGGAGGTGGGGGTTAGAC 
527 HPRT1 confirmation_F181 GATGCTCACCTCTCCCACAC 
528 HPRT1 confirmation_R1181 ACATCCATGGGACTTCTGCC 
528b HPRT1 confirmation_R2 CCGCAACCAGCCTCAATATG 
D.641 Cg.Grik1_F confirmation (edited region), 5' ⇒ 3' AGAATTCAGTGGATAGAGGTCTGAGGAGTG 
D.642 Cg.Grik1_R confirmation (edited region), 3' ⇒ 5' CAGGAAAATGGTGTGTCCATTCTTTGGAAG 
D.643 Cg.Hprt1.1_F confirmation (edited region), 5' ⇒ 3' GCCTTCAATGCCCGGCTTTATATGTTTTTC 
D.644 Cg.Hprt1.1_R confirmation (edited region), 3' ⇒ 5' CTCACAAGGTAAGCGACAATCTATCGAAGG 
Table A6: PCR primers for preparing gRNA expression vectors with Gibson Assembly 
Primer notes sequence 
if426 (GRIK1B) gRNA into hCas9 MfeI site 5' ⇒ 3' 
GCTTGACCGACAATTTGTACAAAAAAGCAGGCTTTAAA
G 
if427 (GRIK1B) gRNA into hCas9 MfeI site 3' ⇒ 5' ATTCTTCATGCAATTTAATGCCAACTTTGTACAAGAAAG
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Table A6, continued: 
Primer notes sequence 
if552 (AAVS1.T2) gRNA into hSpCas9 (FZ lab) NotI site, 5' ⇒ 3' GGGGTTCCTGCGGCCTGTACAAAAAAGCAGGCTTTA 
if553 (AAVS1.T2) gRNA into hSpCas9 (FZ lab) NotI site, 3' ⇒ 5' TGCTGGGGAGCGGCCTAATGCCAACTTTGTACAAGA 
if558 PX165 - EcoRI - hSpCas9(GC), 5' ⇒ 3' 
TCAGCGAGCTCTAGGAATTCTCACACCTTCCTCTTCTTC
TTGGGG 
if559 PX165 - AgeI - hSpCas9(GC), 3' ⇒ 5' TTTTTTCAGGTTGGACCGGTATGGGCGGTAGGCGTGTAC
gR.586 GRIK1A gRNA TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTATTTTAGATATATAGCA 
gR.587 GRIK1A gRNA GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGCTATATATCTAAAATAGC 
gR.674 GRIK1C gRNA TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCAGGTTTACACCCTACGAG 
gR.675 GRIK1C gRNA GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCTCGTAGGGTGTAAACCTGC 
gR.595 AAVS1.T1 gRNA TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGTCCCCTCCACCCCACAGT 
gR.596 AAVS1.T1 gRNA GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACACTGTGGGGTGGAGGGGACC 
g525 HPRT1 gRNA_F TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAAGTAATTCACTTACAGTC 
g526 HPRT1 gRNA_R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGACTGTAAGTGAATTACTTC 
gR.Cg54
0 CHO Grik1 gRNA_F1 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC
CGTTTTCCACCACGTCTGAGT 
gR.Cg54
1 CHO Grik1 gRNA_R1 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAA
CACTCAGACGTGGTGGAAAAC 
gR.Cg54
8 CHO Grik1 gRNA_F2 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC
CGTGGGGATTGTACCACTCGT 
gR.Cg54
9 CHO Grik1 gRNA_R2 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAA
CACGAGTGGTACAATCCCCAC 
gR.Cs534 CHO Hprt1 gRNA_F1 TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTTTGTGTCATTAGTGAAAC 
gR.Cs535 CHO Hprt1 gRNA_R1 GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGTTTCACTAATGACACAAAC 
gR.Cs536 CHO Hprt1 gRNA_F2 TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGGTTGTACCGCTTGACCA 
gR.Cs537 CHO Hprt1 gRNA_R2 GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGGTCAAGCGGTACAACCCC 
Table A7: Quantitative PCR primers and probes for target regions 
Primer notes sequence 
PT-
RPPH1-F RPPH1 housekeeping gene AGTGAGTTCAATGGCTGAGG 
PT-
RPPH1-
R 
RPPH1 housekeeping gene GGCGGAGGAGAGTAGTCT 
Q-
RPPH1 
probe 
RPPH1 housekeeping gene probe 
probe with FAM/ZEN/IBFQ TTGGGTTATGAGGTCCCCTGCG 
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Table A7, continued: 
Primer notes sequence 
Q-
GRIK1-
F1 
GRIK1 edited region (GRIK1B) GGTTTTCTGCATTGCTCAGC 
Q-
GRIK1-
R1 
GRIK1 edited region (GRIK1B) TCCAACTCCAAACCAGAAACT 
Q-
GRIK1-
NHEJ 
insensitiv
e probe 
NHEJ-insensitive probe with 
HEX/ZEN/IBFQ (GRIK1B) TGCTGGTGTCCTGTGTGTTTCTCT 
Q-
GRIK1-
NHEJ 
sensitive 
probe 
NHEJ-sensitive probe with 
FAM/ZEN/IBFQ (GRIK1B) CGAGTGGTATAACCCCCACCCATGCA 
Q-
AAVS1-
F1 
AAVS1 edited region (AAVS1.T2) CTTCAGGACAGCATGTTTGC 
Q-
AAVS1-
R1 
AAVS1 edited region (AAVS1.T2) AGACCCAATATCAGGAGACTAGG 
Q-
AAVS1-
NHEJ 
insensitiv
e probe 
NHEJ-insensitive probe with 
HEX/ZEN/IBFQ (AAVS1.T2) ACCCAGAACCAGAGCCACATTAACC 
Q-
AAVS1-
NHEJ 
sensitive 
probe 
NHEJ-sensitive probe with 
FAM/ZEN/IBFQ (AAVS1.T2) AGGATTGGTGACAGAAAAGCCCCATCC 
Q-
Cg.Actb-
F1 
C. griseus Actb housekeeping gene GCATCCACGAAACTACATTCAA 
Q-
Cg.Actb-
R1 
C. griseus Actb housekeeping gene AGCAATGCCTGGGTACAT 
Q-
Cg.Actb 
probe 
C. griseus Actb housekeeping gene 
probe with FAM/ZEN/IBFQ AACACAGTGCTGTCTGGTGGTACC 
Q-
Cg.Grik1
-F1 
C. griseus Grik1 edited region CTGATGTTTACAAACTGTTTCTGTC 
Q-
Cg.Grik1
-R1 
C. griseus Grik1 edited region AACCGGTGTACCTTGCT 
Q-
Cg.Grik1
-NHEJ 
insensitiv
e probe 
NHEJ-insensitive probe with 
HEX/ZEN/IBFQ (Cg.Grik1) TGGTTTGGAGTTGGAGCTCTCATGC 
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Table A7, continued: 
Primer notes sequence 
Q-
Cg.Grik1
-NHEJ 
sensitive 
probe 
NHEJ-sensitive probe with 
FAM/ZEN/IBFQ (Cg.Grik1) ctacgagtggtacaatccccaccc 
A.4. CHAPTER 4 SPECIFIC 
Relevant primer sequences can be found in the Supplementary Information of our 
publication: Cheng, J., & Alper, H. S. (2016). Transcriptomics-guided design of synthetic 
promoters for a mammalian system. ACS Synth Biol. Article ASAP. Publication Date 
(Web): June 7, 2016. DOI: 10.1021/acssynbio.6b00075. 
A.5. CHAPTER 5 SPECIFIC 
Table A8: Primers for constructing UCP core promoter and CMV enhancer variants 
Primer notes sequence 
a61 Assembly PCR primer for UCP (20nt match to a62) 5' ⇒ 3' 
CTAGCTAGCGCGCGCCTATATAAGTTTGTTTCGTTTAG
TGAACCGTCAGA 
a62 
Assembly PCR primer for UCP (20nt 
match to a61, 17nt match to a63) 3' ⇒ 
5' 
TCGGCGTCTCCAGAGAATCTGACGGTTCACTAAACGA 
a63 Assembly PCR primer for UCP (17nt match to a62) 5' ⇒ 3' 
TTCTCTGGAGACGCCGAGCCGAGCGGTCAGACCTCCA
TAGAAGCGGCCGCAAAAGGAAAA 
f64 Flanking primer for NheI-UCP-NotI 5'⟹3' CTAGCTAGCGCGCGCCTATA 
f65 Flanking primer for NheI-UCP-NotI 3'⟹5' TTTTCCTTTTGCGGCCGCTT 
72 AflII-CMV enhancer 5' ⇒ 3' AGACCCCTTAAGCGCGTTACATAACTTACGGTAAATGGC 
73 NheI-CMV enhancer 3' ⇒ 5' AACTAGCTAGCCAAAACAAACTCCCATTGACGTCAA 
74 AflII-CMV enhancer "long" 5' ⇒ 3' AGACCCCTTAAGTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGC 
75b NheI-CMV enhancer full 3' ⇒ 5' AACTAGCTAGCCCCACCGTACACGCCTACCG 
Table A9: Primers for multiple core promoter work 
Primer notes sequence 
193 NotI-core pCMV, 5' ⇒ 3' TTTTCCTTTTGCGGCCGCAGGTCTATATAAGCAGAGCTCGTTTA 
194 NheI-core pCMV, 3' ⇒ 5' CTAGCTAGCGATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCT 
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Table A9, continued: 
Primer notes sequence 
197 EcoRI-cpCMV no TSS-NotI, 5' ⇒ 3' CGGAATTCAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGCGGCCGCAAAAGGAAAA 
198 NotI-cpCMV no TSS-EcoRI, 3' ⇒ 5' TTTTCCTTTTGCGGCCGCCGGTTCACTAAACGAGCTCTGCTTATATAGACCTGAATTCCG 
199 EcoRI-cpCMV, 5' ⇒ 3' CCGGAATTCAGGTCTATATAAGCAGAGCTCGTTTAGTGAAC 
200 NotI-cpCMV, 3' ⇒ 5' TTTTCCTTTTGCGGCCGCGATCTGACGGTTCACTAAACGAGCTCTGCTTA 
201c PacI-BamHI-cpCMV, 5' ⇒ 3' CCTTAATTAAGGCGCGGATCCAGGTCTATATAAGCAGAGCTCG 
202b EcoRI-cpCMV no TSS, 3' ⇒ 5' CCGGAATTCCGGTTCACTAAACGAGCTCTGCTTATATAGACCT 
203b EcoRI-cpCMV, 3' ⇒ 5' CCGGAATTCGATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCT 
Table A10: Primers for hybrid promoters 
Primer notes sequence 
243 NotI-pEEF1A1.1356, 5' ⇒ 3' ATAAGAATGCGGCCGCGAGTAATTCATACAAAAGGACTCGCCCCTGC 
310b NotI-pEEF1A1.1048 5' ⇒ 3' ATAAGAATGCGGCCGCGGGGGAGAACCGTATATAAGTGCAGTAGTC 
306-1 pEEF1A1 (exon 2) 3' ⇒ 5' TTTGGCTTTTAGGGGTAGTTTTCACGACAC 
307 NotI-pCLUAP1.2000 5' ⇒ 3' ATAAGAATGCGGCCGCATCATATATCTGATAAGGGTCTCATAGGCA 
308 NotI-pCLUAP1.500 5' ⇒ 3' ATAAGAATGCGGCCGCCTGCAACCTCTGCCTGCC 
309 NheI-pCLUAP1 3' ⇒ 5' CTAGCTAGCAACCAATGGACCCTTGGACG 
311 NotI-pTPT.2000 5' ⇒ 3' ATAAGAATGCGGCCGCGGGCAACAGAGCAAGACCCCATCTG 
g311 GA pTPT.2000 5' ⇒ 3' ATTAAGGCGGAATTCCGAAGGAAAAAAGCGGCCGCGGGCAACAGAGCAAGACCCCATCTG 
g311b GA CMVe-pTPT.2000 5' ⇒ 3' AAATGGGCGGTAGGCGTGTACGGTGGGGCGGCCGCGGGCAACAGAG 
312 NotI-pTPT.500 5' ⇒ 3' ATAAGAATGCGGCCGCCGGACTCAGCGGTGCCCC 
313 NheI-pTPT 3' ⇒ 5' CTAGCTAGCGCGCCTCCGGAAGCGACG 
g313 GA pTPT 3' ⇒ 5' TAGCCTCAGGCCCAGCAGCAGCAGCAGCAGCAGCATGCTAGCGCGCCTCCGGAAGCGACG 
g313b GA promoter 3' ⇒ 5' CAGCAGCAGCAGCAGCAGCAGCATGCTAGC 
g314 GA pTUBA1B.2000 5' ⇒ 3' GAAGGAAAAAAGCGGCCGCACAATATACCCTTTTTTTTTTTTGGAGATGGAGTTTCGGTC 
g314b GA CMVe-pTUBA1B.2000 5' ⇒ 3' GGTAGGCGTGTACGGTGGGGCGGCCGCACAATATACCCTTTTTTTTTTTTGGAGATGGAG 
315 NotI-pTUBA1B.500 5' ⇒ 3' ATAAGAATGCGGCCGCGCTTGGGCACTACTCTTCGAATGACTGAAATACTATTTGC 
g315 GA pTUBA1B.500 5' ⇒ 3' GAAGGAAAAAAGCGGCCGCGCTTGGGCACTACTCTTCGAATGACTGAAATACTATTTGC 
g315b GA CMVe-pTUBA1B.500 5' ⇒ 3' GCAAATGGGCGGTAGGCGTGTACGGTGGGGCGGCCGCGCTTGGGCACTACTCTTCG 
g315c GA CMVe-pTUBA1B.500i 5' ⇒ 3' CAAATGGGCGGTAGGCGTGTACGGTGGGGCGGCCGCGGGGTGGGGTCTG 
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Table A10, continued: 
Primer notes sequence 
316 NheI-pTUBA1B 3' ⇒ 5' CTAGCTAGCTCCGGCCCCGCGCGC 
g316 GA pTUBA1B 3' ⇒ 5' CTGTAGCCTCAGGCCCAGCAGCAGCAGCAGCAGCAGCATGCTAGCTCCGGCCCCGCGCGC 
317b NotI-pGGA1.2000 5' ⇒ 3' ATAAGAATGCGGCCGCAAATTAGCCAGGCATGATGGCGCATGCCTG 
317-1 pGGA1 5' ⇒ 3' AGTCTCTCAAAGCAACACATTTGCTCATGG 
318b NotI-pGGA1.500 5' ⇒ 3' ATAAGAATGCGGCCGCGCCTTCATCCTACTTTTTCTCCCTGAATATCTTTTCGCACC 
319b NheI-pGGA1 3' ⇒ 5' CTAGCTAGCTTAAAAGGGCGATAAGCTACATCCTCATGTACCTTGGCC 
319-1 pGGA1 3' ⇒ 5' GGACACTCACTGATTCGCGCCTCC 
320 NotI-pLAIR1.2000 5' ⇒ 3' ATAAGAATGCGGCCGCATGCCATTGCACTCCAGC 
320b NotI-pLAIR1.2000 5' ⇒ 3' ATAAGAATGCGGCCGCATGCCATTGCACTCCAGCCTGGGTGACAGAG 
321 NotI-pLAIR1.500 5' ⇒ 3' ATAAGAATGCGGCCGCAAAAATTTCTTTAAATTGGCCTTTGG 
321b NotI-pLAIR1.500 5' ⇒ 3' ATAAGAATGCGGCCGCAAAAATTTCTTTAAATTGGCCTTTGGAAATTTACCAGCAGTGTG 
322 NheI-pLAIR1 3' ⇒ 5' CTAGCTAGCAGACATAGCGGGTGTCATAGATG 
322b NheI-pLAIR1 3' ⇒ 5' CTAGCTAGCAGACATAGCGGGTGTCATAGATGTGAAAAAGCTTCTGCTATACCAG 
322c NheI-pLAIR1.L 3' ⇒ 5' CTAGCTAGCCTTCTGTCGCGGATGCAACCCTGGAAGGAAG 
323b NotI-pUBC-1778 5' ⇒ 3' ATAAGAATGCGGCCGCCCCTGTTGGCATCAAGTAGGACC 
323c NotI-pUBC-1778 5' ⇒ 3' ATAAGAATGCGGCCGCCCCTGTTGG 
323-1 pUBC 5' ⇒ 3' GGAGGCCATTTTCTTCCCTGTCACC 
323-2 pUBC 5' ⇒ 3' ggaggccattttcttccctgtcacctcagtg 
324 NotI-pUBC-1310 5' ⇒ 3' ATAAGAATGCGGCCGCGCGGGGTTCGCGACC 
324b NotI-pUBC-1310 5' ⇒ 3' ATAAGAATGCGGCCGCGCGGGGTTC 
325 NheI-pUBC 3' ⇒ 5' CTAGCTAGCTGTCTAACAAAAAAGCCAAAAACG 
325b NheI-pUBC 3' ⇒ 5' CTAGCTAGCTGTctaacaaaaaagccaaaaacggcc 
325-1 pUBC 3' ⇒ 5' tcaagcgcaggaccaagtgcagagtggactc 
326-1 pUBC 3' ⇒ 5' TCAAGCGCAGGACCAAGTGCAGAG 
326 NotI-pVIM.2000 5' ⇒ 3' ATAAGAATGCGGCCGCTTTAAGTCACCCAATTCAACTGAC 
327 NotI-pVIM.500 5' ⇒ 3' ATAAGAATGCGGCCGCGTAACCTGCAGTACCCCCTGC 
328 NheI-pVIM 3' ⇒ 5' CTAGCTAGCGATTAATGAGTTCAAATGAAAGGCAATTATG 
332b NotI-pF2R.2000 5' ⇒ 3' ATAAGAATGCGGCCGCGAAGGAAGGAAGGAAGAGAGGGAGGGAGGAAGGAAGGAAG 
332-1 pF2R-3000 5' ⇒ 3' CAAGCCTCAAAAAATACAACTGGCAGAAATATTCCTAGAAGG 
332-1b pF2R-3070 5' ⇒ 3' caagcctcaaaaaatacaactggcagaaatattcctagaaggaatcc 
333b NotI-pF2R.500 5' ⇒ 3' ATAAGAATGCGGCCGCACTCAAGGGCCCTTTCTCATTTAGGGGCAAC 
334b NheI-pF2R 3' ⇒ 5' CTAGCTAGCAGCGAGGAAGGGCGCCCTCC 
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Table A10, continued: 
Primer notes sequence 
334c NheI-pF2R.L 3' ⇒ 5' CTAGCTAGCTGTCCCGGGCTCTGCGCGG 
334-1 pF2R-3070 3' ⇒ 5' agggtgcccacgggtaagatcagggtccaag 
362 NotI-pEIF4A1.776 5' ⇒ 3' ATAAGAATGCGGCCGCGTGGTGGTCTTCCTTAAGGGGCTTCAAATTAGTG 
363 NotI-pEIF4A1.500 5' ⇒ 3' ATAAGAATGCGGCCGCCTGGGGAGGGGACCAACCAGGATTC 
364 NheI-pEIF4A1 3' ⇒ 5' CTAGCTAGCCGCCTGCCGGCGCTCAG 
364b NheI-pEIF4A1ex 3' ⇒ 5' CTAGCTAGCGATCCTTAGAAACTAGGGCGGAGTGCCCGCC 
365 NotI-pPGK1.2000 5' ⇒ 3' ATAAGAATGCGGCCGCATATATTTTCCCAGCACTGTGAATAAAAGTCAGTTGAATGAG 
366 NotI-pPGK1.1500 5' ⇒ 3' ATAAGAATGCGGCCGCACAGCCCTTTCCCCTTCTTGCTG 
367 NotI-pPGK1.1000 5' ⇒ 3' ATAAGAATGCGGCCGCGGCAGCGGACAAGGTGAACCC 
368 NotI-pPGK1.500 5' ⇒ 3' ATAAGAATGCGGCCGCGGACCTGGGCCTCTTCCAACTTC 
368b NotI-pPGK1.500 5' ⇒ 3' ATAAGAATGCGGCCGCGGACCTGGGCCTCTTCCAACTTCTGAGAGG 
369 NheI-pPGK1 3' ⇒ 5' CTAGCTAGCACCCCGCCTCCCGCA 
369b NheI-pPGK1.L 3' ⇒ 5' CTAGCTAGCTTTGGAAATACAGCTGGGGAGAGAGGTCGG 
370 NotI-pGAPDH.2000 5' ⇒ 3' ATAAGAATGCGGCCGCCAAGGGTTGCTTTCTGCCGTG 
371 NotI-pGAPDH.1500 5' ⇒ 3' ATAAGAATGCGGCCGCGAATAGCTGAGTCAGAGGTGGGGC 
372 NotI-pGAPDH.1000 5' ⇒ 3' ATAAGAATGCGGCCGCGTGCCCAAGACCTCTTTTCCCAC 
373 NotI-pGAPDH.500 5' ⇒ 3' ATAAGAATGCGGCCGCGATGGGGAGGGGGAAGTGG 
374 NheI-pGAPDH 3' ⇒ 5' CTAGCTAGCCTCGGACCCCGCCTCC 
374b NheI-pGAPDH (intron) 3' ⇒ 5' CTAGCTAGCGGTGTCTGAGCGATGTGGCTC 
375 NotI-pPGK1 5' ⇒ 3' ATAAGAATGCGGCCGCGGGTTGGGGTTGCGCCTTTTC 
if498 EcoRI - EEF1A1 enhancer (308bp), 5' 
⇒ 3' 
AATTAAGGCGGAATTCGAGTAATTCATACAAAAGGAC
TCGC 
if498b EcoRI - EEF1A1 enhancer (156bp), 5' 
⇒ 3' AATTAAGGCGGAATTCGGCTCCGGTGCCCGTCAG 
if499 pEIF4A1.500 - NotI - EEF1A1 enhancer (308), 3' ⇒ 5' CCTCCCCAGGCGGCCGCACCCTCGGGAAAAAGGC 
if499b pEIF4A1.500 - NotI - EEF1A1 enhancer (156), 3' ⇒ 5' 
CCTCCCCAGGCGGCCGCACCCTCGGGAAAAAGGCGG
AG 
if500 pGAPDH.500.i1 - NotI - EEF1A1 enhancer, 3' ⇒ 5' CTCCCCATCGCGGCCGCACCCTCGGGAAAAAGGC 
if503 pUBC.1310 - NotI - EEF1A1 enhancer (308), 3' ⇒ 5' GAACCCCGCGCGGCCGCACCCTCGGGAAAAAGGC 
if503b pUBC.1310 - NotI - EEF1A1 enhancer (156), 3' ⇒ 5' 
GAACCCCGCGCGGCCGCACCCTCGGGAAAAAGGCGG
AG 
if507 EcoRI - EIF4A1 enhancer (450bp), 5' 
⇒ 3' 
AATTAAGGCGGAATTCCTGGGGAGGGGACCAACCAG
G 
if508 pEEF1A1.1048 - NotI - EIF4A1 enhancer (450bp), 3' ⇒ 5' TTCTCCCCCGCGGCCGCGTGAAGGCCCGCCCCGC 
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Table A10, continued: 
Primer notes sequence 
if519 EcoRI - ACTBe.182, 5' ⇒ 3' AATTAAGGCGGAATTCAGGCGGCCAAC 
if520 pEEF1A1.1048 - NotI - ACTBe.182, 3' 
⇒ 5' TTCTCCCCCGCGGCCGCTC 
if521 NotI - pACTB.2387, 5' ⇒ 3' AGGAAAAAAGCGGCCGCGTTCCATGTCCTTATATGGACTCATCTTTGCCTATTGCGACAC 
if522 NheI - pACTB.2387, 3' ⇒ 5' GCAGCAGCATGCTAGCGGTGAGCTGCGAGAATAGCCGGGCGCG 
if550 EcoRI - LMO1 enhancer (553bp), 5' ⇒ 3' AATTAAGGCGGAATTCGTAGGGGTTGGAGTTCAG 
if551 pEEF1A1.1048 - NotI - LMO1 enhancer (553bp), 3' ⇒ 5' TTCTCCCCCGCGGCCGCAGGGGCTCTGTAGTCTCC 
if554 EcoRI - MMse176.1751, 5' ⇒ 3' AATTAAGGCGGAATTCGAGTTAAAAAGAGGTGATTTACAGTGCTATTTGAGAAGG 
if555 pEEF1A1.1048 - NotI - MMse176.1751, 3' ⇒ 5' 
TTCTCCCCCGCGGCCGCCTTCTCTCTGATATTAAACGG
CTTCCAAATGC 
if556 EcoRI - MMse117.3270, 5' ⇒ 3' AATTAAGGCGGAATTCCCTCAATTTCTCTAATCTCTTTCATAGGCTCCTG 
if557 pEEF1A1.1048 - NotI - MMse117.3270, 3' ⇒ 5' 
TTCTCCCCCGCGGCCGCCCATCTCTACTAAAAATACA
AAAATTAGCCGGGC 
560 MMse176.1751, 5' ⇒ 3' GAGTTAAAAAGAGGTGATTTACAGTGCTATTTGAGAAGGGG 
561 MMse176.1751, 3' ⇒ 5' CTTCTCTCTGATATTAAACGGCTTCCAAATGCAAGC 
562 MMse117.3270, 5' ⇒ 3' CCTCAATTTCTCTAATCTCTTTCATAGGCTCCTGCACTG 
563 MMse117.3270, 3' ⇒ 5' CCATCTCTACTAAAAATACAAAAATTAGCCGGGCATGGTG 
if564 EcoRI - pACTB.1173, 5' ⇒ 3' AATTAAGGCGGAATTCAGGCGGCCAACGCCAAAAC 
if565 NheI - pACTB.1173, 3' ⇒ 5' GCAGCAGCATGCTAGCGGTGAG 
if566 pRPL41.398 - NotI - ACTBe.182, 3' ⇒ 5' AGCACCTATGCGGCCGCTCGAGCCATAAAAGG 
if567 pGAPDH.500 - NotI - ACTBe.182, 3' 
⇒ 5' CTCCCCATCGCGGCCGCTCGAGCCATAAAAGG 
if568 pEEF1A1.350 - NotI - ACTBe.182, 3' 
⇒ 5' GAATTACTCGCGGCCGCTCGAGCCATAAAAGG 
if569 NotI - pRPLP2.479, 5' ⇒ 3' AGGAAAAAAGCGGCCGCTCACTTCCGGAACTGCTGCCCTTCGCCTTTG 
if570 NheI - pRPLP2.479, 3' ⇒ 5' GCAGCAGCATGCTAGCCCTGAGGCGGGCGGAGAGGACGCGAC 
if571 NotI - pEEF1A1.350, 5' ⇒ 3' AGGAAAAAAGCGGCCGCGAGTAATTCATACAAAAGGACTCGC 
if572 NheI - pEEF1A1.350, 3' ⇒ 5' GCAGCAGCATGCTAGCAAAAAGAACGTTCACGGCG 
if588 pRPLP2.479 - NotI - ACTBe.182, 3' ⇒ 5' cggaagtgaGCGGCCGCTCGAGCCATAAAAGG 
if676 pEEF1A1.204/1204, 5' ⇒ 3' AGGAAAAAAGCGGCCGCGGCTCCGGTGCCCGTC 
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Table A11: Primers for other hybrid promoters with introns 
Primer notes sequence 
i264 iS1, 5' ⇒ 3' CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgttactaactttttttcttccatttca 
i265 iS1, 3' ⇒ 5' TTTGGCTTTTAGGGGTAGTTTTCACGACACctgaaatggaagaaaaaaagttagtaacCT 
g224 EcoRI-NotI-reference cpCMV-iA, 5' 
⇒ 3' 
GGCGGAATTCCGAAGGAAAAAAGCGGCCGCAGGTCT
ATATAAGCAGAGCTCGTTTAGTGA 
g225 iA-hrGFP junction, 3' ⇒ 5' AGGCCGGTGTTCTTCAGGATCTGCTTGCTCACCATCGTGTCAAGGACGGTGActg 
g226 iA-SEAP junction, 3' ⇒ 5' GCTGTAGCCTCAGGCCCAGCAGCAGCAGCAGCAGCAGCATCGTGTCAAGGACGGTGActg 
g458 core CMV,  5' ⇒ 3' AGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG 
g430 SEAP towards NheI site 3' ⇒ 5' CAGCAGCAGCAGCAGCAGCAG 
g430b SEAP towards NheI site 3' ⇒ 5' CTCAGGCCCAGCAGCAGCAGC 
g431 rpCMV.660.Gi1 5' ⇒ 3' TATATAAGCAGAGCTCGTTTAGTGAACCGGGCTGGGACTGGCTGAGCCTG 
g432 pF2R.500.Gi1 5' ⇒ 3' GGGGAGGGGGCGCCGAGCGGCTCCAGCGCGGCTGGGACTGGCTGAGCCTG 
g433 pGGA1.500.Gi1 5' ⇒ 3' AAACTGATTTATTTTCGTCATTTTCACAGGGCTGGGACTGGCTGAGCCTG 
g434 pLAIR1.500.Gi1 5' ⇒ 3' TCAGTTTTGCTCCGTTCCTGACCCTGGTAGGCTGGGACTGGCTGAGCCTG 
g485 pEIF4A1.500.Gi1, 5' ⇒ 3' TCCAATGGTGCCTGCGGGCCGGAGCGACTAGGCTGGGACTGGCTGAGCCTG 
g506 pEEF1A1.204.Gi1 5' ⇒ 3' GTGCAGTAGTCGCCGTGAACGTTCTTTTTGGCTGGGACTGGCTGAGCCTG 
645 MST1L.i9, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgagtc
cctggtgctcccggccccgccagGTGTCGTGAAAACTACCCCTAA
AAGCCAAA 
646 AQP12A.i1, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgggtg
cgggtgcagctcgggccctgctgcctggagGTGTCGTGAAAACTACCC
CTAAAAGCCAAA 
647 GUCY2EP.i10, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgaccc
ctgatcacgggccgcctgagtgcgttggctgatgaagGTGTCGTGAAAACT
ACCCCTAAAAGCCAAA 
648 NDOR1.i12, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgtgtat
gctcaggggctgggaaaggaggggagggagctccggctcagGTGTCGTGAA
AACTACCCCTAAAAGCCAAA 
649 SAMD14.i8, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgggtt
gggggtgaactctcctcagtggcatgcacctttttctgtctagGTGTCGTGAAA
ACTACCCCTAAAAGCCAAA 
650 LCA10.i2, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtagggc
acacaggcctgtctcctcgaccctcacctgccagtcctggccagGTGTCGTGAA
AACTACCCCTAAAAGCCAAA 
651 PDHB.i6, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtggcct
tcagcctgtgcctatagtcttcagagggcccaatggtgcctcagcagGTGTCGTG
AAAACTACCCCTAAAAGCCAAA 
652 SYT14P1.i1, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgttaatttt
tttttaaaagttcatttttcatttgcttctgcttttgcctgatccaaagagGTGTCGTGA
AAACTACCCCTAAAAGCCAAA 
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Table A11, continued: 
Primer notes sequence 
653 SIGLEC6.i1, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgagtg
ggccaggggagaggtgccgtggggctgggccgagctgaccctcatgtctccatagGT
GTCGTGAAAACTACCCCTAAAAGCCAAA 
654 SIGLEC17P.i1, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgagtg
gccctggggagaggggccgtggggatgagcccatctgaccctcatgtctccacagGT
GTCGTGAAAACTACCCCTAAAAGCCAAA 
655 ESRP2.i6, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtgagtg
tgggagcaggggctgggggtgacaacagctgaatagGTGTCGTGAAAAC
TACCCCTAAAAGCCAAA 
656 HNRNPH1.i6, 5' ⇒ 3' 
CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGgtaaggt
aagaattgaatttctcagttgaaggatgcttacactcttgtccatctagGTGTCGTGA
AAACTACCCCTAAAAGCCAAA 
Table A12: gBlocks® for hybrid promoters 
fragment sequence 
ACTBe.182 
AATTAAGGCGGAATTCAGGCGGCCAACGCCAAAACTCTCCCTCCTCCTCTT
CCTCAATCTCGCTCTCGCTCTTTTTTTTTTTCGCAAAAGGAGGGGAGAGGGG
GTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAGCGGCGCGGG
GCCAATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCC
GCGGGGGAGAA 
RPL41-regs (5’ regulatory 
element from RPL41) 
AGGAAAAAAGCGGCCGCATAGGTGCTGACGTTTAAATAACACAGCGTCCTC
ATACTAAATCTGGGGGGGAACTGGTAACTCGAAAACCAAATACTCGGTCTT
CCGAAAGAACTAACTCAACCTACCCTTCTACAAGAGGGTCCGAAAACCACT
GTTACGCCCATTGGGTAGCCCCGCCCTTGGGGGGGGCAAAGGGCGTGAAA
GCGGAAGTGACGACACCCGGCGCTCCATTAAATAGCCGTAGACGGAACTTC
GCCTTTCTCTCGGCCTTAGCGCCATTTTTTTGGGTGAGTGTTTTTTGGTTCCT
GCGTTGGGATTCCGTGTACAATCCATAGACATCTGACCTCGGCACTTAGCA
TCATCACAGCAAACTAACTGTAGCCTTTCTCTCTTTCCCTGTAGAAACCTCT
GCGCCGCTAGCATGCTGCTGCCCCCTGGGCAGCCTGCACGAGTGGGTGTAA
ACCGCTAGCTTGTTGCACCGTGGAGGCCACAGGAGCAGAAACATGGAATG
CCAGACGCTGGGGATGCTGGTACAAGTTGTGGGACTGCATGCTACTGTCTA
GAGCTTGTCTCAATGGATCTAGAACTTCATCGCCCTCTGATCGCCGATCACC
TCTGAGACCCACCTTGCTCATAAACAAAATGCCCATGTTGGTCCTCTGCCCT
GGACCTGTGACATTCTGGACTATTTCTGTGTTTATTTGTGGCCGAGTGTAAC
AACCATATAATAAAtcacctcttccgctgttttagctgaagaattaaatCAtcttgtctattaTGTTTTTTA
TGGTTCCATCGGGTGGGGGTTTTCTGTCATTAGAGTTTGCCCTGTCACTACC
TGTGCTATGGAGGGTATGAGCAAAAGGCCAGCAAAAGGCCAGGAACC 
LMO1e.553281 
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCCACATC
CTGAGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTATTCTGCTGGG
CCCAGCGCATGCATCTGAGTGTGTGCCCAGGCGTGCGTGTCGGCGCAAACA
TCATCCATTGTGAAATATCAGTGTTTTCATGGGTGAGTAGTAATTACTGGGT
AATGCTTTAAAACCTTTCCTGAAGGAGCGCAAAGCCATTTTTTTCTAAAGTC
AGGAGTACATTAAAAGGATTACCATGTAGATTTGATTTTTAGATAACACTA
AAATGGATCCCAAATGGACTTCAGCAAAGGGATGCTATCTCCTTAATGGAA
AGTGCATGGCCCGAGGCTCAGGTCCCAGAGCCAGGCTGgggaaggagggagggaag
aggtgtctgcaggggggcaggctggcagattgggtggggggctaggtgggaatggggaaggcagagcaggagggagg
gCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCAGGAGACTAC
AGAGCCCCT 
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Table A13: Primers for creating expression vectors 
Primer notes sequence 
if492 NotI - promoter, 5' ⇒ 3' AGGAAAAAAGCGGCCGC 
if493 hrGFP - NheI - pEIF4A1.636, 3' ⇒ 5' TGCTCACCATGCTAGCGATCCTTAGAAACTAGGG 
494 hrGFP - AscI - bac elements, 5' ⇒ 3' GAGTGGGTGTAAGGCGCGCCGAGCAAAAGGCCAGCAAAAG 
495 hrGFP - AscI - bac elements, 3' ⇒ 5' GGCCTTTTGCTCGGCGCGCCTTACACCCACTCGTGCAG 
682 SEAP, 5' ⇒ 3' ATGCTGCTGCTGCTGCTGCTGCTGG 
683 SEAP, 3' ⇒ 5' TCATGTCTGCTCGAAGCGGCCGGC 
g684 SEAP (30bp) - NheI - pEIF4A1.636,  3' 
⇒ 5' 
CAGGCCCAGCAGCAGCAGCAGCAGCAGCATGCTAGC
GATCCTTAGAAACTAG 
g685 SEAP (30bp) - bac - TB - pEIF4A1.636, 5' ⇒ 3' 
GGGGCGGCCGGCCGCTTCGAGCAGACATGAGAGCAA
AAGGCCAGCAAAAG 
284b NotI-pCMV, 5' ⇒ 3' AAGGAAAAAAGCGGCCGC 
if691 hrGFP - NheI - rpCMV.660, 3' ⇒ 5' TGCTCACCATGCTAGCGTCTTCTATGGAGGTC 
if681 hrGFP - NheI - EEF1A1 exon 2, 3' ⇒ 5' GCTCACCATGCTAGCTTTGGCTTTTAGGGGTAGTTTTC 
g684 SEAP (30bp) - NheI - pEIF4A1.636,  3' 
⇒ 5' 
CAGGCCCAGCAGCAGCAGCAGCAGCAGCATGCTAGC
GATCCTTAGAAACTAG 
g685 SEAP (30bp) - bac - TB - pEIF4A1.636, 5' ⇒ 3' 
GGGGCGGCCGGCCGCTTCGAGCAGACATGAGAGCAA
AAGGCCAGCAAAAG 
g686 SEAP (30bp) - f.SV40pA - bac - TB - pEIF4A1.636, 5' ⇒ 3' 
GGGGCGGCCGGCCGCTTCGAGCAGACATGACAGACA
TGATAAGATACATTGATGAGTT 
g687 SEAP (30bp) - T.GAPDH.2 - bac - TB - pEIF4A1.636, 5' ⇒ 3' 
GGGGCGGCCGGCCGCTTCGAGCAGACATGATGTAGA
CCCCTTGAAGAGGG 
g688 SEAP (30bp) - T.ACTB.4 - bac - TB - pEIF4A1.636, 5' ⇒ 3' 
GGGGCGGCCGGCCGCTTCGAGCAGACATGATTGCTTT
CGTGTAAATTATGTAATGC 
g689 
SEAP (28bp) - 4x USE consensus - 
GAPDH spacer.2 - bac - TB - 
pEIF4A1.636, 5' ⇒ 3' 
GGCGGCCGGCCGCTTCGAGCAGACATGATGTAATGTA
ATGTAATGTAAAATAAAgtaccc 
g690 
SEAP (26bp) - 4x USE consensus - 
EEF1A1 spacer.2 - bac - TB - 
pEIF4A1.636, 5' ⇒ 3' 
CGGCCGGCCGCTTCGAGCAGACATGATGTAATGTAAT
GTAATGTAAAATAAAtgaatttt 
Table A14: Primers for creating endogenous terminator variants 
Primer notes sequence 
g496 hrGFP (30bp) - SV40pA (late), 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAACAGACATGATAAGATACATTGATGAG 
g497 bac elements (30bp) - SV40pA (late), 3' 
⇒ 5' 
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCTACCACAT
TTGTAGAGGTTTTACTTG 
g465 hrGFP (30bp)-minSV40pA.1, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAAccattataagctgcAATAAAcaagttaacaacAAcaattgc 
g466 GRIK1 3' homology (30bp)-minSV40pA.1, 3' ⇒ 5' 
ttccaccacgtctgagtcagggttgcatggGAAACATAaaatgaatgcaattgTT
gttgttaacttgTTTATTgcagc 
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Table A14, continued: 
Primer notes sequence 
g466b ColE1 homology (30bp)-minSV40pA.1, 3' ⇒ 5' 
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCGAAACATA
aaatgaatgcaattgTTgttgttaacttgTTTATTgcagc 
a467 hrGFP-minSV40pA.2, assembly 1 (26bp), 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAAcca
ttataagctgcAATAAAcaagt 
a468 minSV40pA.2, assembly 2 (26, 28bp), 3' ⇒ 5' 
CTGAAACATAaaatgaatgcaattgTTgttgttaacttgTTTATTgcagctt
ataatggT 
a469 minSV40pA.2-GRIK1 3' homology, assembly 3 (28, 20bp), 5' ⇒ 3' 
cAAcaattgcattcatttTATGTTTCAGGTTCAGGGGGAGGTGT
GGGAGGTTTTTTccat 
a469b minSV40pA.2-ColE1 homology, assembly 3 (28, 20bp), 5' ⇒ 3' 
cAAcaattgcattcatttTATGTTTCAGGTTCAGGGGGAGGTGT
GGGAGGTTTTTTGAGC 
a470 minSV40pA.2-GRIK1 3' homology, assembly 4 (20 bp), 3' ⇒ 5' ttccaccacgtctgagtcagggttgcatggAAAAAACCTCCCACAC 
a470b minSV40pA.2-ColE1 homology, assembly 4 (20 bp), 3' ⇒ 5' 
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAAAAAACC
TCCCACAC 
g589 hrGFP-SV40pA.3, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAACAGACATGATAAGATACATTGATGAGTTTG 
g590 ColE1 origin-SV40pA.3, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAAAAAACCTCCCACACCTCC 
g591 hrGFP-SV40pA.4, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTGATGCTATTGCTTTATTTGTAACC 
g592 ColE1 origin-SV40pA.4, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCTACCACATTTGTAGAGGTTTTACTTGC 
a473 hrGFP-TE.1, assembly 1 (25bp), 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGGTATtc
attacaaacttgctcactacAA 
a474 TE.1, assembly 2 (25, 23bp), 3' ⇒ 5' AAtgccacttcatcTTaaagcttaaaattcaTTTATTgtagtgagcaagtttgtaatgaA 
a475 TE.1-GRIK1 3' homology, assembly 3 (23, 18bp), 5' ⇒ 3' 
aagctttAAgatgaagtggcaTTTCTTTTccatgcaaccctgactcagacgtggt
ggaa 
a475b TE.1-ColE1 homology, assembly 3 (23, 17bp), 5' ⇒ 3' 
aagctttAAgatgaagtggcaTTTCTTTTGAGCAAAAGGCCAGC
AAAAGGCCAGGAACC 
a476 GRIK1 3' homology end overlap, assembly 4 (18bp), 3' ⇒ 5' ttccaccacgtctgagtc 
a476b ColE1 homology, assembly 4 (17bp), 3' 
⇒ 5' GGTTCCTGGCCTTTTGC 
g529 ColE1 origin-TE.3, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAAAAGAAAtgccacttcatcTTaaagctt 
g530 hrGFP-TE.3/TE.4, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTGAAACCCAGTGTCTTAGACAAC 
g531 ColE1 origin-TE.2/TE.4, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCTAAACAAAAAAAGCCAAGCACTACCTTG 
a477 hrGFP-TG.1, assembly 1 (24bp), 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTCATG
TACcatcAATAAAgtaccctgtg 
a478 TG.1, assembly 2 (24, 23bp), 3' ⇒ 5' GACCctagaataagacaggacaagTAactggttgagcacagggtacTTTATTgatgGTAC 
a479 TG.1-GRIK1 3' homology, assembly 3 (23, 17bp), 5' ⇒ 3' 
ttgtcctgtcttattctagGGTCTGGGGCAGAGGGGAGGGAAGCT
GGGCTTGTGTCccat 
a479b TG.1-ColE1 homology, assembly 3 (23, 17bp), 5' ⇒ 3' 
ttgtcctgtcttattctagGGTCTGGGGCAGAGGGGAGGGAAGCT
GGGCTTGTGTCGAGC 
a480 TG.1-GRIK1 3' homology, assembly 4 (17bp), 3' ⇒ 5' ttccaccacgtctgagtcagggttgcatggGACACAAGCCCAG 
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Table A14, continued: 
Primer notes sequence 
a480b TG.1-ColE1 homology, assembly 4 (17bp), 3' ⇒ 5' 
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCGACACAAG
CCCAG 
g532 hrGFP-TG.2, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAGACCCCTTGAAGAGGGGAG 
g533 ColE1 origin-GAPDH DSE, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCGACACAAGCCCAGCTTCCCT 
g636 hrGFP-T.ACTB.f, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAAGCGGACTATGACTTAGTTGCGTTACAC 
g637 ColE1 ori-T.ACTB, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCGTTGGCCCCCACTGCCC 
g638 hrGFP-T.ACTB, 5' ⇒ 3' CCCCTGGGCAGCCTGCACGAGTGGGTGTAATTGCTTTCGTGTAAATTATGTAATGCAAAA 
g639 ColE1 ori-T.ACTB, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCCCCCCAACCCAGCCACAC 
g640 ColE1 ori-T.ACTB.f, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCTCCCATAGGTGAAGGCAAAGGC 
Table A15: Primers for creating synthetic terminator variants 
Primer notes sequence 
573 ColE1 origin-DSE consensus-TGAPDH, 3' ⇒ 5' 
GCTGGCCTTTTGCTCAAAACACActagaataagacaggacaagT
Aactggttgag 
574 Levitt consensus-TGAPDH, 3' ⇒ 5' CACACAAAAAACCAACACACAGActagaataagacaggacaagTAactggttgag 
575 Levitt+DSE consensus-TGAPDH, 3' ⇒ 5' 
CACACAAAAAACCAACACACAGAAAAACACActagaataa
gacaggacaagTAactggttgag 
576 TGAPDH long USE,  5' ⇒ 3' TGTAGACCCCTTGAAGAGGGG 
g577 ColE1 origin-DSE consensus, 3' ⇒ 5' GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAAAACACA 
g578 ColE1 origin-Levitt DSE consensus, 3' 
⇒ 5' 
GGTTCCTGGCCTTTTGCTGGCCTTTTGCTCCACACAAA
AAACCAACACACAGA 
579 4x USE consensus-TGAPDH,  5' ⇒ 3' GTGGGTGTAATGTAATGTAATGTAATGTAAcatcAATAAAgtaccctgtgctcaaccagtTActtgtcct 
g580 hrGFP-4x USE consensus-TGAPDH, 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAATG
TAATGTAATGTAAcatc 
g581 hrGFP-4x USE consensus-GAPDH spacer 2, 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAATG
TAATGTAATGTAAAATAAAgtac 
582 
4x USE consensus-poly(A) signal-
GAPDH spacer 2-GAPDH poly(A) 
site, 5' ⇒ 3' 
TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaacca
gtTA 
583 
ColE1 origin-DSE consensus-GAPDH 
poly(A) site-GAPDH spacer 2-poly(A) 
signal, 3' ⇒ 5' 
CCTTTTGCTCAAAACACATAactggttgagcacagggtacTTTAT
TT 
584 
Levitt consensus-GAPDH poly(A) site-
GAPDH spacer 2-poly(A) signal, 3' ⇒ 
5' 
CAAAAAACCAACACACAGATAactggttgagcacagggtacTTT
ATTT 
585 
Levitt+DSE consensus-GAPDH 
poly(A) site-GAPDH spacer 2-poly(A) 
signal, 3' ⇒ 5' 
CAAAAAACCAACACACAGAAAAACACATAactggttgagca
cagggtacTTTATTT 
g612 ColE1 origin-DSE consensus-TEEF1A1, 3' ⇒ 5' 
GCTGGCCTTTTGCTCAAAACACAtgccacttcatcTTaaagcttaa
aattc 
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Table A15, continued: 
Primer notes sequence 
g613 Levitt consensus-TEEF1A1, 3' ⇒ 5' CACACAAAAAACCAACACACAGAtgccacttcatcTTaaagcttaaaattc 
g614 Levitt+DSE consensus-TEEF1A1, 3' 
⇒ 5' 
CACACAAAAAACCAACACACAGAAAAACACAtgccacttc
atcTTaaagcttaaaattc 
f615 hrGFP-terminator flanking primer, 5' 
⇒ 3' CCCCTGGGCAGCCTG 
g616 4x USE consensus-TEEF1A1,  5' ⇒ 3' GTGGGTGTAATGTAATGTAATGTAATGTAAtcattacaaacttgctcactacAATAAAtg 
g617 hrGFP-4x USE consensus-TEEF1A1, 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAATG
TAATGTAATGTAAtca 
618 
4x USE consensus-poly(A) signal-
EEF1A1 spacer 2-EEF1A1 poly(A) 
site, 5' ⇒ 3' 
TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttAAT 
619 
ColE1 origin-DSE consensus-EEF1A1 
poly(A) site-EEF1A1 spacer 2-poly(A) 
signal, 3' ⇒ 5' 
CCTTTTGCTCAAAACACATTaaagcttaaaattcaTTTATTTTA
CATTAC 
620 
Levitt consensus-EEF1A1 poly(A) site-
EEF1A1 spacer 2-poly(A) signal, 3' ⇒ 
5' 
CAAAAAACCAACACACAGATTaaagcttaaaattcaTTTATTT
TACATTAC 
621 
Levitt+DSE consensus-EEF1A1 
poly(A) site-EEF1A1 spacer 2-poly(A) 
signal, 3' ⇒ 5' 
CAAAAAACCAACACACAGAAAAACACATTaaagcttaaaatt
caTTTATTTTACATTAC 
g622 hrGFP-4x USE consensus-EEF1A1 spacer 2, 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAATG
TAATGTAATGTAAAATAAAtga 
657 
4x USE consensus-poly(A) signal-
ACTB spacer 2-ACTB poly(A) site,  5' 
⇒ 3' 
TGTAATGTAATGTAATGTAAAATAAAagtgcacaccttaaaaat
GA 
658 
Levitt+DSE consensus-ACTB poly(A) 
site-ACTB spacer 2-poly(A) signal, 3' 
⇒ 5' 
CAAAAAACCAACACACAGAAAAACACATCatttttaaggtgt
gcactTTTATTT 
659 4x USE consensus-poly(A) signal-ACTB spacer 2-poly(A) site,  5' ⇒ 3' 
TGTAATGTAATGTAATGTAAAATAAAagtgcacaccttaaaaat
CA 
660 Levitt+DSE consensus-poly(A) site-ACTB spacer 2-poly(A) signal, 3' ⇒ 5' 
CAAAAAACCAACACACAGAAAAACACATGatttttaaggtgt
gcactTTTATTT 
g661 hrGFP-4x USE consensus-ACTB spacer 2, 5' ⇒ 3' 
CCCCTGGGCAGCCTGCACGAGTGGGTGTAATGTAATG
TAATGTAATGTAAAATAAAagtg 
662 4x USE consensus-poly(A) signal-GAPDH spacer 2-poly(A) site,  5' ⇒ 3' 
TGTAATGTAATGTAATGTAAAATAAAgtaccctgtgctcaacca
gtCA 
663 
ColE1 origin-DSE consensus-poly(A) 
site-GAPDH spacer 2-poly(A) signal, 
3' ⇒ 5' 
CCTTTTGCTCAAAACACATGactggttgagcacagggtacTTTAT
TT 
664 Levitt consensus-poly(A) site-GAPDH spacer 2-poly(A) signal, 3' ⇒ 5' 
CAAAAAACCAACACACAGATGactggttgagcacagggtacTTT
ATTT 
665 
Levitt+DSE consensus-poly(A) site-
GAPDH spacer 2-poly(A) signal, 3' ⇒ 
5' 
CAAAAAACCAACACACAGAAAAACACATGactggttgagca
cagggtacTTTATTT 
666 4x USE consensus-poly(A) signal-EEF1A1 spacer 2-poly(A) site, 5' ⇒ 3' TGTAATGTAATGTAATGTAAAATAAAtgaattttaagctttCAT 
667 
ColE1 origin-DSE consensus-poly(A) 
site-EEF1A1 spacer 2-poly(A) signal, 
3' ⇒ 5' 
CCTTTTGCTCAAAACACATGaaagcttaaaattcaTTTATTTTA
CATTAC 
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Table A15, continued: 
Primer notes sequence 
668 Levitt consensus-poly(A) site-EEF1A1 spacer 2-poly(A) signal, 3' ⇒ 5' 
CAAAAAACCAACACACAGATGaaagcttaaaattcaTTTATTT
TACATTAC 
669 
Levitt+DSE consensus-poly(A) site-
EEF1A1 spacer 2-poly(A) signal, 3' ⇒ 
5' 
CAAAAAACCAACACACAGAAAAACACATGaaagcttaaaatt
caTTTATTTTACATTAC 
677 
ColE1 origin-MC4R DSE-poly(A) site-
GAPDH spacer 2-poly(A) signal, 3' ⇒ 
5' 
CCTTTTGCTCAATGCTTATGAATAACACGTGactggttgagc
acagggtacTTTATTT 
678 
ColE1 origin-#7 DSE (CstF-64 RRM)-
poly(A) site-GAPDH spacer 2-poly(A) 
signal, 3' ⇒ 5' 
CCTTTTGCTCCAACACACACAACTGactggttgagcacagggtac
TTTATTT 
Table A16: gBlocks® for terminators 
fragment sequence 
TE-TG (3’ UTR from 
EEF1A1 and GAPDH) 
TGTGAAACCCAGTGTCTTAGACAACTGTGGCTTGAGCACCACCTGCTGGTA
TTCATTACAAACTTGCTCACTACAATAAATGAATTTTAAGCTTTAAGATGAA
GTGGCATTTCTTTTAACAGTTACTATGTTGGAATTGGTTACAAATTTTGGAG
TGGATTTCAAAAGTGAGAGCTAACTTCAGTTGATTTCAAGGTAGTGCTTGG
CTTTTTTTGTTTATGTAGACCCCTTGAAGAGGGGAGGGGCCTAGGGAGCCG
CACCTTGTCATGTACCATCAATAAAGTACCCTGTGCTCAACCAGTTACTTGT
CCTGTCTTATTCTAGGGTCTGGGGCAGAGGGGAGGGAAGCTGGGCTTGTGT
C 
  
 192
Appendix B: Sequences 
B.1. COMMON SEQUENCES USED IN THIS WORK 
Table B1: Coding sequences of reporter proteins and antibiotic resistance 
gene sequence 
humanized 
Renilla GFP 
(hrGFP): 
720-bp 
ATGGTGAGCAAGCAGATCCTGAAGAACACCGGCCTGCAGGAGATCATGAGCTTCAAGGTGAAC
CTGGAGGGCGTGGTGAACAACCACGTGTTCACCATGGAGGGCTGCGGCAAGGGCAACATCCTG
TTCGGCAACCAGCTGGTGCAGATCCGCGTGACCAAGGGCGCCCCCCTGCCCTTCGCCTTCGACA
TCCTGAGCCCCGCCTTCCAGTACGGCAACCGCACCTTCACCAAGTACCCCGAGGACATCAGCG
ACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGTGTACGAGCGCACCCTGCGCTACGAGGACGG
CGGCCTGGTGGAGATCCGCAGCGACATCAACCTGATCGAGGAGATGTTCGTGTACCGCGTGGA
GTACAAGGGCCGCAACTTCCCCAACGACGGCCCCGTGATGAAGAAGACCATCACCGGCCTGCA
GCCCAGCTTCGAGGTGGTGTACATGAACGACGGCGTGCTGGTGGGCCAGGTGATCCTGGTGTA
CCGCCTGAACAGCGGCAAGTTCTACAGCTGCCACATGCGCACCCTGATGAAGAGCAAGGGCGT
GGTGAAGGACTTCCCCGAGTACCACTTCATCCAGCACCGCCTGGAGAAGACCTACGTGGAGGA
CGGCGGCTTCGTGGAGCAGCACGAGACCGCCATCGCCCAGCTGACCAGCCTGGGCAAGCCCCT
GGGCAGCCTGCACGAGTGGGTGTAA 
secreted 
alkaline 
phosphatase 
(SEAP): 
1560-bp 
ATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATCATCCCAGTTG
AGGAGGAGAACCCGGACTTCTGGAACCGCGAGGCAGCCGAGGCCCTGGGTGCCGCCAAGAAG
CTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGGGATGGGGGTG
TCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGACAAACTGGGGCCTGAGAT
ACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCCAAGACATACAATGTAGACAAACAT
GTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCAACTTCCAGACC
ATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCAACGAGGTCATC
TCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGTGGTAACCACCACACGAGT
GCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGGTACTCGGACGC
CGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAGCTCATCTCCAA
CATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCATGGGAACCCCAGA
CCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCA
GGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTATGTGTGGAACCGCACTGAGCTCATGCAGGC
TTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAATACGAG
ATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCGCCTG
CTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATC
ATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGAGAGGG
CGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTCT
TCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCTGGCAAGGCCCG
GGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTCAAGGACGG
CGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAGCAGTCAGCAG
TGCCCCTGGACGAAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCGCGCGGCCCGCAG
GCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGGCCTTCGCCGCCT
GCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGACGCCGCGCACC
CGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGA 
Zeocin™ 
resistance: 
375-bp 
ATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGGTCGAG
TTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCC
GGGACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGG
CCTGGGTGTGGGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGA
ACTTCCGGGACGCCTCCGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGT
TCGCCCTGCGCGACCCGGCCGGCAACTGCGTGCACTTCGTGGCCGAGGAGCAGGACTGA 
puromycin 
resistance: 
600-bp 
ATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGC
ACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCAC
ATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAG
GTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGC
GGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGC
GCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGC
CACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGG
AGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCT
CCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCG
CACCTGGTGCATGACCCGCAAGCCCGGTGCCTGA 
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Table B1, continued: 
gene sequence 
hygromycin
-B 
resistance: 
1029-bp 
ATGGGTAAAAAGCCTGAACTCACCGCGACGTCTGTCGAGAAGTTTCTGATCGAAAAGTTCGAC
AGCGTCTCCGACCTGATGCAGCTCTCGGAGGGCGAAGAATCTCGTGCTTTCAGCTTCGATGTAG
GAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTCTACAAAGATCGTTATGT
TTATCGGCACTTTGCATCGGCCGCGCTCCCGATTCCGGAAGTGCTTGACATTGGGGAATTCAGC
GAGAGCCTGACCTATTGCATCTCCCGCCGTGCACAGGGTGTCACGTTGCAAGACCTGCCTGAA
ACCGAACTGCCCGCTGTTCTGCAGCCGGTCGCGGAGGCCATGGATGCGATCGCTGCGGCCGAT
CTTAGCCAGACGAGCGGGTTCGGCCCATTCGGACCGCAAGGAATCGGTCAATACACTACATGG
CGTGATTTCATATGCGCGATTGCTGATCCCCATGTGTATCACTGGCAAACTGTGATGGACGACA
CCGTCAGTGCGTCCGTCGCGCAGGCTCTCGATGAGCTGATGCTTTGGGCCGAGGACTGCCCCGA
AGTCCGGCACCTCGTGCACGCGGATTTCGGCTCCAACAATGTCCTGACGGACAATGGCCGCAT
AACAGCGGTCATTGACTGGAGCGAGGCGATGTTCGGGGATTCCCAATACGAGGTCGCCAACAT
CTTCTTCTGGAGGCCGTGGTTGGCTTGTATGGAGCAGCAGACGCGCTACTTCGAGCGGAGGCAT
CCGGAGCTTGCAGGATCGCCGCGGCTCCGGGCGTATATGCTCCGCATTGGTCTTGACCAACTCT
ATCAGAGCTTGGTTGACGGCAATTTCGATGATGCAGCTTGGGCGCAGGGTCGATGCGACGCAA
TCGTCCGATCCGGAGCCGGGACTGTCGGGCGTACACAAATCGCCCGCAGAAGCGCGGCCGTCT
GGACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAAACCGACGCCCCAGCACTCGTCCGA
GGGCAAAGGAATAA 
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Table B2: Base dual-expression transgene cassette for evaluating promoters used in 
Chapters 4 and 5 
construct sequence 
SEAP-
IRES-
hrGFP-
SV40 
poly(A): 
3097-bp 
ATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATCATCCCAGTTG
AGGAGGAGAACCCGGACTTCTGGAACCGCGAGGCAGCCGAGGCCCTGGGTGCCGCCAAGAAG
CTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGGGATGGGGGTG
TCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGACAAACTGGGGCCTGAGAT
ACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCCAAGACATACAATGTAGACAAACAT
GTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCAACTTCCAGACC
ATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCAACGAGGTCATC
TCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGTGGTAACCACCACACGAGT
GCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGGTACTCGGACGC
CGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAGCTCATCTCCAA
CATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCATGGGAACCCCAGA
CCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCA
GGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTATGTGTGGAACCGCACTGAGCTCATGCAGGC
TTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAATACGAG
ATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCGCCTG
CTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATC
ATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGAGAGGG
CGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTCT
TCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCTGGCAAGGCCCG
GGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTCAAGGACGG
CGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAGCAGTCAGCAG
TGCCCCTGGACGAAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCGCGCGGCCCGCAG
GCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGGCCTTCGCCGCCT
GCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGACGCCGCGCACC
CGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGAGTTTAAACCCCCTCTCC
CTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTAT
ATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTT
CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTC
GTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGC
AGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGAT
ACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTC
AAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGT
ATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACG
TCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATGTCTAGA
ATGGTGAGCAAGCAGATCCTGAAGAACACCGGCCTGCAGGAGATCATGAGCTTCAAGGTGAAC
CTGGAGGGCGTGGTGAACAACCACGTGTTCACCATGGAGGGCTGCGGCAAGGGCAACATCCTG
TTCGGCAACCAGCTGGTGCAGATCCGCGTGACCAAGGGCGCCCCCCTGCCCTTCGCCTTCGACA
TCCTGAGCCCCGCCTTCCAGTACGGCAACCGCACCTTCACCAAGTACCCCGAGGACATCAGCG
ACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGTGTACGAGCGCACCCTGCGCTACGAGGACGG
CGGCCTGGTGGAGATCCGCAGCGACATCAACCTGATCGAGGAGATGTTCGTGTACCGCGTGGA
GTACAAGGGCCGCAACTTCCCCAACGACGGCCCCGTGATGAAGAAGACCATCACCGGCCTGCA
GCCCAGCTTCGAGGTGGTGTACATGAACGACGGCGTGCTGGTGGGCCAGGTGATCCTGGTGTA
CCGCCTGAACAGCGGCAAGTTCTACAGCTGCCACATGCGCACCCTGATGAAGAGCAAGGGCGT
GGTGAAGGACTTCCCCGAGTACCACTTCATCCAGCACCGCCTGGAGAAGACCTACGTGGAGGA
CGGCGGCTTCGTGGAGCAGCACGAGACCGCCATCGCCCAGCTGACCAGCCTGGGCAAGCCCCT
GGGCAGCCTGCACGAGTGGGTGTAAATGCATCAGACATGATAAGATACATTGATGAGTTTGGA
CAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTT
TATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTT
TCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA 
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Table B2, continued: 
construct sequence 
CMV 
enhancer-
SEAP-
IRES-
hrGFP-
SV40 
poly(A): 
3700-bp 
GACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGT
TCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTCGTGACCGC
CCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGA
CTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGT
GTATCATATGCCAAGTCCGGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA
TGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGGCGGCCGCAAAAGGAAAACTAGCTAGCATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGG
CTACAGCTCTCCCTGGGCATCATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAG
GCAGCCGAGGCCCTGGGTGCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTC
ATCATCTTCCTGGGCGATGGGATGGGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGG
CAGAAGAAGGACAAACTGGGGCCTGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCT
CTGTCCAAGACATACAATGTAGACAAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTAC
CTGTGCGGGGTCAAGGGCAACTTCCAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGT
GCAACACGACACGCGGCAACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAG
TCAGTGGGAGTGGTAACCACCACACGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCAC
ACGGTGAACCGCAACTGGTACTCGGACGCCGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGC
CAGGACATCGCTACGCAGCTCATCTCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGA
AAGTACATGTTTCGCATGGGAACCCCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGG
ACCAGGCTGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTA
TGTGTGGAACCGCACTGAGCTCATGCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGT
CTCTTTGAGCCTGGAGACATGAAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTG
ATGGAGATGACAGAGGCTGCCCTGCGCCTGCTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCG
TGGAGGGTGGTCGCATCGACCATGGTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGA
CGATCATGTTCGACGACGCCATTGAGAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGA
GCCTCGTCACTGCCGACCACTCCCACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTC
CATCTTCGGGCTGGCCCCTGGCAAGGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGG
AAACGGTCCAGGCTATGTGCTCAAGGACGGCGCCCGGCCGGATGTTACCGAGAGCGAGAGCG
GGAGCCCCGAGTATCGGCAGCAGTCAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAG
GACGTGGCGGTGTTCGCGCGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACC
TTCATAGCGCACGTCATGGCCTTCGCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGC
CCCCCGCCGGCACCACCGACGCCGCGCACCCGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCT
TCGAGCAGACATGAGTTTAAACCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCG
CTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCA
ATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCT
CGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTG
AAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTG
CCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCA
CGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGG
GCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATG
CTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTT
TCCTTTGAAAAACACGATGATAATGTCTAGAATGGTGAGCAAGCAGATCCTGAAGAACACCGG
CCTGCAGGAGATCATGAGCTTCAAGGTGAACCTGGAGGGCGTGGTGAACAACCACGTGTTCAC
CATGGAGGGCTGCGGCAAGGGCAACATCCTGTTCGGCAACCAGCTGGTGCAGATCCGCGTGAC
CAAGGGCGCCCCCCTGCCCTTCGCCTTCGACATCCTGAGCCCCGCCTTCCAGTACGGCAACCGC
ACCTTCACCAAGTACCCCGAGGACATCAGCGACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCG
TGTACGAGCGCACCCTGCGCTACGAGGACGGCGGCCTGGTGGAGATCCGCAGCGACATCAACC
TGATCGAGGAGATGTTCGTGTACCGCGTGGAGTACAAGGGCCGCAACTTCCCCAACGACGGCC
CCGTGATGAAGAAGACCATCACCGGCCTGCAGCCCAGCTTCGAGGTGGTGTACATGAACGACG
GCGTGCTGGTGGGCCAGGTGATCCTGGTGTACCGCCTGAACAGCGGCAAGTTCTACAGCTGCC
ACATGCGCACCCTGATGAAGAGCAAGGGCGTGGTGAAGGACTTCCCCGAGTACCACTTCATCC
AGCACCGCCTGGAGAAGACCTACGTGGAGGACGGCGGCTTCGTGGAGCAGCACGAGACCGCC
ATCGCCCAGCTGACCAGCCTGGGCAAGCCCCTGGGCAGCCTGCACGAGTGGGTGTAAATGCAT
CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAAT
GCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAA
GTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTT
AAAGCAAGTAAAACCTCTACAAATGTGGTA 
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B.2. CHAPTER 2 SPECIFIC 
Table B3: Constructs for transgene integration 
construct Sequence (transgene region only) 
pCMV-
hrGFP-
IRES-puro 
(GP) 
variant: 
2733-bp 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTA
GTGAACCGTCAGATCCGCTAGCATGGTGAGCAAGCAGATCCTGAAGAACACCGGCCTGCAGGA
GATCATGAGCTTCAAGGTGAACCTGGAGGGCGTGGTGAACAACCACGTGTTCACCATGGAGGG
CTGCGGCAAGGGCAACATCCTGTTCGGCAACCAGCTGGTGCAGATCCGCGTGACCAAGGGCGC
CCCCCTGCCCTTCGCCTTCGACATCCTGAGCCCCGCCTTCCAGTACGGCAACCGCACCTTCACC
AAGTACCCCGAGGACATCAGCGACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGTGTACGAGC
GCACCCTGCGCTACGAGGACGGCGGCCTGGTGGAGATCCGCAGCGACATCAACCTGATCGAGG
AGATGTTCGTGTACCGCGTGGAGTACAAGGGCCGCAACTTCCCCAACGACGGCCCCGTGATGA
AGAAGACCATCACCGGCCTGCAGCCCAGCTTCGAGGTGGTGTACATGAACGACGGCGTGCTGG
TGGGCCAGGTGATCCTGGTGTACCGCCTGAACAGCGGCAAGTTCTACAGCTGCCACATGCGCA
CCCTGATGAAGAGCAAGGGCGTGGTGAAGGACTTCCCCGAGTACCACTTCATCCAGCACCGCC
TGGAGAAGACCTACGTGGAGGACGGCGGCTTCGTGGAGCAGCACGAGACCGCCATCGCCCAG
CTGACCAGCCTGGGCAAGCCCCTGGGCAGCCTGCACGAGTGGGTGTAACTCGAGCCCCTCTCC
CTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTAT
ATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTT
CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTC
GTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGC
AGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGAT
ACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTC
AAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGT
ATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACG
TCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATGGTCGAC
ATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGC
ACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCAC
ATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAG
GTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGC
GGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGC
GCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGC
CACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGG
AGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCT
CCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCG
CACCTGGTGCATGACCCGCAAGCCCGGTGCCTGAGGCGCGCCCAGACATGATAAGATACATTG
ATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTG
ATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCAT
TCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTAC
AAATGTGGTA 
 
  
 197
Table B3, continued: 
construct Sequence (transgene region only) 
pCMV-
puro-IRES-
hrGFP (PG) 
variant: 
2733-bp 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTA
GTGAACCGTCAGATCCGCTAGCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGA
CGACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCA
CACCGTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCG
CGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGAC
CACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTT
GAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAA
GGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGG
CAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGA
GACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTC
GAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACTCGAGCCC
CTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTT
GTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCC
CTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTT
GAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGAC
CCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGT
ATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGA
AAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACC
CCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTA
AAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAT
GGTCGACATGGTGAGCAAGCAGATCCTGAAGAACACCGGCCTGCAGGAGATCATGAGCTTCAA
GGTGAACCTGGAGGGCGTGGTGAACAACCACGTGTTCACCATGGAGGGCTGCGGCAAGGGCA
ACATCCTGTTCGGCAACCAGCTGGTGCAGATCCGCGTGACCAAGGGCGCCCCCCTGCCCTTCGC
CTTCGACATCCTGAGCCCCGCCTTCCAGTACGGCAACCGCACCTTCACCAAGTACCCCGAGGAC
ATCAGCGACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGTGTACGAGCGCACCCTGCGCTACG
AGGACGGCGGCCTGGTGGAGATCCGCAGCGACATCAACCTGATCGAGGAGATGTTCGTGTACC
GCGTGGAGTACAAGGGCCGCAACTTCCCCAACGACGGCCCCGTGATGAAGAAGACCATCACCG
GCCTGCAGCCCAGCTTCGAGGTGGTGTACATGAACGACGGCGTGCTGGTGGGCCAGGTGATCC
TGGTGTACCGCCTGAACAGCGGCAAGTTCTACAGCTGCCACATGCGCACCCTGATGAAGAGCA
AGGGCGTGGTGAAGGACTTCCCCGAGTACCACTTCATCCAGCACCGCCTGGAGAAGACCTACG
TGGAGGACGGCGGCTTCGTGGAGCAGCACGAGACCGCCATCGCCCAGCTGACCAGCCTGGGCA
AGCCCCTGGGCAGCCTGCACGAGTGGGTGTAAGGCGCGCCCAGACATGATAAGATACATTGAT
GAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGAT
GCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTC
ATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAA
ATGTGGTA 
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Table B3, continued: 
construct Sequence (transgene region only) 
pCMV-
SEAP-
IRES-puro 
(SP) variant: 
3573-bp 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTA
GTGAACCGTCAGATCCGCTAGCATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTC
TCCCTGGGCATCATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAGGCAGCCGAG
GCCCTGGGTGCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTC
CTGGGCGATGGGATGGGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAA
GGACAAACTGGGGCCTGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCCAA
GACATACAATGTAGACAAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGG
GGTCAAGGGCAACTTCCAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGCAACAC
GACACGCGGCAACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGG
GAGTGGTAACCACCACACGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGA
ACCGCAACTGGTACTCGGACGCCGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGCCAGGACA
TCGCTACGCAGCTCATCTCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACA
TGTTTCGCATGGGAACCCCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGC
TGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTATGTGTGG
AACCGCACTGAGCTCATGCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTG
AGCCTGGAGACATGAAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGA
TGACAGAGGCTGCCCTGCGCCTGCTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCGTGGAGGG
TGGTCGCATCGACCATGGTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCAT
GTTCGACGACGCCATTGAGAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGT
CACTGCCGACCACTCCCACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTC
GGGCTGGCCCCTGGCAAGGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGT
CCAGGCTATGTGCTCAAGGACGGCGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCC
GAGTATCGGCAGCAGTCAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAGGACGTGGC
GGTGTTCGCGCGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGC
GCACGTCATGGCCTTCGCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCC
GGCACCACCGACGCCGCGCACCCGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAG
ACATGACTCGAGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAA
GGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGC
CCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGA
ATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACA
ACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGC
CAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGT
TGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGAT
GCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTG
TTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAA
ACACGATGATAATGGTCGACATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACG
ACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACA
CCGTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCG
TCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCA
CGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGA
GCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGG
AGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCA
GCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGA
CCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGA
GGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGAGGCGCGCCCAG
ACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCT
TTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTT
AACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAA
GCAAGTAAAACCTCTACAAATGTGGTA 
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Table B3, continued: 
construct Sequence (transgene region only) 
pCMV-
puro-IRES-
SEAP (PS) 
variant: 
3573-bp 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTA
GTGAACCGTCAGATCCGCTAGCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGA
CGACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCA
CACCGTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCG
CGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGAC
CACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTT
GAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAA
GGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGG
CAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGA
GACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTC
GAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACTCGAGCCC
CTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTT
GTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCC
CTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTT
GAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGAC
CCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGT
ATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGA
AAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACC
CCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTA
AAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAT
GGTCGACATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATCATC
CCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAGGCAGCCGAGGCCCTGGGTGCCGCC
AAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGGGATG
GGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGACAAACTGGGGCC
TGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCCAAGACATACAATGTAGAC
AAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCAACTTC
CAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCAACGAG
GTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGTGGTAACCACCACA
CGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGGTACTCG
GACGCCGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAGCTCATC
TCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCATGGGAACC
CCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCT
GGTGCAGGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTATGTGTGGAACCGCACTGAGCTCAT
GCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAA
TACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTG
CGCCTGCTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGACCATG
GTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTG
AGAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCC
ACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCTGGCAA
GGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTCAA
GGACGGCGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAGCAGT
CAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCGCGCGGC
CCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGGCCTTC
GCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGACGCC
GCGCACCCGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGAGGCGCGCCC
AGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATG
CTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAG
TTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTA
AAGCAAGTAAAACCTCTACAAATGTGGTA 
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B.3. CHAPTER 3 SPECIFIC 
Table B4: GRIK1 homology regions based on GRIK1B gRNA target site 
homology sequence 
5’ 
homology 
attaagtgaccacaggccatggttctgaaaacaaatttaaaacaaatcaaaaggaaattatgaatttgaaattctgcagtgaggcatgctatgtagttaatactaat
gtgtaccactaggcctggaccagtataattccaaatgtatgccttgtctcttcctttaggatcatgatttttccccgtggactattcgaaaaacatctaatacactcca
aattcagctctacattttgttcactaatttgttcagccttgcaatccctttcatgcattacaaaatcgctagaccaccacttagactccttctaaccatctgtccataca
aaccccttgaaggcaagtcacccctcttttttgtgtctcccacaggacctaacgacacaatatcttgacattgtagttactatgcaacaagtgtgtgtcacattcgtc
gctacttggtggggtaaatacttgggatgagtgaacctttctttacagttcatctagttgttcagtaatatggaaatgaatgaaaactcagaagaattcagtagaca
tagagctgaggagtacaattccagctgaccaatttgcctataaataagaagtctggtaaatattaacgtctcaaggctctttgcactttgcccaccaaagctgtaa
gtttatgactatggcctttactcttttggtttgaagcttttgtgattaattgttgggttttctgcattgctcagcaggttttggttttgctggtgtcctgtgtgtttctctgata
tttacagactgtttctgttaactaccacaggtttacac 
3’ 
homology 
ccatgcaaccctgactcagacgtggtggaaaacaattttactttactaaatagtttctggtttggagttggagctctcatgcagcaaggtacaccggttgcctatct
ttgtcacacgcatcccacagtgtgctgacaggctttcatgctggtaaactccaccatgaagctagagggtaggatgaaacaccatctcaggaacttaagaaaat
agcaacggactttctagccggttttgaagatgaagcaaaaccaatgacctatatggaactcccttgctatatatctaaaatagcacttctatcaagcaataaatac
aaattttcctgtgggtagcaaaagataaggtaccttagaaatcgtttacaaatttgcatagatggagatgttggtcttctccttctcagccataactccacgagtca
gcagtttaaaggagcgggatctaaatcctttggagattaaattcactgagattcttccaattgccaaccttacctaggacttccacctaattactactctggcaaac
cctactgagattcatttcagcctcccagtaacttttcacaatctccctcaattggtaaccatagcaacaataaactgtaggagttggggaaataaaatttggccata
gaaatgtaatatattttatacatttcctatgaattcggggattctgcttttgtagtgggggaagggggagctattttaacctttggaagaactccatttcttttgtgatttt
ttttttcagcttcaatgtcaggcatatggtatagaaaatttttccaggat 
Table B5: Target loci for editing/integration 
region sequence 
HPRT1 
gatgctcacctctcccacacccttttatagtttagggattgtatttccaaggtttctagactgagagcccttttcatctttgctcattgacactctgtacccattaatcct
ccttattagctccccttcaatggacacatgggtagtcagggtgcaggtctcagaactgtccttcaggttccaggtgatcaaccaagtgccttgtctgtagtgtcaa
ctcattgctgccccttcctagtaatccccataatttagctctccatttcatagtctttccttgggtgtgttaaaagtgaccatggtacactcagcacggatgaaatgaa
acagtgtttagaaacgtcagtcttctcttttgtaatgccctgtagtctctctgtatgttatatgtcacattttgtaattaacagCTTGCTGGTGAAAAGG
ACCCCACGAAGTGTTGGATATAAGCCAGACTgtaagtgaattactttttttgtcaatcatttaaccatctttaacctaaaagagttttat
gtgaaatggcttataattgcttagagaatatttgtagagaggcacatttgccagtattagatttaaaagtgatgttttctttatctaaatgatgaattatgattctttttag
TTGTTGGATTTGAAATTCCAGACAAGTTTGTTGTAGGATATGCCCTTGACTATAATGAATACTT
CAGGGATTTGAATgtaagtaattgcttctttttctcactcatttttcaaaacacgcataaaaatttaggaaagagaattgttttctccttccagcacctcat
aatttgaacagactgatggttcccattagtcacataaagctgtagtctagtacagacgtccttagaactggaacctggccaggctagggtgacacttcttgttgg
ctgaaatagttgaacagctttaatatacaataattgttgcattattatttcagatgataaatgtggtcataagtaagaaataaatgatcgagtttagtcttttaattcact
gtcctttgaatacctgcctcttactctggaggcagaagtcccatggatgtgtttatgaacatggttgaggaagatttaggaagactgcaacagtacactacctaaa
gcaggttttttactccatctttttttgccacgtacactggcctcccactttgatatgcttgaaattatctccttgatttgtctttcaaaactacatattgaggctggttgcg
g 
GRIK1 
ggtttgaagcttttgtgattaattgttgggttttctgcattgctcagcaggttttggttttgctggtgtcctgtgtgtttctctgatatttacagactgtttctgttaactacc
acaggtttacaccctacgagtggtataacccccacccatgcaaccctgactcagacgtggtggaaaacaattttactttactaaatagtttctggtttggagttgg
agctctcatgcagcaaggtacaccggttgcctatctttgtcacacgcatcccacagtgtgctgacaggctttcatgctggtaaactccaccatgaagctagagg
gtaggatgaaacaccatctcaggaacttaagaaaatagcaacggactttctagccggttttgaagatgaagcaaaaccaatgacctatatggaactcccttgct
atatatctaaaatagcacttctatcaagcaataaatacaaattttcctgtgggtagcaaaagataaggtaccttagaaatcgtttacaaatttgcatagatggagatg
ttggtcttctccttctcagccataactccacgagtcagcagtttaaaggagcgggatctaaatcctttggagattaaattcactgagattcttccaattgccaacctt
acctaggacttccacctaattactactctggcaaaccctactgagattcatttcagcctcccagtaacttttcacaatctccctcaattggtaaccatagcaacaata
aactgtaggagttggggaaataaaatttggccatagaaatgtaatatattttatacatttcctatgaattcggggattctgcttttgtagtgggggaagggggagct
attttaacctttggaagaactccatttc 
AAVS1= 
PPP1R12C 
TATATTCCCAGGGCCGGTTAATGTGGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCA
CAGTGGGGCCACTAGGGACAGGATTGGTGACAGAAAAGCCCCATCCTTAGGCCTCCTCCTTCC
TAGTCTCCTGATATTGGGTCTAACCCCCACCTCCTGT 
C. griseus 
Hprt1 
gccttcaatgcccggctttatatgtttttcaaagttacataataagagaaagaaaaaagtacactaatggaacatatttctgctttgttttcaaaatgtgttctcttcaa
gttactggtccaaagtaccttgtttggtaggaacccagacaattctctaatgttgctcttacctctccagaatatatttttctaatgtgagtttcttttcttttgcagCAT
ATTTGTGTCATTAGTGAAACTGGGAAAGCCAAATACAAAGCCTAAgatgagagttcaagttgaatctgcaaacac
gaggagtcccattcatgttcccagtaaaattaccaagcattctagttctgcagccatctgcttagtacagctttttgcatgaaccttctaagaattttatggttttttattt
ttagaaatgtcagttgctgcattcttaaactttttatttgcactatgagccttcgatagattgtcgcttaccttgtgag 
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Table B5, continued: 
region sequence 
C. griseus 
Grik1 
agaattcagtggatagaggtctgaggagtgccatcctagccactaatgggtttgactctgaagtaagaagctagtgagtatttgcccagtgactttcccaatcca
gaagcaattgcttctgctcagttgttgggttttctgcattgctcagcagcttttcctctggttcatctgtgtatctgatgtttacaaactgtttctgtcaattatcacaggtt
tacaccctacgagtggtacaatccccacccgtgcaaccccgactcagacgtggtggaaaacaatttcactttgctaaatagtttctggtttggagttggagctct
catgcagcaaggtacaccggttgcccattttgtcacttgcatcccacagtctgctgataagcgttcgtgctggtgaactccaccatgaaggtagatggtaggat
gaaacacacaggaatagaaaacaacagcaatagagtttctagccagttctcaaaagaagacagaaatagggtctaaatggagcttctttgccatgaatacactt
cttccaaagaatggacacaccattttcctg 
B.4. CHAPTER 4 SPECIFIC 
Table B6: Reference enhancer and promoter regions of highly expressed genes in 
HT1080 
source sequence 
CMV 
regulatory 
region, 
accession 
code 
M60321: 
2105-bp 
CTGCAGTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTTCTGTCGCCGACT
AAATTCATGTCGCGCGATAGTGGTGTTTATCGCCGATAGAGATGGCGATATTGGAAAAATCGA
TATTTGAAAATATGGCATATTGAAAATGTCGCCGATGTGAGTTTCTGTGTAACTGATATCGCCA
TTTTTCCAAAAGTGATTTTTGGGCATACGCGATATCTGGCGATACGGCTTATATCGTTTACGGG
GGATGGCGATAGACGACTTTGGCGACTTGGGCGATTCTGTGTGTCGCAAATATCGCAGTTTCGA
TATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGGCGACATCAAGCTGGCACATGGC
CAATGCATATCGATCTATACATTGAATCAATATTGGCAATTAGCCATATTAGTCATTGGTTATA
TAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATT
TATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTA
ATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTA
AATGGCCCGCCTCGTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC
CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC
CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGGCCCCCTATTGACGTCAATGACGGT
AAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACA
TCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG
ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTT
TGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC
GCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTC
CGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACgtaagtaccgcctatagact
ctataggcacacccctttggctcttatgcatgctatactgtttttggcttggggcctatacacccccgctccttatgctataggtgatggtatagcttagcctataggt
gtgggttattgaccattattgaccactcccctattggtgacgatactttccattactaatccataacatggctctttgccacaactatctctattggctatatgccaata
ctctgtccttcagagactgacacggactctgtatttttacaggatggggtcccatttattatttacaaattcacatatacaacaacgccgtcccccgtgcccgcagt
ttttattaaacatagcgtgggatctccacgcgaatctcgggtacgtgttccggacatgggctcttctccggtagcggcggagcttccacatccgagccctggtc
ccatgcctccagcggctcatggtcgctcggcagctccttgctcctaacagtggaggccagacttaggcacagcacaatgcccaccaccaccagtgtgccgc
acaaggccgtggcggtagggtatgtgtctgaaaatgagctcggagattgggctcgcaccgtgacgcagatggaagacttaaggcagcggcagaagaagat
gcaggcagctgagttgttgtattctgataagagtcagaggtaactcccgttgcggtgctgttaacggtggagggcagtgtagtctgagcagtactcgttgctgc
cgcgcgcgccaccagacataatagctgacagactaacagactgttcctttccatgggtcttttctgcagTCACCGTCCTTGACACGTTATT
GACCATTATTGACCACTCCCCTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCT
TTGCCACAACTATCTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGACTC
TGTATTTTTACAGGATGGGGTCCCATTTATTATTTACAAATTCACATATACAACAACGCCGTCC
CCCGTGCCCGCAGTTTTTATTAAACATAGCGTGGGATCTCCACGCGAATCTCGGGTACGTGTTC
CGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATGCCTCC
AGCGGCTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGC
ACAATGCCCACCACCACCAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAAT
GAGCTCGGAGATTGGGCTCGCACCGTGACGCAGATGGAAGACTTAAGGCAGCGGCAGAAGAA
GATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAACTCCCGTTGCGGTGCTGT
TAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGCGCCACCAGACATA
ATAGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCCTTGACA
CG 
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B.5. CHAPTER 5 SPECIFIC 
Table B7: Core promoters 
variant sequence 
CMV 
with TSS 
AGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC 
CMV 
without TSS 
AGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG 
UCP variant gcgcgcctatataagtttgtttcgtttagtgaaccgtcAGATTCTCTGGAGACGCCGAGCCGAGCGGTCAGACCTCCATAGAA 
Table B8: Additional promoter and enhancer regions 
variant sequence 
EEF1A1. 
1048 
promoter 
GGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCG
CCAGAACACAGgtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttgaattacttccacgcccctggct
gcagtacgtgattcttgatcccgagcttcgggttggaagtgggtgggagagttcgaggccttgcgcttaaggagccccttcgcctcgtgcttgagttgaggcct
ggcttgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgc
gacgctttttttctggcaagatagtcttgtaaatgcgggccaagatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcgtccc
agcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctc
gcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagg
gagctcaaaatggaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtga
ctccacggagtaccgggcgccgtccaggcacctcgattagttctcgagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttcc
ccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctca
gacagtggttcaaagtttttttcttccatttcagGTGTCGTGAAAACTACCCCTAAAAGCCAAA 
ACTB. 
1173 
promoter 
AGGCGGCCAACGCCAAAACTCTCCCTCCTCCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTT
CGCAAAAGGAGGGGAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAG
CGGCGCGGGGCCAATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCCGCG
GCGGCGCCCTATAAAACCCAGCGGCGCGACGCGCCACCACCGCCGAGACCGCGTCCGCCCCGC
GAGCACAGAGCCTCGCCTTTGCCGATCCGCCGCCCGTCCACACCCGCCGCCAGgtaagcccggccagcc
gaccggggcaggcggctcacggcccggccgcaggcggccgcggccccttcgcccgtgcagagccgccgtctgggccgcagcggggggcgcatggg
gggggaaccggaccgccgtggggggcgcgggagaagcccctgggcctccggagatgggggacaccccacgccagttcggaggcgcgaggccgcgc
tcgggaggcgcgctccgggggtgccgctctcggggcgggggcaaccggcggggtctttgtctgagccgggctcttgccaatggggatcgcagggtggg
cgcggcggagcccccgccaggcccggtgggggctggggcgccattgcgcgtgcgcgctggtcctttgggcgctaactgcgtgcgcgctgggaattggc
gctaattgcgcgtgcgcgctgggactcaaggcgctaactgcgcgtgcgttctggggcccggggtgccgcggcctgggctggggcgaaggcgggctcgg
ccggaaggggtggggtcgccgcggctcccgggcgcttgcgcgcacttcctgcccgagccgctggccgcccgagggtgtggccgctgcgtgcgcgcgc
gccgacccggcgctgtttgaaccgggcggaggcggggctggcgcccggttgggagggggttggggcctggcttcctgccgcgcgccgcggggacgcc
tccgaccagtgtttgccttttatggtaataacgcggccggcccggcttcctttgtccccaatctgggcgcgcgccggcgccccctggcggcctaaggactcgg
cgcgccggaagtggccagggcgggggcgacctcggctcacagcgcgcccggctattctcgcagCTCACC 
EIF4A1. 
872 
extended 
5’UTR 
promoter  
GTGGTGGTCTTCCTTAAGGGGCTTCAAATTAGTGGATATGCTTAGCTCAGACCTTCCAGCCAGT
CTCTTGAGACTAAAGGGTTCAGCTTTCCATCCCTGGCTCAGGCACTGCCAACACCTTGTCTTCA
CCCAAACAAATCCCCGAGATGGGAGCAGAGAGCAGGAAGGAGGGAAAGTAGATAAGCCTCAA
GAATAAGGGCATCCGAGAGGGAAGCTGGGGAACTGGACACAAGGGACTGGGGAGGGGACCA
ACCAGGATTCATGATAGTACCCCAAAGCCCTTTACAGTTTTCTTCCATCCCTCCACCATCCAGC
CAGGGGAATCCTCCCATCCCTACGATATCGCTGTTGATTCCTTCATCCCTGGCACACGTCCAGG
CAGTGTCGAATCCATCTCTGCTACAGGGGAAAACAAATAACATTTGAGTCCAGTGGAGACCGG
GAGCAGAAGTAAAGGGAAGTGATAACCCCCAGAGCCCGGAAGCCTCTGGAGGCTGAGACCTC
GCCCCCCTTGCGTGATAGGGCCTACGGAGCCACATGACCAAGGCACTGTCGCCTCCGCACGTG
TGAGAGTGCAGGGCCCCAAGATGGCTGCCAGGCCTCGAGGCCTGACTCTTCTATGTCACTTCCG
TACCGGCGAGAAAGGCGGGCCCTCCAGCCAATGAGGCTGCGGGGCGGGCCTTCACCTTGATAG
GCACTCGAGTTATCCAATGGTGCCTGCGGGCCGGAGCGACTAGGAACTAACGTCATGCCGAGT
TGCTGAGCGCCGGCAGGCGGGGCCGGGGCGGCCAAACCAATGCGATGGCCGGGGCGGAGTCG
GGCGCTCTATAAGTTGTCGATAGGCGGGCACTCCGCCCTAGTTTCTAAGGATC 
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Table B8, continued: 
variant sequence 
F2R. 
500.L 
extended 
5’UTR 
promoter 
ACTCAAGGGCCCTTTCTCATTTAGGGGCAACCCTGTCACTACATCATAAACTTTTAAATCCGTG
ATCCCCACGTTACAAAAGCAGAAGTCCCTTTTAGACTTTTAGCGAAAACTGAACTTTGCCGGTG
TCCCACACGGAGGGAGGGAGGACGGGAGGCCACGCCAGGGCTGCGGGGCTGCAGGGCGTGGA
CGCATCCTGGCCGGGGCGTCCACTGTCGACGTCTCCACATCCCAGGAGGGTCGAGACGGCCGC
GGGAAGCAGCCTGCGAGCCGTGCGGCCCCATTCCAAGGACCCCGCCAGTGTGAGTCACTGACA
GCTTCGCGAATCAACGGTGCCCAGAGGAAAAAACTTCTCATTTGGACTTCTAGGCCCGGCAGT
GGCCGGCGGCCAGGGCCCCCCAGTAGGGCAGGGCGGGGCGGGGCGGGGCGCACAGAGCCAGA
GGGGCTTGCGAGCGGCGGCTGAGGGACCGCGGGGAGGGGGCGCCGAGCGGCTCCAGCGCAGA
GACTCTCACTGCACGCCGGAGGGCGCCCTTCCTCGCTCGCGCCCGCGCGACCGCGCGCCCCAGT
CCCGCCCCGCCCCGCTAACCGCCCCAGACACAGCGCTCGCCGAGGGTCGCTTGGACCCTGATCT
TACCCGTGGGCACCCTGCGCTCTGCCTGCCGCGAAGACCGGCTCCCCGACCCGCAGAAGTCAG
GAGAGAGGGTGAAGCGGAGCAGCCCGAGGCGGGGCAGCCTCCCGGAGCAGCGCCGCGCAGAG
CCCGGGACA 
LAIR1. 
500.L 
extended 
5’UTR 
promoter 
AAAAATTTCTTTAAATTGGCCTTTGGAAATTTACCAGCAGTGTGCTGGTAAAGTCTTGACAATC
AGCTCTCTGAAAAAAAAAGCAAAAAGAAAAACAAAAAACAACCCCGACGTGTAGCATTTGCC
GATTTCTCTGGTGTAAATACTCACAGCATGGCTTTGACATGAGTTTTACATTTGGTAAAAGCAA
ATTGTGCCTACTTTGAATAGAAGGATTGGGACAGAGATATGGTTCTTGTCAGGCACTAATTAGG
GAGTAAGGCTTGTCTAATATTGCCTTGGCTCTCAAGCAAAATAAAAAAAAAAAAGTAACGTTT
GGGAATCTGTGTTGCTTCCTCAGCCCCATCCTGGGTAAAATCGGAGACGTATACAGGGCAGGG
AGAAGCTGTTTATTTCCGTGCCTGCGGCTGGAGCTTCTTAAGGATTTGAGCTGTGATGCTGGCA
CCTGGCAGACCACATCCTGTGCGGTTTTCAGTTTTGCTCCGTTCCTGACCCTGGTATAGCAGAA
GCTTTTTCACATCTATGACACCCGCTATGTCTTGGTAAACCCTGGAAGGGAAAGGAGGACAAG
GTTAAAATACTGTTCCGAGGACCTGGTCTCTCCACAGCGCAGGCTGGAGGTGGCAGCCCGTGG
AAAGCCAAGTTCATCCACCATCGGAGCCCAGGCCAGGCTGCCAAGGCTAATATTCAGGACAAA
GCCAGGCACAGGTCGGGAATCCTATGAAGATGATCATCGTCCTGAGGTCTTCCTTCCAGGGTTG
CATCCGCGACAGAAG 
PGK1. 
500.L 
extended 
5’UTR 
promoter 
GGACCTGGGCCTCTTCCAACTTCTGAGAGGTCTCTATTACTAAGTAAGCCTTAAGAAGCAGAAT
TCCATGAAGGGAGCTAGGAAACCAGGATTTTCCAAAAGGAGGTGGCATTTGCATTGATCCTGG
TAGGGCAGCCTCGAATTCCACGGGGTTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCG
CAGGGACGCGGCTGCTCTGGGCGTGGTTCCGGGAAACGCAGCGGCGCCGACCCTGGGTCTCGC
ACATTCTTCACGTCCGTTCGCAGCGTCACCCGGATCTTCGCCGCTACCCTTGTGGGCCCCCCGG
CGACGCTTCCTGCTCCGCCCCTAAGTCGGGAAGGTTCCTTGCGGTTCGCGGCGTGCCGGACGTG
ACAAACGGAAGCCGCACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAGGGAGCAATGG
CAGCGCGCCGACCGCGATGGGCTGTGGCCAATAGCGGCTGCTCAGCAGGGCGCGCCGAGAGC
AGCGGCCGGGAAGGGGCGGTGCGGGAGGCGGGGTGTGGGGCGGTAGTGTGGGCCCTGTTCCT
GCCCGCGCGGTGTTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCGGCAGTCGGCTCCCTCGTT
GACCGAATCACCGACCTCTCTCCCCAGCTGTATTTCCAAA 
RPL41. 
398 
promoter 
ATAGGTGCTGACGTTTAAATAACACAGCGTCCTCATACTAAATCTGGGGGGGAACTGGTAACT
CGAAAACCAAATACTCGGTCTTCCGAAAGAACTAACTCAACCTACCCTTCTACAAGAGGGTCC
GAAAACCACTGTTACGCCCATTGGGTAGCCCCGCCCTTGGGGGGGGCAAAGGGCGTGAAAGCG
GAAGTGACGACACCCGGCGCTCCATTAAATAGCCGTAGACGGAACTTCGCCTTTCTCTCGGCCT
TAGCGCCATTTTTTTGGGTGAGTGTTTTTTGGTTCCTGCGTTGGGATTCCGTGTACAATCCATAG
ACATCTGACCTCGGCACTTAGCATCATCACAGCAAACTAACTGTAGCCTTTCTCTCTTTCCCTGT
AGAAACCTCTGCGCC 
RPLP2. 
479 
promoter 
tcacttccggaactgctgcccttcgcctttgccgcgaaaagtgcctgacgggggctgggaagggggagggggaaggagtcaacgactccctccccgtcgt
cattggctgagcgcctcgtgacgtcactctgaggcgcctcatgcggcgccgcgcacgggtcccagagccttctgggtagcGGTTTAACCCCGC
CTCTTGCGTCGGCGCCTTCCTTTTCCTCCCTGTCGCCACCGAGGTCGCACGCGTGAGACTTCTCC
GCCGCCTCCGCCGCAGACGCCGCCGCgtgagtgtggtgaccgggcccggggtgccggctggggacgcggagtccgtggggatg
cggggtgggcggcggggtatttttgggacggaggcctacgggccgagccacgcgcggcctcgcccggcggccccgggatgggccggcaggaggccg
ccggggtaactccgccgtcgcgtcctctccgcccgcctcagG 
GAPDH 
intron 1 
with 
flanking 
exons 
GGCTGGGACTGGCTGAGCCTGGCGGGAGGCGGGGTCCGAGTCACCGCCTGCCGCCGCGCCCCC
GGTTTCTATAAATTGAGCCCGCAGCCTCCCGCTTCGCTCTCTGCTCCTCCTGTTCGACAGTCAGC
CGCATCTTCTTTTGCGTCGCCAGgtgaagacgggcggagagaaacccgggaggctagggacggcctgaaggcggcaggggcgg
gcgcaggccggatgtgttcgcgccgctgcggggtgggcccgggcggcctccgcattgcaggggcgggcggaggacgtgatgcggcgcgggctgggc
atggaggcctggtgggggaggggaggggaggcgtgtgtgtcggccggggccactaggcgctcactgttctctccctccgcgcagCCGAGCCAC
ATCGCTCAGACACC 
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Table B8, continued: 
variant sequence 
EEF1A1e. 
308 
GAGTAATTCATACAAAAGGACTCGCCCCTGCCTTGGGGAATCCCAGGGACCGTCGTTAAACTC
CCACTAACGTAGAACCCAGAGATCGCTGCGTTCCCGCCCCCTCACCCGCCCGCTCTCGTCATCA
CTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCC
CACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGC
GCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGT 
EEF1A1e. 
156 
GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGA
GGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGT
CGTGTACTGGCTCCGCCTTTTTCCCGAGGGT 
EIF4A1e. 
450 
CTGGGGAGGGGACCAACCAGGATTCATGATAGTACCCCAAAGCCCTTTACAGTTTTCTTCCATC
CCTCCACCATCCAGCCAGGGGAATCCTCCCATCCCTACGATATCGCTGTTGATTCCTTCATCCCT
GGCACACGTCCAGGCAGTGTCGAATCCATCTCTGCTACAGGGGAAAACAAATAACATTTGAGT
CCAGTGGAGACCGGGAGCAGAAGTAAAGGGAAGTGATAACCCCCAGAGCCCGGAAGCCTCTG
GAGGCTGAGACCTCGCCCCCCTTGCGTGATAGGGCCTACGGAGCCACATGACCAAGGCACTGT
CGCCTCCGCACGTGTGAGAGTGCAGGGCCCCAAGATGGCTGCCAGGCCTCGAGGCCTGACTCT
TCTATGTCACTTCCGTACCGGCGAGAAAGGCGGGCCCTCCAGCCAATGAGGCTGCGGGGCGGG
CCTTCAC 
ACTBe. 
182 
AGGCGGCCAACGCCAAAACTCTCCCTCCTCCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTT
CGCAAAAGGAGGGGAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAG
CGGCGCGGGGCCAATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGA 
Table B9: Additional regulatory regions from literature 
source sequence 
LMO1 
derived281: 
553-bp 
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCCACATCCTGAGACTTAGG
GGTGACCCTGGGTTGAGTGGACTGGTTTATTCTGCTGGGCCCAGCGCATGCATCTGAGTGTGTG
CCCAGGCGTGCGTGTCGGCGCAAACATCATCCATTGTGAAATATCAGTGTTTTCATGGGTGAGT
AGTAATTACTGGGTAATGCTTTAAAACCTTTCCTGAAGGAGCGCAAAGCCATTTTTTTCTAAAG
TCAGGAGTACATTAAAAGGATTACCATGTAGATTTGATTTTTAGATAACACTAAAATGGATCCC
AAATGGACTTCAGCAAAGGGATGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTCAGGT
CCCAGAGCCAGGCTGgggaaggagggagggaagaggtgtctgcaggggggcaggctggcagattgggtggggggctaggtgggaatgg
ggaaggcagagcaggagggagggCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCAGGAGAC
TACAGAGCCCCT 
MMse176 
mutant282: 
1742-bp 
gagttaaaaagaggtgatttacagtgctatttgagaaggggtattaaggaatttgccagggcactgacgcgtgtcaggtgtaaacctcaggttgagagagagc
taagtattttctgtccatgaGggtgataagcgagggcctgaagaaagagggactggggaggacactggcaccagaaataggaaagggcttGttgggggt
gggaaggatgggtcaGggtgctatctaGaaagttgCctggcaAtggatgtaggatgtgggagtgagacatcaaacatgaagcagtcgcttaaagtctgaa
gaaaCactagatatatGaacTgcaggagatagtagggaaactggaccggctcctcataaaacttcccgccttctatctccgggaggatcgcagggcatttc
cgccaagacaggtgagactgcggttctgacctgcgggcctccgtgcatatgcgctagggcacctgggggccggcagagccgttcccctacgcaaagtaag
cgtgttatgtctacaacccaaTggggacactgagagccccaaaggccctgctttcttcccagagaacAGCgcccatctgTGtaGtttctacctggctctat
gaggtgagaacacaCtccccgctagcacagaaatcctacaaactcctgtgggggctgcgcttggaagcagaggctgtgtaagaggtgactTggggggta
gggaaaaacacgaagattttcacacagggtgagaacccaagagactggagaccacggaccaatccctgcaaaaagcagccagggtagaaagggaagag
ctgagcggacttcacgatagctaatttgtgttacaaagccgatacggctgatgctcgTtttttctcctatgGcatgcaggcgacatgttacttcctattcccataaa
ccctccactgtaggattaacacctaagacaccaaccaagacaaaaaaagatatgacccttggTgtacagtctgtttttgaaactccagaaagtcaggggaaa
gcgcgaacgcagtcccccactaccacaaattatgcagtcgagtttcccacatttggggaaatcgcaggggtcagcacatccggagtgcaatggataagcctc
gcTctgggaaaaccaccttcgtgatcatggtatctcccctgccaggtaagtatgaaacCttgtgcctctgccccgacacagcctcatacgcctcactctttaca
cacacggtcacttgccccgcgcactcccgagccctttccagccctgacacacagctgggattctcacttccgatcagcggtcctgaacccgctcccagggca
cgggaactcccttcgtggcgaagcagcaagtggcgaagcagcagcctctgcgctgcctcatctacatagaagtcgccctgtccgtgatgtcaccgacagtg
ccttgcccagtccccgtctgcctttctgccactcaaccgaccaatctgctgccagagCcgccaagGggaagtgacgtctgcctctccctttttccctcccgcc
cctgcgtctgttctctcccaaagaagctggtccttagcctgtgttaaggagcaaCctttcggtggccagatggagccggggcatccttcttcaaataatggctttt
aattcgcagactagaatgtttcggattacaaaagaaaccggttctcttcacatccttatccttgtgatgcagcattccgcttgcatttggaagccgtttaatatcaga
gagaag 
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B.6. CHAPTER 6 SPECIFIC 
Table B10: Base expression cassette for evaluating terminators 
construct sequence (transgene region only) 
pEIF4A1.63
6-hrGFP 
CTGGGGAGGGGACCAACCAGGATTCATGATAGTACCCCAAAGCCCTTTACAGTTTTCTTCCATC
CCTCCACCATCCAGCCAGGGGAATCCTCCCATCCCTACGATATCGCTGTTGATTCCTTCATCCCT
GGCACACGTCCAGGCAGTGTCGAATCCATCTCTGCTACAGGGGAAAACAAATAACATTTGAGT
CCAGTGGAGACCGGGAGCAGAAGTAAAGGGAAGTGATAACCCCCAGAGCCCGGAAGCCTCTG
GAGGCTGAGACCTCGCCCCCCTTGCGTGATAGGGCCTACGGAGCCACATGACCAAGGCACTGT
CGCCTCCGCACGTGTGAGAGTGCAGGGCCCCAAGATGGCTGCCAGGCCTCGAGGCCTGACTCT
TCTATGTCACTTCCGTACCGGCGAGAAAGGCGGGCCCTCCAGCCAATGAGGCTGCGGGGCGGG
CCTTCACCTTGATAGGCACTCGAGTTATCCAATGGTGCCTGCGGGCCGGAGCGACTAGGAACT
AACGTCATGCCGAGTTGCTGAGCGCCGGCAGGCGGGGCCGGGGCGGCCAAACCAATGCGATG
GCCGGGGCGGAGTCGGGCGCTCTATAAGTTGTCGATAGGCGGGCACTCCGCCCTAGTTTCTAA
GGATCGCTAGCATGGTGAGCAAGCAGATCCTGAAGAACACCGGCCTGCAGGAGATCATGAGCT
TCAAGGTGAACCTGGAGGGCGTGGTGAACAACCACGTGTTCACCATGGAGGGCTGCGGCAAGG
GCAACATCCTGTTCGGCAACCAGCTGGTGCAGATCCGCGTGACCAAGGGCGCCCCCCTGCCCTT
CGCCTTCGACATCCTGAGCCCCGCCTTCCAGTACGGCAACCGCACCTTCACCAAGTACCCCGAG
GACATCAGCGACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGTGTACGAGCGCACCCTGCGCT
ACGAGGACGGCGGCCTGGTGGAGATCCGCAGCGACATCAACCTGATCGAGGAGATGTTCGTGT
ACCGCGTGGAGTACAAGGGCCGCAACTTCCCCAACGACGGCCCCGTGATGAAGAAGACCATCA
CCGGCCTGCAGCCCAGCTTCGAGGTGGTGTACATGAACGACGGCGTGCTGGTGGGCCAGGTGA
TCCTGGTGTACCGCCTGAACAGCGGCAAGTTCTACAGCTGCCACATGCGCACCCTGATGAAGA
GCAAGGGCGTGGTGAAGGACTTCCCCGAGTACCACTTCATCCAGCACCGCCTGGAGAAGACCT
ACGTGGAGGACGGCGGCTTCGTGGAGCAGCACGAGACCGCCATCGCCCAGCTGACCAGCCTGG
GCAAGCCCCTGGGCAGCCTGCACGAGTGGGTGTAAGGCGCGCC 
pEIF4A1.63
6-SEAP 
CTGGGGAGGGGACCAACCAGGATTCATGATAGTACCCCAAAGCCCTTTACAGTTTTCTTCCATC
CCTCCACCATCCAGCCAGGGGAATCCTCCCATCCCTACGATATCGCTGTTGATTCCTTCATCCCT
GGCACACGTCCAGGCAGTGTCGAATCCATCTCTGCTACAGGGGAAAACAAATAACATTTGAGT
CCAGTGGAGACCGGGAGCAGAAGTAAAGGGAAGTGATAACCCCCAGAGCCCGGAAGCCTCTG
GAGGCTGAGACCTCGCCCCCCTTGCGTGATAGGGCCTACGGAGCCACATGACCAAGGCACTGT
CGCCTCCGCACGTGTGAGAGTGCAGGGCCCCAAGATGGCTGCCAGGCCTCGAGGCCTGACTCT
TCTATGTCACTTCCGTACCGGCGAGAAAGGCGGGCCCTCCAGCCAATGAGGCTGCGGGGCGGG
CCTTCACCTTGATAGGCACTCGAGTTATCCAATGGTGCCTGCGGGCCGGAGCGACTAGGAACT
AACGTCATGCCGAGTTGCTGAGCGCCGGCAGGCGGGGCCGGGGCGGCCAAACCAATGCGATG
GCCGGGGCGGAGTCGGGCGCTCTATAAGTTGTCGATAGGCGGGCACTCCGCCCTAGTTTCTAA
GGATCGCTAGCATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCAT
CATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAGGCAGCCGAGGCCCTGGGTGC
CGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGG
GATGGGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGACAAACTGG
GGCCTGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCCAAGACATACAATGT
AGACAAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCA
ACTTCCAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCA
ACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGTGGTAACC
ACCACACGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGG
TACTCGGACGCCGACGTGCCTGCCTCGGCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAG
CTCATCTCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCATGG
GAACCCCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAG
AATCTGGTGCAGGAATGGCTGGCGAAGCGCCAGGGTGCCCGGTATGTGTGGAACCGCACTGAG
CTCATGCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACA
TGAAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTG
CCCTGCGCCTGCTGAGCAGGAACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGA
CCATGGTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGC
CATTGAGAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCA
CTCCCACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCT
GGCAAGGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTG
CTCAAGGACGGCGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCA
GCAGTCAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCGC
GCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGG
CCTTCGCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGA
CGCCGCGCACCCGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGA 
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Table B10, continued: 
construct sequence (transgene region only) 
pEEF1A1.1
356-hrGFP 
GAGTAATTCATACAAAAGGACTCGCCCCTGCCTTGGGGAATCCCAGGGACCGTCGTTAAACTC
CCACTAACGTAGAACCCAGAGATCGCTGCGTTCCCGCCCCCTCACCCGCCCGCTCTCGTCATCA
CTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCC
CACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGC
GCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAG
AACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAAC
ACAGgtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttgaattacttccacgcccctggctgcagtacgtgat
tcttgatcccgagcttcgggttggaagtgggtgggagagttcgaggccttgcgcttaaggagccccttcgcctcgtgcttgagttgaggcctggcttgggcgc
tggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttc
tggcaagatagtcttgtaaatgcgggccaagatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcgtcccagcgcacatgt
tcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgccgccgtg
tatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagggagctcaaaatg
gaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtgactccacggagta
ccgggcgccgtccaggcacctcgattagttctcgagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtg
ggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaa
agtttttttcttccatttcagGTGTCGTGAAAACTACCCCTAAAAGCCAAAGCTAGCATGGTGAGCAAGCAGA
TCCTGAAGAACACCGGCCTGCAGGAGATCATGAGCTTCAAGGTGAACCTGGAGGGCGTGGTGA
ACAACCACGTGTTCACCATGGAGGGCTGCGGCAAGGGCAACATCCTGTTCGGCAACCAGCTGG
TGCAGATCCGCGTGACCAAGGGCGCCCCCCTGCCCTTCGCCTTCGACATCCTGAGCCCCGCCTT
CCAGTACGGCAACCGCACCTTCACCAAGTACCCCGAGGACATCAGCGACTTCTTCATCCAGAG
CTTCCCCGCCGGCTTCGTGTACGAGCGCACCCTGCGCTACGAGGACGGCGGCCTGGTGGAGAT
CCGCAGCGACATCAACCTGATCGAGGAGATGTTCGTGTACCGCGTGGAGTACAAGGGCCGCAA
CTTCCCCAACGACGGCCCCGTGATGAAGAAGACCATCACCGGCCTGCAGCCCAGCTTCGAGGT
GGTGTACATGAACGACGGCGTGCTGGTGGGCCAGGTGATCCTGGTGTACCGCCTGAACAGCGG
CAAGTTCTACAGCTGCCACATGCGCACCCTGATGAAGAGCAAGGGCGTGGTGAAGGACTTCCC
CGAGTACCACTTCATCCAGCACCGCCTGGAGAAGACCTACGTGGAGGACGGCGGCTTCGTGGA
GCAGCACGAGACCGCCATCGCCCAGCTGACCAGCCTGGGCAAGCCCCTGGGCAGCCTGCACGA
GTGGGTGTAAGGCGCGC 
fully viral 
construct: 
rpCMV.660
-hrGFP-
SV40pA 
GACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGT
TCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTCGTGACCGC
CCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGA
CTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGT
GTATCATATGCCAAGTCCGGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA
TGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCAC
GCTGTTTTGACCTCCATAGAAGACGCTAGCATGGTGAGCAAGCAGATCCTGAAGAACACCGGC
CTGCAGGAGATCATGAGCTTCAAGGTGAACCTGGAGGGCGTGGTGAACAACCACGTGTTCACC
ATGGAGGGCTGCGGCAAGGGCAACATCCTGTTCGGCAACCAGCTGGTGCAGATCCGCGTGACC
AAGGGCGCCCCCCTGCCCTTCGCCTTCGACATCCTGAGCCCCGCCTTCCAGTACGGCAACCGCA
CCTTCACCAAGTACCCCGAGGACATCAGCGACTTCTTCATCCAGAGCTTCCCCGCCGGCTTCGT
GTACGAGCGCACCCTGCGCTACGAGGACGGCGGCCTGGTGGAGATCCGCAGCGACATCAACCT
GATCGAGGAGATGTTCGTGTACCGCGTGGAGTACAAGGGCCGCAACTTCCCCAACGACGGCCC
CGTGATGAAGAAGACCATCACCGGCCTGCAGCCCAGCTTCGAGGTGGTGTACATGAACGACGG
CGTGCTGGTGGGCCAGGTGATCCTGGTGTACCGCCTGAACAGCGGCAAGTTCTACAGCTGCCA
CATGCGCACCCTGATGAAGAGCAAGGGCGTGGTGAAGGACTTCCCCGAGTACCACTTCATCCA
GCACCGCCTGGAGAAGACCTACGTGGAGGACGGCGGCTTCGTGGAGCAGCACGAGACCGCCA
TCGCCCAGCTGACCAGCCTGGGCAAGCCCCTGGGCAGCCTGCACGAGTGGGTGTAACAGACAT
GATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTAT
TTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAC
AACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCA
AGTAAAACCTCTACAAATGTGGTA 
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